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Abstract  
Cancer is one of the major causes of morbidity in the world. Although the 
overall survival of cancer has been significantly improved by chemotherapy in 
the last three decades, the success of cancer chemotherapy is still severely 
limited by the lack of selectivity of anti-cancer drugs to malignant cells leading 
to dose-limiting toxicity and the resistance of cancer cells to the conventional 
anti-cancer drugs.  
 
Gene-directed enzyme prodrug therapy (GDEPT) was designed to direct the 
anti-cancer drugs to specifically target the cancer cells by using cancer 
specific promoter to drive the expression of enzyme which can convert 
prodrug into anti-cancer drug specifically in cancer cells. However, this 
strategy is hindered by the lack of strong cancer specific promoters to 
specifically express drug-converting enzymes in cancer cells. In consequence, 
there is not enough anti-cancer drug activated inside the cancer cells. The 
first part of this study was to employ NF-κB binding sites as a novel enhancer 
system to improve the promoter activity of carcinoembryonic antigen (CEA) 
and human telomerase reverse transcriptase (hTERT) for GDEPT. In this 
system, the basal CEA promoter sequences were placed downstream of the 4 
or 8 NF-κB DNA binding sites linked in tandem (κB4 or κB8). The system was 
designed to serve two particular purposes: to exploit the high levels of intra-
tumoural NF-kB expression and keep the relative tumour specificity of the 
 II 
CEA and hTERT promoters. The results demonstrated that κB enhancer 
systems increased the transcriptional activity of CEA and hTERT promoter 
without compromising its cancer specificity. The fidelity of the κB4-CEA 
enhancer-promoter system was therefore improved by the increased 
transcriptional contrast between the cancer and normal cells. Moreover, in 
comparison with CEA promoter alone, κB-CEA enhancer-promoter system 
expressed human thymidine phosphorylase (TP) protein at significantly higher 
levels which were comparable to those expressed by CMV promoter. The κB-
CEA-TP system transfected cells demonstrated significantly higher sensitivity 
to 5'-Deoxy-5-Fluorouridine (5'-DFUR), a prodrug of 5-fluorouracil (5-FU). 
 
The second part of this study was involved in using NF-κB inhibitor as a 
chemosensitizer to sentizise the anti-cancer drug-induced chemoresistance 
cells to anti-cancer drugs. The results derived from this study manifested that 
the anti-alcoholism drug, Disulfiram (DS), and anti-inflammatory drug, 
triptolide (PG490), markedly enhanced the cytotoxicity of several conventional 
anti-cancer drugs in colon, lung and breast cancer cell lines. PG490 induced 
caspase-dependent cell death accompanied by a significant decrease in Bcl-2 
levels. PG490 induced the expression of p53 and down-regulated p21 
expression. This study indicated that some clinically used non-cancer-
chemotherapeutic drugs may be developed as chemosensitizers for cancer 
chemotherapy. 
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1. Introduction 
1.1 General introduction 
Nuclear factor kappa B (NF-κB) is a family of transcription factors ubiquitously 
expressed in almost all animal cell types. In normal cells, NF-κB is localized in 
cytoplasm as an inactive form. High NF-κB activity has been identified in a 
wide range of cancer types. Under some insults, NF-κB activity in cancer cell 
can be further induced. The NF-κB-activating factors include stress, cytokines, 
ultraviolet irradiation, oxidized low density lipoprotein, bacterial or viral 
antigens, radiotherapy and chemotherapy[1-3]. The activated NF-κB triggers 
the expression of  several downstream genes. The NF-κB-governed genes 
play key roles in regulating immune and inflammatory responses, apoptosis, 
carcinogenesis and developmental processes. The persistent activation of 
NF-κB is thought to contribute to uncontrolled growth of cancer cells. 
Therefore, the perturbation of NF-κB activity has been linked to cancer, 
inflammatory and autoimmune diseases and improper immune development[4].  
 
Chemotherapy is one of the main treatments for cancer. Although overall 
survival rate in cancer patients has been markedly improved by chemotherapy 
in the last a couple of decades, the therapeutic outcome of advanced cancer 
patients is very poor. The major obstacles for the success of cancer 
chemotherapy include chemoresistance and the non-specific toxicity of anti-
cancer drugs. Anti-cancer drug induced DNA damage can trigger the 
 3
expression of anti-apoptotic genes which confer drug resistance. Identifying 
and targeting these genes may result in improving chemotherapeutic 
outcomes. NF-κB is one of the major anti-apoptotic factors induced by 
chemotherapy. High NF-κB activity is contributed to the over-expression of 
some anti-apoptotic genes which mediate resistance to apoptosis[5,6]. The 
constitutive and inducible NF-κB activity in cancer cells is one of the major 
causes of chemoresistance[7]. It has been widely recoganized in the recently 
years that effective repression of NF-κB significantly enhance chemotherapy 
reagent-mediated killing of cancer cells and totally reverse acquired and de 
novo chemoresistance. Therefore, identification and validation of novel NF-κB 
inhibitors attracts the interests in fundamental cancer research and clinical 
oncology. 
 
Due to the remarkable advances in our understanding of cancer biology and 
cancer genetic, several relatively cancer-specific anti-cancer prodrugs have 
been developed and gene-directed enzyme prodrug therapy (GDEPT) has 
been invented to improve prodrug activity. One of the major limitations for the 
application of GDEPT in clinic is the lacking of strong cancer specific promoter 
driving expression of prodrug-converting enzyme in cancer cells. High NF-κB 
activity is specifically detected in cancer cells and inducible by chemotherapy. 
Therefore NF-κB DNA binding site may be an attractive enhancer for GDEPT 
application. 
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1.2  NF-κB family 
NF-κB is a transcription factor discovered by David Baltimore’s group via its 
interaction with an 11-base pair sequence in the immunoglobulin  light-chain 
enhancer in B cells[8]. NF-κB is found in almost all animal cell types. There are 
NF-κB proteins in invertebrates, such as the fruit fly Drosophila, sea urchins, 
sea anemones and sponges. However, NF-κB is notably absent in yeast. This 
may be partly due to one of the primary roles of these factors to control a 
variety of physiological aspects of immune and inflammatory responses[9]. 
 
1.2.1 The structure of NF-κB family members 
The NF-κB/Rel family in mammalian cells contains five members: RelA (p65), 
RelB, c-Rel, NF-κB1 (p50; p105), and NF-κB2 (p52; p100) (Fig. 1.1). All of 
NF-κB family members possess a structurally conserved 300 amino acid. 
sequence called the REL region[10] The C-terminal domain of this region is 
responsible for dimerization and IκB binding, whereas the N-terminal domain 
is primarily responsible for DNA binding specificity. 
 
Based on sequences C-terminal to the Rel homology domain, Rel/NF-κB 
proteins can be divided into two classes: class I NF-κB proteins include NF-
κB1 (p50; p105), and NF-κB2 (p52; p100) which have long C-terminal 
domains that contain multiple copies of inhibitory ankyrin repeats in large 
precursors, p105 and p100, which undergo processing to generate the mature 
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NF-κB subunits, p50 and p52, respectively[11]. The processing of p105 and 
p100 is mediated by the ubiquitin/proteasome pathway and involves selective 
degradation of their C-terminal region. The generation of p52 from p100 is a 
tightly-regulated process and the production of p50 is constitutively processed 
from p105[12]. The class II Rel proteins consist of RelA (p65), RelB and c-Rel 
which contain C-terminal transcription activation domains[13] and are lack of 
the inhibitory ankyrin repeats.  
 
Members of class I NF-κB protein are generally not activators of transcription, 
except when they form dimers with members of class II Rel protein. The 
dimerized Rel/NF-κB transcription factors bind to 9-10 base pairs DNA sites 
(called κB sites). The consensus κB DNA bunding sequence is 
5’GGGRNNYYCC-3’, where R is purine, Y is pyrimidine, and N is any base[8]. 
All vertebrate Rel proteins can form homodimers or heterodimers, except for 
RelB, which can only form heterodimers[9]. This combinatorial diversity 
contributes to the regulation of distinct sets of genes, in that the individual 
dimers have distinct DNA-binding site specificities for a collection of related 
κB sites. The heterodimer of the p65/RelA and p50 subunits is the major 
Rel/NF-κB complex in most cells. So the term NF-κB commonly refers 
specifically to a p50-RelA heterodimer. Unlike RelA, RelB and c-Rel, the p50 
and p52 NF-κB subunits do not contain transactivation domains in their C 
terminal halves. Nevertheless, the p50 and p52 NF-κB members play critical 
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roles in modulating the specificity of NF-κB function. Although homodimers of 
p50 and p52 are, in general, repressors of κB site transcription; both p50 and 
p52 participate in target gene transactivation by forming heterodimers with 
RelA, RelB or c-Rel[1]. In addition, p50 and p52 homodimers also bind to the 
nuclear protein Bcl-3. Such complexes can function as transcriptional 
activators[14]. The different Rel/NF-κB proteins show distinct abilities to form 
dimers, preferences for different κB sites and abilities to bind to IκB inhibitor 
proteins[15]. Thus, different Rel/NF-κB complexes can be induced in different 
cell types by distinct signals and interact in distinct ways with other 
transcription factors and regulatory proteins to regulate the expression of 
distinct gene sets. These types of considerations are likely to be responsible 
for the opposite effects of Rel/NF-κB complexes in different cell types under 
different stimuli. 
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1.2.2 The activation of NF-κB 
NF-κB exists in the cytoplasm in an inactive form associated with regulatory 
proteins called inhibitors of NF-κB (IκBs). Activation of the NF-κB is initiated 
by the signal-induced degradation of IκB proteins. This occurs primarily via 
activation of the IκB kinase (IKK). With the degradation of the IκB inhibitor, the 
NF-κB complex is then freed to enter the nucleus where it can 'turn on' the 
expression of specific genes that have DNA-binding sites for NF-κB. The 
activation of these genes by NF-κB then leads to the given physiological 
responses including inflammatory or immune response, cell survival response 
and cellular proliferation. Interestingly, NF-κB also turns on expression of its 
Figure 1.1: The NF-κB/Rel/IκB family of proteins.  
The NF-κB family is shown in (a). The class I of NF-κB proteins are on the left hand 
side and the class II Rel proteins right hand side. (b) IκB family of proteins. 
Characterized by five (IκBα) or seven (IκB β, γ, ε and Bcl-3) copies of ankyrin repeats. 
Number of amino-acids present shown on the right of each protein. This figure is 
adapted from Qiutang Li and Linder M Verma[1] 
 8
own repressor, IκBα. The newly synthesized IκBα then re-inhibits NF-κB and, 
thus, forms an auto negative-feedback loop, which results in oscillating levels 
of NF-κB activity[16]. 
 
As a family member of "rapid-acting" primary transcription factors, NF-κB is 
normally present in cells in an inactive state and does not require new protein 
synthesis for its activation. This allows NF-κB to act as a "first responder" to 
hazardous cellular stimuli. NF-κB is commonly activated within minutes by a 
variety of stimuli, e.g. inflammatory cytokines (TNF-α and IL-1), T-cell 
activation signals, growth factors, phorbol esters (TPA) and stress inducers[3]. 
NF-κB is also activated by chemical and physical cytotoxic agents like 
chemotherapeutic drugs, oxidative stress, UV light and ionizing radiations[3]. 
 
1.2.2.1 The native inhibitors of NF-κB 
In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by 
IκBs which are proteins that contain multiple copies of an inhibitory sequence 
called ankyrin repeats. By virtue of their ankyrin repeat domains, the IκB 
proteins mask the nuclear localization signals (NLS) of NF-κB proteins and 
keep them sequestered in an inactive state  in the cytoplasm[17]. 
 
IκBs are a family of related proteins that have an N-terminal regulatory 
domain, followed by six or more ankyrin repeats and a PEST domain near 
their C terminus. The IκB family consists of IκBα, IκBβ, IκBγ, IκBε, and Bcl-3 
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(Fig.1.1), the best-studied and major IκB protein is IκBα. Phosphorylation at 
Ser32 and Ser36 sites of IkBα by IKK complex leads to polyubiquitination of 
IkBα at sites Lys21 and Lys22. Consequently, IkBα is degraded by the 26S 
proteasome resulting in the release of NF-κB dimers[18,19]. p105 and p100 also 
function as IκB proteins, due to the presence of ankyrin repeats in their C-
terminal . Of all the IκB members, IκBγ is unique in that it is synthesized from 
the nf-kb1 gene using an internal promoter, thereby resulting in a protein that 
is identical to the C-terminal half of p105[20]. The c-terminal half of p100, that 
is often referred to as IκBδ, also functions as an inhibitor[21].  
 
Different IκB molecules might control the regulation of distinct genes in 
various tissues by inhibiting specific NF-κB subsets. IκBγ is associated with 
p65 and to a lesser extent with c-Rel, whereas IκBα and IκBβ associate with 
p65, but not c-Rel in endothelial cells. IκBα is associated with transient NF-κB 
activation, whereas IκBβ is involved in sustained activation[22-24]. These make 
IκB attractive target for specific therapies. 
 
IKBs have different affinities for individual Rel/NF-κB complexes, and are 
expressed in a tissue-specific manner[25].  The best-studied NF-κB-IκB 
interaction is that of IκBα with the NF-κB p50-RelA dimer.  This interaction 
blocks the ability of NF-κB to bind to DNA and results in the NF-κB complex 
being primarily in the cytoplasm due to a strong nuclear export signal in 
IκBα[26]. Due to the IκBα gene containing functional NF-κB sites in the 
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promoter region, transcriptional activation of IκBα expression by NF-κB leads 
to rapid re-synthesis of IκBα protein and blockade of NF-κB nuclear 
translocation[27,28]. This auto-regulatory loop is both sensitive to and rapidly 
influenced by NF-κB activating stimuli[29]. That is, the NF-κB-IκBα complex is 
continuously shuttling between the nucleus and the cytoplasm, but its rate of 
nuclear export exceeds its rate of import and thus the complex is generally 
cytoplasmic. Biochemical studies and direct structural determinations showed 
that IκBα makes multiple contacts with NF-κB. These interactions cover 
sequences of NF-κB that are important for DNA binding[26]. In contrast, when 
IκBβ interacts with the NF-κB complex, the complex is retained in the 
cytoplasm and does not undergo nucleo-cytoplasmic shuttling[30].  
 
1.2.2.2 The NF-κB activation pathways 
In normal unchallenged cells, NF-κB remains in the cytoplasm as an inactive 
form by binding to IκB proteins. Activation of the NF-κB is initiated by the 
degradation of IκB proteins via activation of the IκB kinase (IKK). The IκB 
kinase enzyme complex is part of the upstream NF-κB signal transduction 
cascade. The IKKs complex consists of at least three subunits, including the 
kinases IKK-α, IKK-β and IKK-γ. IKKγ, also termed NF-kappa B essential 
modulator (NEMO), is a "master" regulatory protein. IKK resides at a key 
convergence site for multiple signaling pathways that lead to NF-κB 
activation[31]. When activated by signals, usually coming from the outside of 
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the cell, the IKK phosphorylates two serine residues located in an IκB 
regulatory domain. The phosphorylated IκB molecules (e.g. serines 32 and 36 
in human IκBα) are modified by polyubiquitination and then degraded by 
the26S proteasome[32]. Although much has been learned since its discovery, 
the precise mechanism of NF-κB activation is still far from fully understood. 
There are three signaling pathways leading to NF-κB activation: classical, the 
alternative pathways[8], in which common regulatory step is the activation of 
an IκB kinase (IKK) complex, and the IKK-independent pathway (Fig. 1.2). 
Classical activation pathway 
The classical pathway is typically triggered by ligand binding to TNFα, T-cell 
receptors (TCR), B-cell receptors (BCR), the Toll-like receptor (TLR) or 
interleukin-1 receptor (IL-1R) superfamily members. These stimuli can trigger 
the phosphorylation and activation of β subunit of IkB Kinases (IKK). IκBα is 
phosporylated by IKKβ at 2 serine residues (Ser32 and Ser36) present in their 
N terminal[33,34]. Phosphorlation triggers polyubiquitination at sites equivalent 
to Lys21 and Lys22 of IκBα and degradated by 26S proteasome, releasing free 
NF-κB (RelA/p50) dimmers to the nucleus[18]. 
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Figure 1.2: NF-κB activation pathways. 
(a) the classical pathway (b) the alternative or IKKα – dependent pathway and (c) the 
IKK-independent pathway of activation. TNF: tumour necrosis factor, IL: interleukin, 
NEMO: NF-κB essential modulator, IKK: IκB kinase, NIK: NF-κB inducing kinase, CK: 
casein kinase. Adapted from Viatour et al[2]. 
. 
  
Alternative pathway 
Apart from the above pathway, there is another pathway which is involved in 
the specific activation of RelB/p52 heterodimers and is not required for 
activation of the more ubiquitous RelA/p50 dimers. Unlike the classical 
pathway, the alternative pathway is based on IKKα homodimers[35]. The 
p52/p100 protein binds to RelB through its amino-terminal RHD and keeps the 
dimer in the cytoplasm through its carboxy-terminal IκB-like domain. The 
activated IKKα dimers induces the degradation of the latter and results in the 
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nuclear entry of p52:RelB dimers[35]. Only a small number of stimuli are known 
to activate NF-κB via this pathway and these factors include LTβR, 
lymphotoxin B and B cell activating factor (BAFF) and CD40L via NF-κB 
inducing kinase (NIK)[36].  
IKK-independent pathway  
The activation of NF-κB by this pathway is independent of IKK and is based 
on activation of casein kinase 2 (CK2) which induces IκBα degradation 
through the phosphorylation of carboxy-terminal sites[37]. This pathway only 
plays a minor role in physiological NF-κB activation and might contribute to 
skin carcinogenesis[37].  
 
1.2.2.3 The biological roles of NF-κB 
Different members of the NF-κB/Rel family have distinct functions and various 
NF-κB proteins play pivotal roles in defense of the host against certain 
pathogens. Studies in knockout mice have shown that lack of RelA leads to 
embryonic lethality and liver degeneration[38]; whereas mice lacking p50 or 
RelB are immunodeficient but otherwise develop normally to adulthood[39]. 
The B cells from p50 knockout mice show abnormal mitogen responses and 
antibody production[40]. RelB plays a role in the development and 
differentiation of dendritic cells and a mutation disrupting RelB impairs antigen 
presentation[41]. Other NF-κB proteins, including C-Rel and p52, are also 
essential for normal immune function. Unlike either of the corresponding 
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single knockout mice, p50/p52 double knockout mice exhibit impaired 
development of osteoclasts and B cells[42]. 
 
1.3 NF-κB and apoptosis 
For every cell, there is a time to die, this programmed cell death known as 
apoptosis. Apoptosis is important in controlling cell number and proliferation 
as part of normal development. Normal cells undergo apoptosis in response 
to stress-inducing events in the cell, such as DNA damage. Dysregulation of 
apoptosis is critical for cancer development and tumour cell survival[43]. The 
apoptotic cell death program is carried out by intracellular protease enzymes 
called caspases that destroy a large set of cellular proteins important for cell 
viability. There are two types of caspase activation pathways, intrinsic and 
extrinsic[4,44], leading to apoptosis.  
 
The intrinsic apoptosis pathway is triggered by p53 tumour-suppressor in 
response to DNA damage and other types of severe cell stress[45]. p53 
activates the intrinsic pathway through transcriptional upregulation of pro-
apoptotic members of the BCL2 family including PUMA, NOXA, BAX and BAK 
leading to the release of cytochrome c from the mitochondria. Cytochrome c 
binds APAF1 forming an “apoptosome” that activates the apoptotic protease 
caspase 9. Caspase 9 activates the effector caspases 3, 6, and 7 which are 
responsible for destroying critical components of the cell and inducing 
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apoptosis (Fig.1.3). In contrast with PUMA, NOXA, BAX and BAK, the anti-
apoptotic members of the BCL2 family, e.g. BCL2, BCLXL, and MCL1, 
regulate the mitochondria-initiated caspase activation pathway by preventing 
the release of cytochrome c in the presence of apoptotic stimuli[46]. Failure of 
cancer cells to enter apoptosis often through p53 mutations, which are 
identified in more than half of human cancers[47], can result in resistance to 
chemotherapy and radiotherapy[48,49]. 
 
The extrinsic apoptosis pathway triggers apoptosis independently of p53 in 
response to pro-apoptotic ligands, e.g. Apo2L/TRAIL[50]. These ligands 
activate specific pro-apoptotic receptors, like DR4 and DR5. Ligand-induced 
activation of DR4 and DR5 leads to the recruitment of the adaptor Fas-
associated death domain (FADD) and initiator procaspases 8 and 10 to 
rapidly form the death-inducing signalling complex (DISC). The self-cleaved 
and activated procaspase 8 and 10 activate the effector caspases 3, 6, and 7 
which will trigger apoptosis (Fig. 1.3)[4,51]. 
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Although the stimuli and initiating caspases are different, both intrinsic and 
extrinsic apoptosis pathways converge to a final common pathway involving 
the activation of effector caspases. Moreover, there can be cross-talk between 
these two. Caspase 8 cleaves the pro-apoptotic BCL2 family member BID, 
which in turn engages the mitochondria through BAX and BAK, leading to 
activation of caspase 9 and further activation of caspases 3, 6, and 7[4,45].  
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Figure 1.3:  Apoptosis pathways 
These are regulated by proteins such as the p53, NF-κB. APAF1: apoptotic protease 
activating factor-1, BAX: BCL2-associated protein, FADD: Fas-associated death 
domain protein, Cytc: Cytochrome c. 
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NF-κB transcription factors have been shown to have a role in regulating the 
apoptotic program, either as essential for the induction of apoptosis or, 
perhaps more commonly, as blockers of apoptosis[52]. Whether Rel/NF-
kappaB promotes or inhibits apoptosis appears to depend on the specific cell 
type and the type of inducer[15]. In response to many normal physiological 
stimuli (such as TNF), NF-κB is activated and suppresses apoptotic potential 
through the transcriptional activation of genes whose products block 
apoptosis[52]. The Antiapoptotic genes activated by NF-κB include the cellular 
inhibitors of apoptosis (c-IAP1, c-IAP2, and IXAP), the TNF receptor–
associated factors (TRAF1 and TRAF2), the Bcl-2 homologue A1/Bfl-1 and 
IEX-IL[5,6,53,54].  
 
Under physiologic conditions, the activation of NF-κB  appears to be a very 
strong antiapoptotic signal in the TNF pathway[55-57]. It has been demonstrated 
that the activity of NF-κB prevents TNFα-mediated apoptosis in 
hepatocytes during normal liver regeneration[58] and during embryonic 
liver development[59]. However, in response to certain stimuli, NF-κB activation 
may lead to induction of apoptosis[60]. This may be explained by the activation 
of some proapoptotic proteins such as interferon-regulated factor-1, c-myc 
and caspases such as caspase1[4]. NF-κB may inhibit apoptosis by cross-
competing for transcriptional coactivators and antagonizing the function of 
p53[61].  
 18
Cell cycle is a critical element in determining the degree of cellular apoptosis 
and proliferation. Components of the cell cycle machinery are frequently 
altered in human cancer. As malignant cells develop, both genetic and 
epigenetic mechanisms commonly affect the expression of cell cycle 
regulatory proteins, causing overexpression of cyclins and loss of expression 
of cdk inhibitors[62]. NF-κB activates the expression of cyclin D1, a key 
regulator of G1 checkpoint control, by direct binding to the NF-κB binding sites 
in its promoter[63]. Inhibition of NF-κB activation can reduce cyclin D1 activity 
and subsequently result in delayed cell cycle progression[64].   
  
1.4 NF-κB and human diseases 
As a ubiquitously distributed transcription factor, the status of NF-κB activity 
influences the development and treatment outcomes of many human 
diseases. 
 
1.4.1 NF-κB and carcinogenesis 
 Constitutive activation of the NF-κB pathway is involved in some forms of 
cancer such as leukemia, lymphoma, colon cancer and ovarian 
cancer[65].  Cancer and inflammation had been first associated in the 1850s by 
Rudolf Virchow[66,67] who hypothesized a very strong link between the site of 
chronic inflammation and origin of cancer. Numerous types of cancers have 
been associated with chronic inflammation[68,69]. As an inflammatory related 
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and inducible transcription factor, activation of NF-κB and subsequent 
production of chemokines, cytokines, growth factors and anti-apoptotic 
proteins has been related to the carcinogenesis, progress and therapeutic 
outcomes of different kinds of cancers (Fig. 1.4). One of the most important 
factors that link NF-κB to carcinogenesis is reactive oxygen species (ROS). 
Implication of ROS in carcinogenesis has long been established. ROS 
activate NF-κB activity in the cells therefore we can frame the role of NF-κB in 
carcinogenesis[70]. Role of NF-κB as an oncogene is also very well studied 
and established in line with its ability to induce growth promoting genes, e.g. 
cyclin D1, c-myc and c-myb[71] and also its ability to promote cell survival by 
inducing anti-apoptotic genes such as c-IAP1, c-IAP2 and XIAP[72] (Fig. 1.4). 
Some other oncogenes also mediate their effects by activation of NF-κB. The 
oncogene Ras modulates cancer cell apoptosis by regulation of NF-κB 
pathway in pancreatic and prostate cancers[73]. Pim2 is another oncogenic 
kinase which promotes cell survival by activating NF-κB[74]. Her/Neu is an 
oncogene activated in most of the invasive breast cancers. The activated 
Her/Neu activates NF-κB pathway via the Akt pathway[75]. Therefore, NF-κB is 
important for survival of cancer cells and mediates aggressive tumour 
phenotype. Although the maintenance of appropriate levels of NF-κB activity 
is a critical factor in achieving normal cellular proliferation, constitutive NF-κB 
activation is likely involved in the enhanced growth properties seen in avariety 
of cancers. The potential applications of inhibition of the NF-κB pathway in 
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cancer chemotherapy are in their early stages. However, such approaches 
offer the promise of enhancing the efficacy of cancer chemotherapy and 
reducing abnormal cytokine production, which may contribute to the growth of 
certain tumours. A better understanding of the regulation of the NF-κB 
pathway may provide opportunities for the development of new treatments to 
inhibit prolonged activation of this pathway.  
Although NF-κB activation in most circumstances is tumour-promoting, it can 
also be tumour suppressive in certain genetic conditions (Fig. 1.4). The p53-
dependent pro-apoptotic effect of NF-κB has been demonstrated in some 
cancer cell lines[76] and has been well reviewed[77].  
 
Figure 1.4: The tumour promoting and suppressing effects induced by NF-κB  
Light green boxes: Tumour promoting activities of NF-κB. Light purple boxes: Tumour 
suppressing activities of NF-κB. In most circomstances, NF-κB is a tumour promoter. 
Only in some cell types with specific genetic backgrounds, NF-κB demonstrates tumour 
activating effect. 
 
1.4.2 NF-κB and other disease 
NF-κB transcription family plays a central role in immune and inflammation 
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response through its ability to induce genes regulating immune and 
inflammatory responses[78]. These genes include at least 27 different 
cytokines and chemokines coding genes, receptors involved in immune 
recognition such as members of the MHC, proteins involved in antigen 
presentation, and receptors required for neutrophil adhesion and migration[79]. 
Intriguingly the NF-κB induced cytokines, e.g. TNFα and IL-1, are also very 
strong NF-κB inducers. This mutual stimulating relationship establishes a 
positive autoregulatory loop which magnifies the inflammatory response and 
lead to chronic inflammation[41]. NF-κB also is a transcriptional regulator of 
HIV[78]. Two NF-κB binding sites in the HIV long terminal repeat (LTR) have 
been proposed to be involved in viral transcription and replication[80]. It has 
been reported that HIV infection induces NF-κB activation. The activated NF-
κB may play several roles in HIV infection: to promote viral replication, prevent 
virus-induced apoptosis and mediate the immune response to the invading 
pathogen[81].  
 
1.5 Cancer chemotherapy 
1.5.1Overview of cancer 
Cancer is a major cause of morbidity in the world. More than one in three 
people will be diagnosed  with cancer during their lifetime and one in four will 
die from cancer[82]. Cancer occurs when cells in part of body begin to grow out 
of control. Generally, production of new cells is regulated to keep the number 
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of any particular type cell constant. In the case of cancers, the new cells grow 
unregulated and give rise to clones of cells that can expand to a considerable 
size and develop into a tumour. The benign tumour is confined to a few cell 
layers and does not invade surrounding tissues. Cancer is a malignant tumour 
which infiltrates the surround normal tissues and also tends to metastasize to 
invade distant organs. Among over 200 different types of cancers, lung, breast, 
colorectal and prostate cancers account for over half of all cases diagnosed[83]. 
 
1.5.2 General strategy of cancer treatment 
The strategy of solid tumour treatment highly depends on the stage of a 
certain cancer. The stage of cancer is a descriptor of the scale of cancer cell 
spread. The tumour stage is based on the size of a tumour, the involvement of 
the lymph nodes and the distance metastasis. There are several different 
systems for cancer staging. The Duke's classification system is the original 
staging system[84]. TNM (Tumour, Node, and Metastisis) is another solid 
cancer staging system developed by American Joint Committee on Cancer 
(AJCC)[85]. Treatments for cancer include conventional therapy (surgery, 
radiotherapy and chemotherapy) and biological therapy. Surgery is the 
original and still remains as the major therapeutic measure for those tumours 
at earlier stages. Radiotherapy involves using high energy radiation to locally 
eradicate cancerous cell while sparing normal ones. It is mainly used, in 
combination with surgery and/or chemotherapy, for non-metastatic or 
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recurrent cancer treatment. It is often used prior to surgery to reduce the size 
of a tumour, or after surgery to destroy any remaining cancer cells, and to 
relieve symptoms. 
 
1.5.3 Conventional cancer chemotherapy 
Although surgery is the primary option for solid cancer treatment, the systemic 
chemotherapy is the major means for the treatment of advanced cancer 
patients. The major chemotherapeutic principle is the use of cytotoxic drugs to 
destroy cancer cells by preventing cancer cells from further multiplying. In the 
last several decades, cancer treatment outcomes have been significantly 
improved by chemotherapy, in combination with surgery and/or 
radiotherapy[86-88]. 
 
1.5.3.1 Conventional chemotherapeutic drugs 
There are around 50 different anti-cancer drugs which can be subdivided into 
several groups based on their chemical structures and anti-cancer 
mechanisms. The majority of anti-cancer drugs can be broadly classified into 
5 catagories, e.g. antimetabolites, topoisomerase inhibitors, alkylating 
agents, anthracyclines and plantalkaloids[89]. All of these drugs affect cell 
division or DNA synthesis.  
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1.5.3.1.1 Antimetabolites 
Antimetabolites are a class of drugs that interfere with DNA and RNA growth 
by substituting for the normal building blocks of RNA and DNA. These agents 
target S phase cells. They are commonly used to treat a broad range of 
cancer types e.g. leukemias, tumours of the breast, ovary and the intestinal 
tract, etc. 5-Fluorouracil (5-FU) and gemcitabine are the representative agents 
in this group.  
5-fluorouracil (5-FU) 
5-FU is most widely used and studied anti-cancer drug. It has been used in 
the treatment of various kinds of tumours including colorectal, pancreatic, 
breast and ovarian cancers over 40 years and remains as a cornerstone 
therapeutic agent[90]. 5-FU is an analogue of uracil in which the hydrogen 
atom in position 5 of uracil is replaced by the similar sized atom of fluorine 
(Fig. 1.7E) and designed to occupy the active sites of enzyme targets thereby 
blocking metabolism in malignant cells. 5-FU was first invented based on the 
insightful observation that rat hepatoma tumours incorporate uracil into DNA 
to a significantly greater extent than corresponding normal tissue[91]. Some 
scientists postulated that a chemically modified uracil molecule might be 
effective in disrupting tumour DNA biosynthesis. 5-FU acts by the formation of 
FdUMP which is an inhibitor of thymidylate synthase (TS) which involved in 
synthesis of DNA. Normally, in the presence of the cofactor 5, 10 methylence 
tetrahydro folate (MeTHF) serving as the methyl donor, TS and dUMP form a 
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ternary complex which enables transfer of methyl group onto dUMP to form 
thymidine 5’-monophosphate (dTMP). Following 5-FU exposure and adequate 
FdUMP formation, the methyl transfer does not take place because the 
fluorine atom in 5 position of FdUMP is more tightly bound than hydrogen. TS 
is then trapped in a slowly reversible ternary complex. The formation of dTMP 
is therefore blocked. As a consequence, the cancer cells will die from the lack 
of thymidine 5’-triphosphate (dTTP) for DNA replication and repair[92] (Fig. 1.5).  
5-FU is toxic to all human cells undergoing DNA synthesis but displays its 
selectivity by targeting rapidly cycling tumour cells. It mainly exerts its anti-
cancer effects in the S-phase (inhibition of DNA synthesis) and G1-phase 
(incorporation of 5-FU derivatives into RNA). Therefore 5-FU also introduces 
cell cycle disturbance in cancer cells. 5-FU induces G1/S phase checkpoint 
block and inhibits cancer cells to traverse into S-phase[93]. Cell cycle 
progression is regulated by cyclin dependant kinases (CDKs). 
Phosphorylation of retinoblastoma (Rb) family proteins by activated CDKs 
results in release of transcription factors that cause cell cycle progression. Rb 
is phosphorylated by cyclin D1 and CDK4/6 in the early G1 phase. The 
phosphorylation of Rb by CDK2 is aided by cyclin E in the late G1 phase, with 
the release of the transcriptional factor, E2F. There is an up-regulation of 
cyclin E and down-regulation of cyclin D1 in 5-FU treated cells. This results in 
an inactivation of G1 regulator cyclin D1/CDK4 and increased binding of p21, 
a cyclin dependant kinase inhibitor (CKI), to CDK4. Increased p21-CDK4 
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binding causes release of cyclin E/CDK2 in the late G1 phase. Thus the 
alteration of p21, cyclin D1 and E, and augmented binding of p21 to CDK4 
induce G1-S phase arrest by 5-FU[94].      
 
Gemcitabine (2´, 2´-difluorodeoxycytidine, dFdC) 
dFdC is a deoxycytidine analogue which differs structurally from other cytidine 
analogues, like cytosine arabinoside (Ara-C), by the presence of fluorine 
substitutes at 2´ position of furanose ring (Fig. 1.6)[95]. It was first synthesized 
in the 1980s by Eli Lilly Inc., Indianapolis, IN[96] as an antiviral agent. 
Extensive research and observation led to the discovery of its anti-
tumourogenic properties. Consequently it has been an area of research for 
numerous years and today it is an effective single agent in the treatment of 
metastatic pancreatic cancer[97] and in combination chemotherapy in non-
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Figure 1.5: The 5-fluorouracil metabolism pathway  
MeTHF: methylence tetrahydro folate. TS 5-FU inhibits DNA Synthesis by trapping TS in 
a slowly reversible ternary complex (lower part of figure). 5-FU can also inhibit RNA 
synthesis (upper part of figure).  
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small cell lung[98], bladder[99] and breast cancers[100]. It has also been used for 
other cancers like ovarian cancer, mesothelioma and head and neck cancers. 
 
 
Inside the cell dFdC is first phosphorylated to its monophosphate (dFdCMP) 
by deoxycytidine kinase (dCK), followed by subsequent phosphorylations that 
yields its active forms, gemcitabine diphosphate (dFdCDP) and triphosphate 
(dFdCTP)[101] (Fig. 1.6). Phosphorylation of dFdC by dCK is considered to be 
the rate limiting step for further phosphorylation of active metabolites. dCK 
deficiency is therefore considered to be a form of acquired and intrinsic 
resistance mechanism to dFdC in numerous cancers[102] (Fig. 1.6). dFdC is 
also phosphorylated by thymidine kinase 2 (TK2), a mitochondrial enzyme, 
Figure 1.6: Mechanism of action of dFdC and possible resistance inducing targets.  
Dotted brackets indicate possible mechanism of resistance. GEM: gemcitabine, DA: 
deaminases, NTs: nucleoside transporters, EP: efflux pumps, dCK: deoxycytidine kinase, 
5´NT: 5´nucleotidase, P: phosphate, RR: ribonucleotide reductase, CTP: cytosine 
triphosphate.  
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although substrate specificity of TK2 is quite low as compared to that of dCK 
and its role in dFdC tumour toxicity is yet to be defined[103]. 
 
dFdC mainly arrests cells in S-phase and induces secondary apoptotic cell 
death[104] although its killing effects are not limited to S-phase of cell cycle and 
equally effective against confluent cells and cells in log phase growth[105]. 
dFdC has multiple intracellular targets. Its antiproliferative activity mostly 
depends on numerous inhibitory actions of DNA synthesis. dFdCTP competes 
with dCTP as a weak inhibitor of DNA polymerase (Fig. 1.6). Once penetrating 
DNA it waits for incorporation of one or more nucleotides which leads to DNA 
polymerization termination and a single strand breakage[106]. The addition of 
the ‘extra’ nucleotide and its non terminal position in the DNA chain protects it 
from detection and repair by DNA repair enzymes (masked chain termination) 
locking the drug in a penultimate position in DNA[107]. dFdCTP is presumably 
also known to incorporate into RNA resulting in inhibition of RNA synthesis 
(Fig. 1.6). The exact molecular events of this RNA incorporation are yet fully 
elucidated but the effect is reported to be cell line, time and concentration-
dependent[108]. dFdCDP, on the other hand, inhibits the enzyme ribonucleotide 
reductase (RR) (Fig. 1.6), which is increased in many of the in vitro[102] and in 
vivo[96] models of acquired dFdC resistance. RR supports the reduction of 
ribonucleotides to their corresponding deoxyribonucleotides necessary for 
DNA synthesis and DNA repair. Its inhibition leads to depletion of dCTP, a 
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potential dCK inhibitor, resulting in more efficient phosphorylation of dFdC[96]. 
Other reported activities of dFdC metabolites that increase accumulation of 
dFdC in the cell and reduce its metabolism (self-potentiation) include 
depletion of dCTP pools by dFdCTP which, in turn, increases the 
incorporation of dFdCTP in the DNA. Increased concentration of dFdCTP 
directly affects dCMP-deaminase with a consequent decrease in dFdC 
catabolism[109,110].  
 
1.5.3.1.2 Topoisomerase inhibitors 
Topoisomerases convert a superhelical DNA to a less twisted, covalently 
closed form during DNA replication. There are two topoisomerases, e.g. 
topoisomerases I and II. Topoisomerase inhibiting drugs prevent religation of 
DNA by stabilizing the covalent topoisomerase-DNA complex. Therefore 
targeting topoisomerases can block DNA replication and induce double-strand 
(topoisomerase I inhibition) and single-strand (topoisomerase II inhibition) 
DNA break in cancer cells[111]. Topoisomerase I inhibitors arrest cells in the 
G2/M phase[112]. The typical topoisomerase inhibitors include irinotecan (CPT-
11), topotecan, etoposide (VP16) and teniposide.  
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Topotecan (Fig. 1.7A) is a topoisomerase I inhibitor[113]. Topotecan is known 
to have cytotoxic properties against lung, breast and ovarian cancers[114]. 
Topotecan transforms from a closed ring lactone form that predominates at pH 
less than 4 to an open ringed hydroxyl form which predominates at pH greater 
than 10[115]. It is the pharmacologically active lactone form that inhibits DNA 
topoisomerase I. 
 
Etoposide (VP-16; Fig. 1.7B) is a commonly used antineoplastic drug used in 
Figure1. 7: The chemical structure of anti-cancer drugs 
(A) Topotecan, (B) Etoposide, (C) Doxorubicin, (D) Lomustine and (E) 5-Fluorouracil. 
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the treatment of various kinds of cancer like testicular cancer, small-cell lung 
cancer and several other malignancies[116,117]. It inhibits DNA topoisomerase 
II[118]. The chemical structure of etoposide is composed of a semi-synthetic 
glucoside derivative of podophyllotoxin. 
 
1.5.3.1.3 Anthracyclines  
Anthracyclins are anti-tumour antibiotics that interfere with enzymes involved 
in DNA replication. These agents work in all phases of the cell cycle. Thus, 
they are widely used for a variety of cancers. Examples of anthracyclines 
include daunorubicin, doxorubicin, epirubicin and idarubicin. 
 
Doxorubicin (Adriamycin; Fig. 1.7C) is a representative anthracyclin widely 
used in the chemotherapy of solid tumours, lymphomas and leukemias[119]. It 
is considered as the most effective therapeutic agent for breast cancer 
chemotherapy[120]. The anti-cancer mechanisms of doxorubicin are 
multifactorial. It inhibits DNA topoisomerase II. Doxorubicin consists of a 
planar anthraquinone nucleus attached to an amino-containing sugar. The 
planar ring inserts perpendicularly to the long axis of the double helix, 
between two DNA base pairs, with the amino sugar linked to the sugar-
phosphate backbone through hydrogen bonds. It may also alter membrane 
fluidity, ion transport and hence biochemical equilibria by binding to cell 
membrane. Doxorubicin is also known to cause DNA damage by generating 
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semiquinone species that can lead to production of free radicals and hydroxyl 
radicals. Cytoplasmic and nuclear proteinase complexes called proteasomes 
can degrade proteins through non-lysosomal mechanisms and are involved in 
modulating the activity of doxorubicin[119]. The 26S proteasome is believed to 
play an important role in processing and degradation of regulatory proteins 
involved in the control of cell growth and metabolism[121,122]. Doxorubicin is 
transported by the proteasome to the nucleus of the cells through a series of 
steps. After diffusing into the cancer cells, doxorubicin binds to the 20S 
proteasomal subunit in the cytoplasm. An ATP-dependent process then drives 
this complex into the nucleus through nuclear pores. Due to its higher affinity 
to DNA, doxorubicin dissociates from the proteasome and binds to DNA[123]. 
Doxorubicin binds as reversible non competitive inhibitor of protease to the 
allosteric site of the chymotrypsin-like protease activity of 20S proteasome[124]. 
This causes accumulation of undergraded proteins that signal apoptosis. 
 
 1.5.3.1.4 Alkylating agents  
Alkylating agents involve reactions with guanine in DNA. These drugs add 
methyl or other alkyl groups onto molecules where they do not belong. This in 
turn prevents the cancer cell from reproducing. As a class of drugs, they work 
in all phases of the cell cycle. Alkylating agents are commonly used to treat 
acute and chronic leukemia, lymphoma, Hodgkin’s disease, multiple myeloma 
as well as cancers of the lung, breast and ovary[125]. Lomustine (CCNU) is one 
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of the alkylating agents (Fig. 1.7D). 
 
1.5.3.2 The major limitations of conventional chemotherapy 
Although the outcomes of cancer treatment have been significantly improved 
by chemotherapy in the last three decades, the clinical success of cancer 
chemotherapy has been severely hindered by the high non-specific toxicity to 
the vital tissues and organs and de novo and acquired chemoresistance. 
 
1.5.3.2.1 Chemoresistance 
The resistance of cancer cells to chemotherapeutic drugs is one of the major 
limitations for its clinical use. Resistance to anti-cancer drugs can be either 
intrinsic (present in the cancer cell before treatment) or acquired after 
treatment. Apart from resistance to the drugs being administered, cancer cells 
can also develop cross-resistance to many other drugs with different 
moelcular structures and intracellular targets. This phenomenon is known as 
multiple drug resistance. The molecular targets and metabolic pathways are 
widely different for different anti-cancer drugs. Therefore the molecular 
chemoresistant mechanisms also vary for different anti-cancer drugs. The 
major chemoresistant mechanisms are as follows. 
 
 Altered expression and/or activity of drug efflux pumps  
Two genes code for the formation of proteins that are involved in the transport 
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of drugs out of the cell. Multiple drug resistance gene（MDR1） codes for P-
glycoprotein (Pgp)[126] and multidrug resistance-associated protein gene 
codes for multidrug resistance-associated protein (MRP)[127]. The 
overexpression of Pgp, a member of the ATP-binding cassette family[128], is 
responsible for the energy dependent efflux of numerous chemotherapeutic 
drugs including etoposide and doxorubicin[129-131]. Topoisomerase inhibitors 
can induce the overexpression of breast cancer resistance 
protein/mitoxantrone resistance/placenta-specific ATP binding cassette 
(BCRP/MXR/ABCP), a member of the ATP-binding cassette (ABC) family of 
transporter proteins, in human tumour cells[132]. The decreased accumulation 
of the drug due to the enhanced efflux by the energy dependent pump may 
result in resistance to the drug. Another member of the ABC transporter family, 
Mrp4, has the ability to transport numerous compounds including organic 
anions as well as antiviral and retroviral compounds that find it difficult to 
penetrate the central nervous system[133-135]. Topoisomerase I inhibitors like 
topotecan is also one of the substrates for Mrp4. Thus Mrp4 overexpression is 
believed to block drug penetration in tumour cells and confer resistance to 
them against these drugs[136]. 
  
Metabolizing and conjugating enzymes 
The human body is exposed to a wide array of xenobiotics in one’s lifetime 
from food components to environmental toxins to pharmaceuticals.The 
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glutathione S-transferase enzyme system is naturally present in the body as a 
detoxification mechanism[137]. When cancer cells are exposed to anti-cancer 
drugs, the levels of these enzymes increase. The enzymes combine with the 
drugs, forming a complex called a conjugate that is less toxic and 
ineffective[138]. It has been reported that glutathione-S-transferase (GST) is  
responsible for resistance to alkylating agents[139]. The thiolate moiety of the 
tripeptide glutathione is believed to play a role in detoxification by 
nonenzymatic conjugation with alkylating agents[140] resulting in a more water 
soluble and less toxic product.  
 
Topoisomerase is a nuclear enzyme responsible for many aspects of DNA 
functioning, so it is a target of many anti-cancer drugs. In order to be effective, 
the drug must form a three-way complex with the enzyme and DNA. Anything 
that interferes with the formation of this complex will result in resistance. 
Previous studies have reported resistance to topoisomerase inhibitors due to 
the presence of an altered topoisomerase in the resistant cells[141,142]. 
 
Amplification of nuclear DNA-binding enzymes 
The vitamin folic acid assumes a primary role in the synthesis of DNA. Since 
rapidly dividing cancer cells have a great demand for DNA synthesis, anti-
cancer drugs were developed that target the synthetic pathway. 5-flurouracil 
blocks the action of thymidylate synthase. It has been observed that 5-FU 
 36
resistant tumours express high TS protein levels indicating this as the cause 
of poor prognosis of 5-FU-based chemotherapy in colorectal cancer 
patients[143]. There are other enzymes like uridine phosphorylase and orotate 
phosphorybosyltransferase that can metabolize 5-FU[144]. Hence the cause of 
resistance could also be TS independent.  
 
Mismatch repair deficiency  
There is an accumulation of cells in G2 phase associated with cytotoxicity of 
alkylating agents in MMR-dependent manner[145]. The MMR system thus limits 
the replication of cells that have been targeted by drug-induced mispairs and 
cannot be repaired. One of two heterodimers of MutS homologues are 
involved in mismatch recognition. hMutS-α (heterodimer of hMSH2 and 
hMSH6) is involved in binding to mismatches and small insertion/deletion 
loops while hMutS-β (heterodimer of hMSH2 and hMSH3) binds to the larger 
insertion/deletion loops[146]. Cells with a defective MMR are resistant to the 
alkylating agents as they do not arrest in G2 phase. There is a 100-fold higher 
sensitivity observed in mammalian cells with a proficient MMR than MMR 
deficient counterparts[147].  
 
Modulation of the antiapoptosis pathways 
p53 can transcriptionally activate bax, a bcl-2 family member that promotes 
apoptosis. Mutations in the p53 gene and dysregulation of p53-dependent 
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cellular processes are often associated with cancer and resistance to radio- 
and chemotherapy[148-151]. One biological property of p53 that can explain 
these findings is its ability to promote apoptosis in response to anti-cancer 
drugs[152]. Many Advances have been taken to reconstitute the (wildtype) p53 
tumour suppressor pathway or restorate p53 function by targeting mutant p53 
in cancer cells[153]. It has been found that NF-κB also involve in drug 
resistance through regulates expression of an array of endogenous apoptosis 
inhibitors[154]. To date, there is no completely satisfying explanation for the 
development of multiple drug resistance. It is apparent that in many cases 
there is a coordinated involvement of many systems. 
 
 1.5.3.2.2 Dose-limiting toxicities  
Apart from resistance of cancer cells to anti-cancer drugs, the toxicity of the 
chemotherapeutic drugs to normal tissues is another obstacle for the clinic 
application. Chemotherapy drugs attack proliferating cells with very limited 
distinguishing effect on cancer and fast growing normal cells, such as those in 
the bone marrow and digestive system. The non-specific killing effect 
contributes to all the side effects introduced by chemotherapy. Different drugs 
cause different side effects and different individual might suffer different side 
effects[155]. The most common side effects include suppression of 
haemopoiesis, nausea, vomiting, hair loss, fatigue and diarrhea which 
seriously limit the continuation of chemotherapy. When cancer cells become 
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resistant to drugs, the anti-cancer drug doses must be increased; a large dose 
drug can lead to severe multiorgan toxicities. 
 
1.5.4 Targeted chemotherapy 
As researchers have come to learn more about the inner workings of cancer 
cells, they have begun to create new drugs that attack cancer cells more 
specifically than traditional chemotherapy drugs can. These drugs target 
different properties that set cancer cells apart from normal cells. Most of them 
attack cells with mutant versions of certain genes, or cells that overexpress 
Growth factors, cytokines and ligands[156]. They often have less serious side 
effects than those commonly caused by chemotherapy drugs. For example, 
protein kinases are frequently mutated in human malignancies. Imatinib is the 
first and typical member of a new class of agents that act by inhibiting 
particular tyrosine kinase enzymes, instead of non-specifically inhibiting 
rapidly dividing cells[157]. Preclinical studies using NF-κB inhibitors and 
proteasome inhibitorshave demonstrated that these agents inhibit cancer cells 
growth as well. Now geno-projects  determine  more effective and harmless 
therapeutic methods for every cancer patients by the individual difference of 
pharmacogenetics and molecular biology. The new strategy is dependent on 
the general analysis for the personal life science from pharmacokinetics, 
pharmacodynamics, and oncogenomics[158]. 
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1.5.5 Prodrug chemotherapy 
Various researchers have proposed utilization of biochemical modulators. A 
biochemical modulator is a pharmacological agent designed to enhance the 
biological effect of the chemotherapy, either by selectively increasing the anti-
tumour action or by selectively protecting the host. Prodrugs have been 
developed for cancer treatment to reduce non-specific toxicity. A prodrug is a 
compound which is not originally cytotoxic but can be converted to the active 
forms in cancer cells by some cancer specific enzymes after 
biotransformation in human body. In theory, prodrug can specifically target 
cancer cell and spare normal tissues and improve therapeutic index[159].  
 
1.5.6 NF-κB pathway and chemotherapy 
Chemotherapy has been shown to be of benefit to improve survival in patients 
with cancer. However, its clinical application has been limited due to acquired 
or inherent resistance observed in cancer cells. Although numerous factors 
have been identified, the molecular mechanisms for drug resistance are still 
not fully elucidated. It has been found that NF-κB regulates expression of an 
array of endogenous apoptosis inhibitors, like c-IAPs, X-IAP, c-FLIP, A1/Bfl-1, 
and IEX-1L[154], membrane stabilizing proteins, like Bcl-2 family members or 
adapter molecules that trigger antiapoptotic pathways on death receptors and 
mitochondrial pathway[72]. It acts against the apoptosis induced by 
chemotherapeutic drugs, ionizing radiation and death ligands thus promoting 
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tumour growth and reduced anti-cancer effect[7,160]. An elevated basal activity 
of NF-κB is held responsible for resistance against topoisomerase I and II 
inhibiting drugs[161]. While constitutive activation, which has been observed in 
solid tumours, is seen in the resistant phenotype[162]. The controversy remains 
whether the chemoresistance induced by basal or constitutive NF-κB is 
determined by the type of cell and/or anti-cancer drug. Based on these 
previous studies and fundamental principles, inhibition of NF-κB pathway is 
currently being pursued to improve cancer therapeutic efficacy. Many natural 
substances have been found to downregulate NF-kB production, including 
curcumin[163], green tea[164], resveratrol[165]. Wang et al. used Disulfiram (DS) 
to directly downregulate the activity of NF-κB and to improve cytotoxity of 5-
FU[166]. Cusack et al. used the proteasome inhibitor PS-341 to inhibit 
degradation of IκB enhancing the chemosensitivity of CPT-11[167]. Weiver et al. 
used constructed adenovirus vector, super-repressor IκBα-SR to block the 
degradation of IκB and enhance chemotherapy response[168]. Moreover, 
various pharmacological substances (e.g. thalidomide, bortezomib, 
sulphasalazine) have already entered clinical studies partially showing 
promising results for certain types of cancer[169,170]. 
 
NF-κB inhibitor and Chemosensitizers 
The systemic toxicity caused by high dose-chemotherapy and drug resistance 
is the major obstacle for the success of cancer chemotherapy. Therefore, 
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development of low toxicity or non-toxic chemosensitizers to enhance the anti-
cancer effect of conventional chemotherapeutic agents and reverse 
chemoresistance is an area of significant interest in cancer research and 
oncology. Inhibition of NF-κB activation has been shown to be a useful 
strategy for increasing the sensitivity towards cytostatic drug treatment in vitro 
and in vivo. Many drugs have been investigated for the application as 
chemosensitizers, in which two clinically used non-caner-therapeutic drugs, 
Disulfiram (DS) and triptolide (PG490), manifest strong anti-tumour and 
chemosensitizing activity. Development of a novel anti-cancer drug normally 
take up to 15 years and cost an average of US$ 897 million[171]. Therefore 
translation of old drugs into their novel anti-cancer applications becomes more 
and more attractive to scientists and oncologists. 
 
Disulfiram is a member of the dithiocarbamate family and an aldehyde 
dehydrogenase inhibitor. DS has been used in clinic as an anti-alcoholism 
drug[172] for over 60 years. In the recent years, the anti-cancer activity of DS 
has been demonstrated in several institutions. It has been known to exhibit its 
anti-tumour activity in a number of cell lines including human melanoma 
cells[173], human colorectal cancer cell lines[166], prostate cancer cells[174] and 
human breast cancer cells[175]. DS can also enhance the cytotoxicity of certain 
anti-cancer drugs like 5-FU[166], cyclophosphamide[176] and nitrogen 
mustard[177]. It can enhance the sensitivity of Pgp transfected cells to 
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vinblastine and colchicine by inhibiting the maturation of Pgp[178].  
 
The molecular anti-cancer mechanisms of DS are still not fully elucidated. It 
has been reported that DS strongly inhibits cancer angiogenesis[179,180]. It also 
inhibits the activities of NF-κB, AP-1 and bcl-2 and induces G1/S arrest and 
apoptosis in human hepatoma cells[181]. The anti-cancer effect of DS may be 
induced by its pro-apoptotic redox-related mitochondrial membrane 
permeabilization[173] activity. The complexation of DS and Zn resulting in 
inhibition of Zn2+-dependent matrix metalloproteinases[180]. The complexation 
of DS and Cu results in inactivation of Cu/Zn superoxide dismutase[179] and 
hence decreased production of reactive oxygen species. DS is believed to be 
active and in the two-electron oxidized form of diethyldithiocarbamate, 
capable of inducing apoptosis, when it is in a complex with Cu2+[182]. DS has 
the potential to react with sulfhydryl groups and hamper the functioning of the 
enzymes containing them[183] . Hence sulfhydryl groups on NF-kB are also a 
probable target of DS[166]. DS is also a DNA topoisomerase[184] and 26S 
proteasome inhibitor[185]. The proteasome is an important agent that plays key 
roles in cellular signalling. Cancer cells are more dependent on proteasomal 
activities and angiogenesis than normal cells[186-188]. Proteasome inhibition 
seems to influence cancer cells more than normal cells. One of the reasons 
for this observation is believed to be because of the anti-cancer induced 
activation of NF-κB, which aids in tumour promotion, survival and metastasis. 
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This factor helps the proteasome inhibitors to selectively target malignant cells 
in cancer therapy[189,190]. It is also known that cancer cells possess high 
amounts of copper in vivo[191]. Thus therapeutic strategies exploiting these 
characteristics can selectively target cancer cells. Because of these reasons, 
DS is believed to have the potential to efficiently target cancer cells. DS has 
displayed a biphasic pattern of response to cytotoxic dose regarding cell 
viability and NF-κB inhibition in many cell lines[192,193]. The caspase inhibition 
by thiol oxidation achieved by DS[194] is believed to play a role in this 
observation of biphasic pattern, where DS might inhibit proteasome in lower 
doses and inhibit caspases in higher doses[195]. 
 
PG490 was extracted from the Chinese medicinal herb, Tripterygium wilfordii 
Hook F (TWHF), a member of the Celastraceae family. Historically, the 
extracts of TWHF have been used for more than two centuries in traditional 
Chinese medicine to treat a variety of autoimmune and inflammatory diseases 
including rheumatoid arthritis[196]. Biochemical analysis has shown that 
Tripterygium contains a vast array of natural products with strong biological 
activities, which may explain its multiple uses in traditional and allopathic 
medicine. Recently, it was reported that PG490, a purified compound from 
Tripterygium, possessed anti-tumour properties and induced apoptosis in a 
broad range of solid tumours and leukemic cells[197-199]. PG490 also 
potentiates the activities of other agents and therefore may be useful not only 
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as a single compound but also in combination with other cytotoxic drugs for 
cancer treatment. For example, triptolide sensitized tumour necrosis factor -
resistant tumour cells to tumour necrosis factor –induced apoptosis[200]  and 
showed cooperative  proapoptotic effects with doxorubicin[201]. PG490-88, a 
water-soluble prodrug of PG490, is converted to PG490 in the serum[202], can 
cause tumour regression of lung and colon tumour xenografts also acts in 
synergy with CPT-11 to cause tumour regression. A phase I trial of PG490-
88 for solid tumours began recently. 
 
Despite the recognized potent anti-tumour activity of PG490, the exact targets 
and function (or molecular mechanism of action) of PG490 are still unknown. 
So far it is only known that PG490 blocks TNF-kB–mediated induction of c-
IAP1 and c-IAP2 and inhibits expression of the PMA-induced genes tumour 
necrosis factor-α, IL-8, macrophage inflammatory protein-2α, intercellular 
adhesion molecule-1, integrinβ6, vascular endothelial growth factor, 
granulocyte-macrophage colony-stimulating factor, GATA-3, fra-1, and 
NF45[203]; PG490 inhibits constitutively expressed cell cycle regulators and 
survival genes cyclins D1, B1, and A1, cdc-25, bcl-x, and c-jun. and reduces 
expression of cell cycle regulators and survival genes such as cyclins D1, B1, 
A1, cdc-25, bcl-x c-jun[203]. PG490 also inhibits the activation of NF-
KB[200,203,204] pathway to induce caspase activation[197,205]. 
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It was reported that PG490 direct cancer cells to undergo apoptosis in p53 
independent manner. This attracts many scientists attention. Because many 
chemotherapeutic drugs use p53-mediated pathways to induce growth arrest 
and apoptosis, the dysfunction of p53 may partially explain the resistance of 
cancer to drug treatment[206]. The tumour suppressor protein p53 responds 
to different forms of cellular stress such as DNA damage caused by ionizing 
radiation or chemotherapeutic drugs by targeting the checkpoint genes that 
inhibit cell cycle progression and/or trigger apoptosis[207]. In combination with 
chemotherapeutic drugs PG490 enhanced apoptosis through signaling 
pathways involving both p53 and p21[201]. 
 
1.6 Gene-directed enzyme prodrug therapy 
1.6.1 Human cancer gene therapy 
Despite improvements in surgery, radiotherapy and chemotherapy for cancer 
treatment the overall five year survival is still relatively low. Therefore, novel 
treatments need to be developed in order to add to the therapeutic 
armamentarium. Since scientists discovered the molecular structure of genes 
and the molecular basis of numerous human diseases, they were fascinated 
by the possibility of treating certain diseases by transfer of foreign DNA into 
the affected cell. The foreign DNA could either replace defective genes, or 
code for therapeutic proteins. This concept is named gene therapy[208]. Gene 
therapy is a rapidly developing research field for cancer treatment. Recent 
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studies divide cancer gene therapy into four major areas: transfer of tumour 
suppressor genes to block tumour cell proliferation; transfer of  genes 
encoding cytokines and stimulatory markers to enhance immunogenicity 
against tumour; transfer of suicide genes that convert inactive prodrugs into 
compounds that are cytotoxic to a tumour or transfer of drug-resistance genes 
into haematopoietic stem cells to increase their resistance to 
myelosuppressive chemotherapeutic agents minimizing toxicity to the 
patient[209]. All these strategies aim to selectively destruct human malignant 
disease while avoiding the destruction of non-malignant cells and tissues 
thereby minimizing toxicity to the patient. A number of apoptosis-inducing 
proteins encoding genes e.g. p53, p202, Fas, E1A, BAX, Bik and PEA3 have 
been used for this approach. Introducing the suicide genes under the control 
of cancer specific promoter systems will specifically express these proteins in 
cancer cells and induce cancer apoptosis. In combination with chemotherapy, 
this strategy showed improvement of cancer treatment outcome. The 
weakness of this strategy is that only the transfected cells can be targeted. 
Because of the low transfection rate, especially in vivo, it is impossible for 
using this procedure to completely eliminate cancer cells especially those 
metastatic cancer cells[210].  
 
1.6.2 Gene-directed enzyme prodrug therapy 
Over the last five years the most exciting developments in cancer gene 
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therapy have come in the field of gene directed enzyme prodrug therapy 
(GDEPT). Fig 1.8 shows the general principle of GDEPT. Cancer GDEPT is 
involved in 2 major steps. In the first step, a cDNA encoding drug-activating 
enzyme under the control of a cancer specific promoter is introduced into 
cancer cells where it will produce an active enzyme. In the second step, a 
non-toxic prodrug, a substrate of the exogenous or cancer specific enzyme, is 
administered systemically. In theory, GDEPT should have two main 
advantages. First, the local expression of an activating enzyme ensures that 
the peripheral toxicity often associated with chemotherapy is reduced[211]. 
Second, the use of a relatively harmless prodrug ensures that high doses can 
be administered to the patient, resulting in high concentrations of the cytotoxic 
drug being produced in vicinity of the tumour. Following the death of the 
tumour cell, the cytotoxic drug may be able diffuse into neighbouring cells and 
kill them, a phenomenon known as the bystander effect. The bystander effect 
ensures that it is not necessary to transfect all of the cells in the tumour. It has 
actually been shown that 100% cell death can be achieved in vitro following 
transfection of only 10% of the cells. GDEPT is comprised of three 
components: the prodrug to be activated, the enzyme (usually nonhuman) 
used for prodrug activation and the delivery system for the corresponding 
gene[212].  
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There are several GDEPT systems which have been investigated for use in 
cancer gene therapy are listed in Table 1.1. The enzymes proposed for 
GDEPT falls into two categories. The first comprises foreign enzymes of 
nonmammalian origin, with or without human homologues. Examples are viral 
tyrosine kinase (TK), bacterial cytosine deaminase (CD), carboxypeptidase 
G2 (CPG2), purine nucleoside phosphorylase (PNP) and nitroreductase (NR). 
The second category consists of enzymes of human origins that are absent or 
expressed only at low concentrations in tumour cells, such as deoxycytidine 
kinase (dCK) and cytochrome P450[213]. The human homologues of enzymes 
Vector 
Tumour 
Enzyme 
encoding gene 
Nontoxic 
Prodrug 
enzyme 
Toxic drug Toxin spreads to 
neighboring cells 
Figure 1.8: Principle of gene-directed enzyme prodrug therapy (GDEPT) 
 An appropriate vector (typically viral) is used to deliver a prodrug-activating enzyme 
coding gene into tumour cells. The subsequently administrated prodrug will be 
converted into a toxic metabolite in the transduced cells. The active drug will 
selectively kills the cancer cells.The surrounding untransfected cancer cells might 
also be killed following prodrug activation.  
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in the first category have different substrate structural requirements than the 
foreign enzymes have. Their main disadvantage as therapeutic agents may be 
the potential to elicit an immune response in humans, although this may 
actually provide benefits to therapy. Enzymes of the second category are 
unlikely to induce immune responses, but their use will in most cases lead to 
some prodrug activation in normal cells.  
Table 1.1 Enzyme-prodrug combinations for suicide gene therapy[214] 
Enzyme Prodrug Product Mechanism 
HSV-tk Gancidovir Gancidovir triphosphate Blocks  DNA  synthesis 
Cytosine deaminase 5-Fluorocytosine 5-Flurouracil(5-FU) Pyrimidine antagonist; blocks DNA and RNA synthesis 
Nitroreductase Nitobenzyloxycarbonyl anthracylines Anthracyclines DNA crosslinking 
Carboxylesterase CPT-11 SN38 Topoisomerase inhibitor 
Cytochrome P450 Cyclophosphamide Phosphoramide mustard 
DNA alkylating agent; blocks 
DNA snthesis 
Purine nucleoside 
phosphorylase 6-Mercaptopurine-DR 6-Mercaptopurine 
Purine antagonist; blocks DNA 
synthesis 
 
HSV1-Tk/GCV system 
The first GDEPT system described was the thymidine kinase gene of the 
Herpes Simplex virus (HSVtk) in combination with the prodrug, Ganciclovir[215]. 
Thymidine kinase (TK) isolated from herpes simplex virus 1 (HSV1) is the 
most intensely studied prodrug-activating enzyme and has been used 
extensively in both preclinical and clinical studies to treat some solid tumours. 
Ganciclovir and acyclovir are guanosine analogues that are poorly 
metabolized by mammalian cellular TK. The TK from HSV1 can convert 
ganciclovir to an intermediate which in turn is converted to di- or tri-
phosphates by celluar kinases and hence incorporated into DNA. The 
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phosphorylated ganciclovir can only kill dividing cells. The active proliferation 
of cancer cells provides the selectivity in cancer cells. The HSV-TK/GCV 
system also shows excellent bystander killing effect as both local due to the 
diffusion of GCV and host immune system mediated forms are active and 
could even result in immune mediated tumour regression in distant 
metastases[216,217] . 
 
Cytocine deaminase (CD)/ flurocytosine (FC) 
This is the second widely studied suicide gene/prodrug system. FC is an 
antifungal non toxic agent. CD is a bacterial/fungal gene that produces 
cytosine deaminase that can convert FC to 5-FU[218]. CD/FC therapy has been 
studied in a wide variety of cancers, most notably in CRC using CEA promoter. 
Phase I trial of CD driven by tumour specific erbB2 promoter in breast cancer 
showed significant level of CD expression. Moreover It also has strong 
bystander killing effect due to the diffusion of 5-FU and do not require gap 
junctions which are usually absent in cancerous condition[219]. 
 
Thymidine phosphorylase (TP)/5’-DFUR 
TP is identical in structure and function to tumour-associated angiogenic 
factor and platelet-derived endothelial cell growth factor[220]. It induces 
neovascularization and prevents tumour cells from entering apoptosis. TP 
expression correlates with fast malignant growth, aggressive invasion 
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potential, and poor patient prognosis. TP play a crucial role in activation of 
capecitabine. However, it is only detected in 24% to 66%[221] of tumours with 
5-FU resistant tumours expressing even lower levels[222]. Consequently, 
insufficient conversion of CAP into 5-FU currently is a major limitation of CAP-
based chemotherapy. A human breast cancer cell line transfected with the 
human TP cDNA yielded cells with 165-fold increased sensitivity to 5’-DFUR 
over the parental line. Strong promoters such as CMV have been used to 
increase TP expression in cancer cells and demonstrated enhanced 
cytotoxicity of 5’-deoxy-5-fluorocytidine (5-FC) and 5’-DFUR in vitro and in 
vivo. But, the lack of specificity of these promoters limits the clinical 
development of GDEPT strategies. 
 
1.6.2.1 Prodrugs 
There are several prodrugs have been investigated along with their activing 
enzymes as list in Table 1.1. The prodrugs of 5-FU will be reviewed in detail 
as it was used in this study. 
 
Prodrugs of 5-FU 
5-FU has been used in cancer chemotherapy of over 5 decades and confered 
a survival benefit  over supportive care[223]. But there are a lot of side effects 
derived from non-specific killing effect e.g. myelosuppression and 
gastrointestinal disorders (diarrhea, nausea, vomiting) due mainly to 
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phosphorylation of 5-FU in the digestive tract for example[224]. Hand-foot 
syndrome, stomatitis and neuro- and cardiotoxicities are associated 
with continuous infusions. Other adverse effects associated with both bolus-
dose and continuous-infusion regimens include nausea and vomiting, diarrhea, 
alopecia and dermatitis[159].  
 
Several prodrugs of 5-FU have been developed to diminish toxicity and 
enhance activity. All prodrugs of 5-FU are characterized by a pyrimidine ring 
with a fluoride in position 5. They are designed to be well absorbed intact from 
the gastrointestinal tract and subsequently enzymatically converted into 5-FU 
in the liver or within the tumour itself in order to expose the tumour to 5-FU for 
a longer time but at lower concentration than those observed after 
administration hence minimizing toxicity.   
 
FdUrd (5-Fluoro-2’-deoxyuridine), the first generation of 5-FU prodrug, is 
more efficiently metabolized by the liver than 5-FU. Hence, it is mainly used to 
treat liver metastases of colon cancer by hepatic arterial administration. Even 
if severely compromised by the FdUrd induced hepatoxicity, it has been 
demonstrated in a meta-analysis of randomized trials that hepatic arterial 
administration of FdUrd is superior in terms of response rate and survival to 
intravenous treatment[225].  
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5’-deoxy-5-fluorouridine (5’-DFUR) is the second generation of 5-FU 
prodrug and has a molecular structure consisting of a molecule of 5-FU to 
which a pseudopentose is bonded in position 1. Rationale for its development 
has been the need of the enzyme TP, a tumour-associated angiogenesis 
factor[226], for cleavage and activation into 5-FU. The high level of this enzyme 
in tumours and in the intestinal tract compared with normal tissues left hope 
for an enhanced selectivity. The first clinical trials of 5’-DFUR with an 
intravenous administration has indicated good activity for colorectal cancers[91]. 
The main limitation of 5’-DFUR derives from its gastrointestinal toxicity, 
attributed to liberation of 5-FU in the small intestine under the action of 
thymidine phosphorylase (TP)[227]. 
 
Capecitabine (Xeloda, CAP) is the third generation and oral version of 5-FU 
prodrug. Its molecular structure is N4-pentyloxycarbonyl-5’-deoxy-5-
fluorocytide (Fig. 1.9). CAP was designed as an oral formulation and 
circumvents the unacceptable toxicity of the second generation prodrug 5’-
DFUR. CAP was designed as a prodrug of 5’-DFUR that could not be 
metabolized by TP in the intestine. After oral administration, CAP crosses the 
gastrointestinal barrier intact and is rapidly and almost completely absorbed, 
diarrhea should not thus occur with its use[228]. It is subsequently converted 
into 5-FU in a three-stage mechanism involving several enzymes (Fig. 1.9). In 
the first step, it is metabolized into 5’-deoxy-5-fluorocytidine (5’dFCR) by a 60 
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kDa carboxylesterase in the liver. 5’dFCR is then deaminated into 5’-DFUR by 
cytidine deaminase mainly localized in liver and tumour tissues. Finally, 5’-
DFUR is transformed into 5-FU under the action of TP, an enzyme with higher 
activity in tumour than in normal tissues[229,230]. Higher levels of 5-FU are thus 
produced within tumours with minimal exposure of healthy tissue to 5-FU.  TP 
is identical to the angiogenic agent ‘platelet derived endothelial cell growth 
factor’ (PD-ECGF)[220].  
 
Figure 1.9: Structure and metabolic pathway of capecitabine.  
CE: Carboxylesterase; CD: Cytidine deaminase. Capecitabin is converted into 5-FU in 
three-stage mechanism. 5’-DFUR could be converted into 5’-DFUR either in liver or 
tumour cell. 
 
CAP was rationally designed to provide an oral therapy. Oral administration 
enables convenient, patient-oriented and home-based therapy. An additional 
advantage, which makes CAP an attractive compound, is its assumed 
targeting of tumour tissue[231]. The proposed accumulation of 5-FU in tumours 
by metabolic targeting has been confirmed by measurement of 5-FU 
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concentrations in colorectal cancer tissue compared with adjacent normal 
tissue[232]. Its activity and safety had already been tested in two large phase III 
trials. Van et al found a significant difference in the patientsresponse rate to 
CAP and FU/LV (26% for CAP VS 17% for FU/LV). However, medium overall 
survival time (12.9 months vs 12.8 months) was not significant improved[233]. 
CAP is currently approved for first-line treatment of metastatic colorectal 
cancer and is now commercialized in Europe as a momotherapy. The major 
adverse events associated with CAP were mild to moderate in severity, with a 
particularly low incidence of alopecia and myelosuppression compared with 
FU/LV. The most common side effects of CAP are: diarrhea, nausea, vomiting, 
stomatitis (sores in mouth and throat), abdominal (stomach area) pain, upset 
stomach, constipation, loss of appetite and dehydration[234]. 
 
Targeting tumour tissues by CAP may result in a favorable balance of 
treatment efficacy and toxicity. Tumour specific high level TP expression 
would potentially enables the enrichment of 5-FU in tumour cells while 
reducing exposure of normal tissues. However, TP is only detected in 24% to 
66%[221] of tumours with 5-FU resistant tumours expressing even lower 
levels[222]. Consequently, insufficient conversion of CAP into 5-FU currently is 
a major limitation of CAP-based chemotherapy.  Since the conversion of CAP 
to 5-FU is mediated by TP, the combination of CAP with agents that 
upregulate TP concentrations in tumour tissue offers the potential to improve 
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efficacy further[235,236]. 
 
Although, in theory, prodrug should have two main advantages, which may 
translate into an improved therapeutic index, there are some drawbacks which 
limit the success of prodrug-based cancer treatment. Firstly, in some tumours, 
the prodrug activating enzymes are not expressed at high levels. This will limit 
the conversion of prodrugs to their active counterparts and reduce the 
therapeutic effect. Secondly, the prodrug-catalyzing enzymes are not solely 
expressed in cancer cells. They are also expressed in some normal tissues, 
normally at lower levels. The expression of these enzymes in normal tissues 
will introduce non-specific systemic toxicity. Thus, increasing these prodrug-
catalyzing enzymes in cancer cells is an approach to improve the therapeutic 
effect of prodrugs for cancer chemotherapy[237].  
 
1.6.2.2 Delivery systems 
To date, clinical trials have focused on the delivery of genes specifically to the 
tumour site by intratumoural injection using both viral and nonviral delivery 
agents. A number of strategies are now being developed. These include 
exploitation of natural viral tropisms, such as those exhibited by adenoviruses 
to target lung epithelium, retargeting viruses using a bispecific molecule to 
simultaneously block native receptor binding, redirecting virus to a tissue-
specific receptor, genetically modifying the virus to ablate native receptor 
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interactions and incorporating a novel ligand into one of the virus’ coat 
proteins and using tissue-specific ligands or monoclonal antibodies 
incorporated onto the surface of liposomes to direct them to target cells[238,239]. 
Some non-virus delivery systems have developed as well. However, none of 
these systems is really cancer specific. 
  
1.6.2.3 Cancer specific promoter systems 
GDEPT may be considered as using gene therapy to improve conventional 
chemotherapy. In theory GDEPT should have two main advantages e.g. the 
high cancer specificity and the effect of bystander killing which may translate 
GDEPT into an improved therapeutic index. The greater selection of GDEPT 
is due to use tissue or tumour specific promoters so that the transgene is only 
expressed in tumour cells and not in the surrounding tissue. For instance, 
since cERB2 is overexpressed by the majority of breast tumours the cERB2 
promoter has been used in a clinical trial of cytotoxic gene therapy for 
metastatic breast cancer[240]. Similarly the CEA promoter can be used to 
improve specificity of gene expression for colorectal cancer[241].The CEA 
promoter is inactive in hepatocytes but active in colon-derived malignant cells. 
The selectivity of CEA has been proved by comparing the effects of two 
adenovirus constructs carrying the gene for HSVtk with either a CEA promoter 
or the ubiquitously activated cytomegalovirus (CMV) promoter. The Ad.CEA-tk 
construct allowed expression of HSVtk within the metastatic tumours while the 
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Ad.CMV-tk construct led to widespread expression of HSVtk within both the 
metastases and the surrounding liver. However, the CEA promoter is much 
less effective than CMV leading to a 30% reduction in HSVtk expression 
despite increasing the dose of adenovirus. This balance between selectivity 
and effectiveness epitomizes the problems faced by many gene therapy 
strategies. A similar strategy has been reported using the cytosine deaminase 
(CD) gene and treatment with 5-fluorocytosine (5-FC) for the treatment of 
mice with colorectal cancer xenografts[242]. When the CD gene is under the 
control of a CEA promoter the tumour regression and survival rates are 
improved with a lower incidence of bone marrow suppression compared with 
those treated with CD under the control of an SV40 promoter[243].  
  
Promoters and enhancers 
Gene expression is regulated by a complex interaction of factors to produce 
diverse effects. Promoter is a DNA sequence that enables a gene to be 
transcribed. Promoter includes the region of transcription start and the 
adjacent upstream region of about several tens of nucleotides. One promoter 
is found in all genes that produce proteins. The core or basal promoter 
contains a sequence of 7 nucleotides, TATAAAA, which is named TATA box. 
Apart from the basal promoter, there are ubiquitous upstream promoter 
sequences which attract other sequence-specific transcription factors (e.g. 
TFIIB and TFIIA) and help construct the transcription complex. Different genes 
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are thus regulated by different promoters and combinations of transcription 
factors even though transcription factors are shared among genes within the 
cell. Enhancer is a short region of DNA that can be bound with transcription 
factors to enhance transcription levels of genes in a gene-cluster. An 
enhancer does not need to be particularly close to the gene it acts on, and 
need not be located on the same chromosome. Enhancers can be located 
upstream, downstream, or even within the gene they control. It enhances  the 
level of transcription depends on the type of tissue, developmental stage, 
stage of the cell cycle, induction by hormones or other molecular signals. 
Cellular promoters that are preferentially activated under certain conditions 
like diseased states as well as novel molecular adaptations of these 
promoters have been harned to drive transgene expression in the target cell 
population. Promoters which are using for cancer therapy can be spilt into 
subgroups of tissue-specific promoters, tumour-specific promoter depending 
on their discrete characteristics.  
 
Tissue-specific promoters 
Tissue-specific promoters are using to exploit genes that are switched on only 
in certain tissues. A panel of tissue-specific promoters is currently used in 
cancer gene therapy. For instance tyrosinase is used for 
melanocytes/melanoma[244]. Similarly prostate-specific antigen is used for 
prostate[245]. One of the main limitations of this type of promoter is that 
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transgeneexpression may lead to cytotoxic effects in normal as well as tumour 
tissue derived from that same cell type. Therefore, the use of such promoters 
must be restricted to tissues in which damage is not critical for the survival of 
the host, e.g. prostate, melanocytes or thyroid. If the tissue/organ is critical, 
then the transgenes must be delivered directly to the tumour site to prevent 
normal tissue toxicity or be delivered with retroviruses which are less efficient 
at infecting nondividing slowly proliferating normal tissues, such as the liver. 
 
Tumour-specific promoters 
Tumour-specific promoters can be subdivided into cancer-specific promoter 
and tumour-specific promoter depending on discrete characteristics. 
 
General cancer-specific promoters 
A common problem with the use of the tissue-specific promoters is that 
transgene expression can also occur in the normal tissue hence tissue 
damage may happen not only in certain acceptable organs but also in organs 
such as brain and liver.  
 
The most attractive cancer promoter nowadays is telomerase promoter. In 
cells, to prevent the loss or mutation of essential genes, the end of each 
chromosome is tied up by a special strand of DNA called a telomere. each 
successive round of cell division, telomeres progressively decrease in length, 
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loosing up to 200 base pairs of terminal DNA from the tips of their 
chromosomes[246]. The more times a cell divides, the shorter the telomere 
becomes and ultimately after a limited number of cell divisions, the length of 
the telomere becomes so short that the cell ceases to divide, eventually die. 
Telomerase is a naturally occurring enzyme, that catalyses the extension of 
telomeres in cells. Telomerase is only found to be active in sperm, ovum and 
during the development of the embryo[247]. In these situations it is necessary 
for cells to repair their telomeres. Once the body is fully formed and telomeres 
of sufficient length have been synthesized, the telomerase activity is shut off 
in the majority of cells and their telomeres begin to shorten as they reproduce. 
In germline cells and some other cells involved in the immune system, 
telomerase remains active in order to keep the length of their telomeres 
constant. Telomerase actually comprises of two components, both of which 
are essential for telomerase to be active in a cell. The first component is 
Human telomerase reverse transcriptase (hTERT). hTERT catalyses the 
lengthening of the telomere [248]. The second component is human telomerase 
RNA (hTR) which acts as a template for replication. hTR is approximately 445 
nucleotides long. It has found that approximately 90% of human cancers 
possess active telomerase. Whereas normal somatic tissues have either 
much lower or undetectable activity[249]. This highlights the critical role 
telomerase plays in tumour progression. A number of studies have used these 
two promoters to drive transgene expression for therapeutic benefit. Pan and 
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Koeneman first described the use of the hTERT promoter in a retroviral 
system and combined it with a Cre/loxP site-specific recombination system to 
allow the killing of p53-negative tumour cells while sparing normal wild-type 
cells[250]. Since then, many papers have reported the use of both promoters in 
several different tumour types in combination with several different transgenes.  
 
Limited cancer specific promoters 
Certain types of tumour often overexpress genes of oncofoetal origin that are 
silent in normal tissue. Their promoters are being utilized for transcriptional 
regulation of therapeutic genes. The well-characterised promoters of these 
tumour specific genes are the carcinoembryonic antigen (CEA).  
 
CEA is a cell surface glycoprotein containing approximately 60% 
carbohydrates with a molecular mass of 180 – 200 kDa[251]. The human CEA 
family has been fully characterized. It comprises 29 genes of which 18 are 
expressed in which 7 belong to the CEA subgroup and 11 to the pregnancy 
specific glycoprotein subgroup. The sequence controlling CEA expression has 
been analyzed. Five DNA binding sites (FP1 to FP5) were identified in the 
promoter region of CEA gene[252]. The first 3 elements are essential for 
specific CEA transcription. The promoter regions of the CEA family members 
lack the classical TATA and CCAAT elements. The upstream stimulatory factor 
(USF), Sp1 and Sp1-like transcription factors were identified that bind to these 
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sites and positively regulate the transcription of CEA gene. If counting the 
translational starting point (ATG) as +1, the positions of these DNA binding 
sites are: FP1, -165 - -141; FP2, -207 - -184; FP3, -232 - -211; FP4, -299 - -
276; FP5, -568 - -560. The general schematic structure of promoter region of 
CEA gene is shown in Fig. 1.10. 
 
There is a 2.1 kb transcription enhancer fragment between 4.0 to 6.1 kb 
upstream of the CEA protein translation initiation site[252-254]. 
 
Some years after its discovery, the researchers found that CEA protein could 
be detected in serum from patients with colon cancer and other carcinomas 
using sensitivity radioimmunoassay. Only low or neglectable levels of CEA 
are detected in the serum from healthy individuals and patients with other 
diseases[255]. This created a burst of interest in this tumour marker and CEA 
assays were applied to a number of clinical questions related to diagnosis, 
staging, monitoring and prognosis of carcinomas. The tumour associated 
carcinoembryonic antigen in human colon cancer tissue extract was first 
Figure 1.10: The schematic structure of the promoter region of human CEA gene. 
Translational starting point (ATG), footprint sites (FP1 to FP5). FP1, FP2, FP3 are 
essential for cancer specific CEA transcription. Arrow: transcriptional starting point. 
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- 4 kb - 6.1 kb 
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described by Gold and Freedman in 1965. CEA present in low amounts in 
several types of normal epithelial cells[256]. Its highly increased expression is 
most often associated with colon, stomach, pancreas, lung and breast 
cancers[257]. It has been reported that CEA is heterogenously overexpressed 
in more than 90% of primary CRC[258].  
 
Many studies have shown that the CEA promoter have lead to high-level 
selective expression of transgenes in CEA-positive cell lines. For example, 
comparing the effects of two adenoviral constructs carrying the gene for 
HSVtk with either a CEA promoter or the ubiquitously activated 
cytomegalovirus (CMV) promoter. The construct carrying CEA allowed 
expression of HSVtk within the metastatic tumours while the construct 
containing CMV led to widespread expression of HSVtk within both the 
metastases and the surrounding liver[241]. A similar strategy has been reported 
utilization of the CEA promoter in an adenovirus vector for CD gene 
expression improves the selectivity of 5-FC/5-FU conversion in CEA-
expressing tumours, compared with those treated with CD under the control of 
an SV40 promoter[80]. As shown previously, the expression of suicide genes, 
E. coli CD and HSV-tk, under the transcriptional control of CEA promoter 
sequences, is limited to CEA-positive colon[259], gastric[260], lung[261], 
pancreatic[262] and cholangiocarcinoma cells[263]. In contrast, the CEA-negative 
lung carcinoma cells[261] do not express reporter or suicide genes when their 
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expression is directed by CEA promoter. These data strongly suggest that 
CEA promoter sequences are active only in CEA-positive cells, fulfilling the 
criteria for tumour specific targeting of suicide genes.  
 
Although the use of CEA for targeted gene therapy has demonstrated cancer 
specific. The therapeutic efficacy of tumour-specific gene therapy using the 
CEA promoter may be limited because of the low transcriptional activity of this 
promoter especially in the case of distant metastases[264]. It is shown that the 
CEA promoter is 10-300 times weaker compared to stronger but non specific 
Rous sarcoma virus or cytomegalovirus promoters[265]. This has led to the 
search for more efficient vector system consisting of the promoter and 
enhancer which are expected to increase the expression of therapeutic gene 
while the CEA provide the necessary specificity. It has been reported that 
using a 2.1 kb CEA enhancer (-4.0 - -6.1) in combination with CEA essential 
promoter region, the cancer specific transcriptional activity of CEA promoter 
could be significantly improved. Using this enhancer-promoter cassette, the 
cytotoxicity of 5-FC is significantly enhanced in vitro and in vivo[265]. The 
efficacy of CEA enhancer is CEA gene expression-dependent. In the low CEA 
expression cancer cells, the transcriptional activity of the CEA enhancer-
promoter system remains at very low levels which limit the general use of this 
system for cancer GDEPT. Some researchers have also tried to use cre/loxP 
system to improve CEA promoter activity and it is efficient in some 
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experimental tumours[264]. However, it has recently reported that Cre/Lox-
dependent transcriptional activity is not enhanced relative to the expression 
using cancer specific promoters and CMV activity is not always significantly 
stronger than some cancer specific promoters[266]. Therefore using Cre/Lox-P 
approach, the target cell range is also limited. This balance between 
selectivity and effectiveness is the major obstacle for using CEA promoter-
based prodrug gene therapy in vivo and in clinical trials. 
 
1.7 Project aims 
The clinical application of gene directed enzyme prodrug therapy (GDEPT) is 
severely limited by the lack of cancer specific promoter with strong 
transcriptional activity. In comparison with normal cells, significantly higher 
NF-kB activity is detected in tumour cells. So the first aim of this study was to 
exploit the potential application of high levels of intra-cellular NF-kB activity 
and the relative tumour specificity of the CEA promoter in cancer gene therapy. 
A mammalian cell expression vector with NF-kB-CEA enhancer-promoter 
cassette upstream of the human thymidine phosphorylase (TP) gene coding 
sequence was constructed. The TP enzyme will be specifically expressed in 
cancer cells and selectively activate the prodrug, 5-DFUR, into its active anti-
cancer derivative, 5-FU, within colorectal cancer (CRC) cells. The effect of this 
enhancer-promoter system on improving the cytotoxicity of 5’-DFUR in cancer 
cell lines in vitro will be investigated. 
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The correlation between high NF-κB activity and 5-FU resistance has been 
reported[154]. The influence of NF-κB in the cytotoxicity of some other anti-
cancer drugs is still largely unknown. The second aim of this study was to 
investigate whether NF-κB activation also plays a part in the chemoresistance 
of breast cancer cells to gemcitabine. 5-FU and dFdC are antimetabolites 
commonly used in oncology. Both drugs share effective therapeutic cancer 
range and with several overlapping molecular targets. The potential cross-
resistance between these two drugs and the potential effect of NF-κB on the 
cross-resistance were also investigated in this project. 
 
Due to the fatal non-specific toxicity of high dose chemotherapy, more 
attention has been paid to development of novel chemosensitizers. 
Chemosensitizer is compound which is non- or low toxic by itself but can 
enhance cytotoxicity of conventional anti-cancer drugs. Because of its 
antiapoptotic effect, NF-κB pathway becomes a very attractive target for 
development of novel chemosensitizers in the recent years. It has been 
reported that both DS and PG490 are effective NF-κB pathway 
inhibitors[166,203]. The third aim of this study is to investigate the 
chemosensitizing effect of DS and PG490 on the cytotoxicity of a panel of 
anti-cancer drugs in human breast, lung and colon cancer cell lines. 
 
 
 68
 
 
 
 
 
 
 
 
 
 
Chapter 2  
Materials and Methods 
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2.1 Materials 
2.1.1 General reagents, enzymes and kits 
Promega UK Ltd., Southampton, UK 
Restriction enzymes apart from Pmel and PacI and associated buffers, pfu 
polymerase, Luciferase assay kit, Gel shifting assay kit, 1Kb DNA ladder, Dual 
Luciferase Assay reagents, Access RT-PCR system  
New England Biolabs  
Pmel and PacI enzymes and associated buffers 
CALBIOCHEM, San Diego, USA 
20S proteasome Fluorometric (AMC) assay kit 
Invitrogen, Paisley, UK 
SeaBlue plus 2 prestained protein markers, G418, Trizol, 10 × TAE buffer 
Amersham Biosciences, UK 
Enhanced Chemiluminescence Western Blot Signal Detection Kit 
Roche Diagnostics Ltd., East Sussex, UK 
Complete EDTA free protease inhibitor tablets, Rapid Ligation kit 
GeneFlow, UK 
30% acrylamide:bis-acrylamide (37.5:1), 10 × Transfer buffer, 10 × 
electricpresis buffer 
Qiagen, West Sussex, UK 
Qiaquik gel extraction kit, Qiafilter maxiprep kit, Qiafilter miniprep kit 
 
 70
Bio-Rad, UK 
DC Protein Assay Kit 
ERIE SCIENTICFIC Company Portmouth.N.H., US 
Microscope slide 
Millipore, Hertfordshire, UK  
PVDF (polyvinylidene difluoride) membrane  
Sigma, Dorset, UK 
Methanol, Isopropanol, Glycine, HEPES, Sodium chloride, Thymidine, 
KH2PO4, Sodium hydroxide, DTT, EDTA, Nonident p40, Ethidium Bromide, 
Agarose, LB broth, polydIdC (PdIdC), APS(Ammonium persulfate),Triton X-
100, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] MTT 
Tween20, Tris base 
FUJI Corporation Japan 
FUJI X-ray film 
 
2.1.2 Antibodies  
Novocastra, UK  
Anti-thymidine phosphorylase mouse monoclonal antibody 
Sigma, Dorset, UK 
Anti-vinculin monoclonal antibody, Anti-tubulin monoclonal antibody, Anti-CEA 
monoclonal antibody, FITC-conjugated anti-mouse IgG 
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Amersham Biosciences, UK 
Horse radish peroxidase conjugated secondary anti-mouse and anti-goat 
antibodies  
Santa Cruz Biotechnology Inc 
NF-κB/ p50, p65, dCK, RRM1, PCNA, p21, Bcl-2, Cyclin D1, Cyclin E, Bax, 
VEGF, Cyclin D3, Cdk2, CdK4 
Neomarkers, Fremont, CA,  
TS (Thymidylate Synthase) 
BD Bioscience, US 
Ki-67 
BD Pharmingen, US 
p53 
BioMoL International, L. P, UK 
PARP (poly(ADP-ribose) polymerase)  
Abcam, Cambridge, UK 
CEA (Carcino Embryonic Antigen) 
 
2.1.3 Pharmacological compounds 
Eli Lilly Inc., Indianapolis, IN, USA  
Gemcitabine 
Sigma, Dorset, UK 
5-FU, 5’-DFUR, Thymine, Thymidine, Disulfirum, Doxorubicin, Topotecan, 
Etoposide 
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2.1.4 Radiochemical 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont UK 
γ[P] 32 dATP 
 
2.1.5 Tissue culture 
American Tissue Culture Collection, Rockville, USA 
Human CRC cell lines: HT29, HCT15, HCT116, LoVo, Caco2, DLD-1, BE  
RKO, 
Human breast cancer cell lines: MCF7, ZR75,  MDA..MB 231  
Lung cancer cell lines: LDAN, NCI-H23, NCI-H125, CALU. 
Fibroblast: LF114, LF152, WI38, EWLU. 
Squamous carcinoma: A431. 
Astrocytoma: G-CCM. 
Clonetics, USA 
Human normal primary cells: HMEC, HUVEC 
PromoCell, Heidelberg, Germany 
Human normal primary cells: HNEpC 
Prof. PG Johnston, University of Belfast 
Colorectal cancer cell lines: H630WT, H630R10 
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Dr Angel Armesilla, University of Wolverhampton, UK  
Human endothelial cell line: EAhy926 
Dr Weiuang Wang, University of Wolverhampton, UK 
NF-κB p50+p65 transfected (MCF-7p50+65,P, P2, C4) and mock 
transfected,(MCF-7pcDNA3) MCF-7 human breast cancer cell line 
Lonza, UK 
RPMI 1640, DMEM (Dulbecco’ Modified Eagle’s Med), L-glutamine, Fetal 
Bovine Serum, Penicillin-Streptomycin, trypsin-EDTA 
Invitrogen, Paisley, UK 
Lipofectamine transfection reagent, Optimem, G418 
Promega UK Ltd., Southampton, UK 
Hygromycin B, Kanamycine 
 
2.1.6 Buffers 
Tris-EDTA(TE) buffer 
Tris                                              10 mM 
EDTA                                           0.1 mM 
pH                                                   7.4 
RIPA buffer(10 x )  
Tris HCL     25mM 
Sodium dodecyl sulphate  0.1%(W/V) 
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Triton-X 100      1%(V/V) 
NaCl               0.15 M 
EDTA       1 mM 
Protease inhibitor cocktail tablet   1/ 10ml 
Separating buffer        
Tris HCl                         181.5 g/l 
SDS                    4 g/l 
pH                     8.9 
Stacking gel buffer       
Tris HCl                              59 g/l 
SDS                     4 g/l 
pH                      6.7 
10 x TBS          
Tris base                   2.422 g 
NaCl                    16.36 g 
Add water to 1 liter,                 
 PH                                                            7.4 
· 1 × TBS-T: 0.5% Tween 20, pH 7.4, prepared from 10x TBS using 
distilled water. 
Buffer A for EMSA 
                                HEPES (pH 8.0)                                              10 mM 
KCl                                                          10 mM 
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EDTA                                                       0.1 mM 
EGTA                                                       0.1 mM 
Dithiothreitol                                               1 mM 
Protionase inhibitor 
BufferC for EMSA 
                                         HEPES (pH 8.0)                                          29 nM 
NaCl                                                       0.4 M 
                                                EDTA                                                    1 mM 
                                                EGTA                                                    1 mM 
                                                Glyerol                                                     5% 
5 × binding buffer  
Tris(pH 7.6)                                            50 mM  
         KCl,                                                    250 mM 
                                               Dithiothreitol,                                          25 mM 
EDTA                                                     5 mM 
                                               Glycerol                                                    25% 
Sorengens glycine buffer  
Glycine                                                    1 M 
NaCl                                                       1 M 
pH                                                         10.7 
2.2 Cell culture 
The human colorectal cancer cell lines RKO, H630, LoVo, CaCo2, DLD-I, 
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HT29, HT15, HCT116 and BE were cultured at 37℃ in a fully humidified 5% 
carbon dioxide atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal calf serum (FCS) supplemented with penicillin (100 U/ml), 
streptomycin (100 μg/ml) and L-glutamine 0.25 mM. EAhy926 was cultured in 
RPMI-1640 with 10% FCS and 100 U/ml penicillin and 100 μg/ml streptomycin. 
The cells were subcultured using a stand trypsin/EDTA method once the cells 
were grown into a confluent monolayer in tissue culture flasks. Briefly the 
growth medium was removed from the cells and phosphate-buffered saline 
(PBS) to remove all traces of serum. Trypsin/EDTA solution dispensed into 
culture vessels to completely cover the monolayer and incubated the cells at 
37℃ for 3 minutes to ensure that cells are detached from the base of the flask 
(this step is only for colorectal cancer cell lines). After this 20 ml fresh medium 
was added to the flask for next passage to grow.  
 
Normal human mammary epithelial cells (HMEC), human primary endothelial 
cells and normal human nasal epithelial cells (HNEpC) were subcultured and 
maintained according to the instructed culture system for each cell. 
   
The human breast cancer parental cell line MCF7wt and NF-κB p50+p65 
transfected MCF-7 (MCF7p50+65; P, P2, C4) and empty vector transfected 
(MCF-7pcDNA3) cell lines generated in our lab by Dr. Weiguang Wang. These 
cell lines were cultured in RPMI 1640 medium  supplemented with, 10% 
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FCS ， 100 U/ml penicillin ，  100 μg/ml streptomycin and appropriate 
concentrations of the selection drugs (MCF-7pcDNA3: G418, 500 µg/ml; 
MCF-7p50+65: G418, 500 µg/ml + hygromycin, 150 µg/ml).  
 
2.3 Cytotoxicity assay 
To evaluate the effect of anti-cancer drugs on cell viability, MTT assay was 
carried out. Cells were cultured in 96-well plates (1 × 104/well) and left 
overnight to allow attachment to the bottom of the wells. Cells were exposed 
to different concentrations of anti-cancer drug prepared by a two times serial 
dilution using medium i.e. 40 µM, 20 µM, 10 µM, 5 µM, 2.5 µM, 1.25 µM, 
0.625 µM, 0.3125 µM. The non-drug treated cells were used as negative 
controls. The spent media was removed from the wells using a fine needle. 
The medium (200 μl) with different concentrations of drug was distributed in 
the each well such that there are 3 wells with same drug concentration and 
cell type in each plate. They were incubated at 37  for 72℃  hours. The media 
was removed and 200 μl of fresh media was added followed by 50 μl of MTT 
(5 mg/ml) was added and the plates are wrapped by the aluminum foil to 
prevent the deterioration of MTT by light. After incubation for 4 hours at 37 , ℃
the solution was removed and 175 μl of 99.9% DMSO and 25 μl Sorensen’s 
glycine buffer was added. The plates were read by a spectrophotometer at a 
wavelength of 540 nm. The readings are tabulated and IC50 of the cell lines 
was calculated form the graph. For the bystander effect test, the pcDNA3 and 
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pcDNA3-TP transfected RKO and H630 cells are mixed at the following ratios: 
0/100, 5/95, 10/90, 20/80, 40/60 and 100/0 and then subjected to MTT 
analysis described above.  
 
2.4 Western blotting 
2.4.1 Sample preparation  
The cancer cells were cultured in T75 flasks until 90% confluent and 
harvested by trypsinization. The cells were collected by centrifugation at 1500 
rpm for 5 minutes and washed with ice-cold 1× PBS. Pellets were then 
washed again with 1 × PBS to remove any traces of medium or trypsin 
followed by total protein extraction using radioimmunoprecipitation (RIPA) 
buffer. Resuspended pellets were subjected to ultrasonication (10 seconds × 
2) and then centrifuged at high speed (14,000 rpm, 10 minutes) to separate 
cell debris. Supernatant was collected and stored at – 20℃ until use. 
  
2.4.2 Assessment of total protein content  
The Bradford (Bio-Rad) Protein Assay (Bradford 1976) was employed to 
determine the total protein concentration of each sample. Standard solutions 
were created from a stock solution of 3.0 mg/ml BSA and RIPA buffer in order 
to create a standard curve. After mixing, 5 µl of each standard and sample 
was pipetted into a 96 well plate, the absorbance read at 650 nm on an Opsys 
MR photometer (Dynex Technologies, West Sussex, UK), and protein 
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concentration calculated by linear regression using Microsoft Excel 
programme. All samples were then normalized by dilution factor. 
 
2.4.3 SDS PAGE electrophoresis   
The protein samples were mixed with distilled water, loading buffer (4 ×) and 
1ul of DTT (1 M) and then incubated at 99℃ for 10 minutes. The samples 
were loaded onto SDS Poly-acrylamide gels along with the protein marker. 
Gels were run at 200 V for 1 hour using 1 x running buffer. 
 
2.4.4 Transfer of proteins onto membrane 
After separated by SDS PAGE, the protein was transferred to PVDF 
(polyvinylidene difluoride) membrane using 1 × transfer buffer containing 20% 
methanol and a semi-dry electrophoretic transfer chamber (Millipore) (20 V, 1 
hour 15 minutes).  
 
2.4.5 Blocking of the membrane  
The 1 × TBS-T supplemented with 5% fat-free milk was used to block the 
membrane for 1 hour along with agitation in order to prevent non-specific 
binding of primary and secondary antibody. Failure to block efficiently can lead 
to high background.  
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2.4.6 Antibody application  
The indicated primary antibodies were diluted in the proper ratio with 5% milk 
and incubated with membranes overnight at 4℃. On the following day, the 
membrane was washed twice in 1 × TBS-T for 10 minutes and incubated with 
second antibodies conjugated with horse radish peroxidase for one to three 
hours with agitation. Before detection of proteins, membranes were again 
washed with 1 × TBS-T two times for 10 minutes.  
  
2.4.7 Signal detection 
The signal was detected by ECL western blotting detection kit. The membrane 
was soaked in ECL solution for 1 minute, briefly dried and wrapped in cling 
film and then exposed to X-ray films.  
 
2.5 Electrophoretic mobility shift assay (EMSA) 
2.5.1 Nuclear protein extraction 
Nuclear extracts were prepared according to the method of Cogswell et 
al.,[267]. Briefly, cultured cells were collected and washed with 1× PBS and 
suspended in 500 µl of ice cold lysis buffer A. Following 15 minutes ice 
incubation 25 µl of 10% NP-40 (nonidet P40 detergent) was added and 
centrifuged. Pellet obtained was resuspended in 1000 µl of the lysis buffer 
and again subjected to microcentrifugation at 2500 rpm, for 5 minutes at 4℃, 
in the absence of detergent. Nuclear pellet obtained was then resuspended in 
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ice cold nuclear extraction buffer C and left on the rotor overnight at 4℃. 
Nuclear extract was microcentrifuged at high speed (14,000 rpm) for 10 
minutes, supernatant (nuclear protein) was stored at - 70℃ until used. Protein 
concentration was determined by Bradford Protein Assay. 
 
2.5.2 Probe labeling  
The oligonucleotide has to be labeled before performing the experiment. DNA 
is radiolabeled by 5´ end labeling using [γ-32P]ATP and T4 polynucleotide 
kinase. According to following protocol: 2 µl of oligonucleotide was placed in a 
DNase, RNase-free eppendorf tube with 1 μl of 10 x reaction buffer, 1 µl of T4 
polynucleotide kinase and ddH2O up to 10 µl, incubated for 1 hour at 37℃. 
The reaction was stopped by adding 1 µl of 50 mM EDTA, then 89 ul of TE 
(pH 7.5), 25 µl of 5M NH4OAC and 250 µl of ethanol were added. The 
reaction mixture was stored at - 20℃ for minimum 2 hours before spinning for 
30 minutes at 13,000 rpm at 4℃. After removing supernatant, the pellet was 
resuspended in 50 µl TE buffer. 
 
2.5.3 Electrophoresis 
The nuclear proteins (5 – 8 μg/reaction) were incubated with 5 × binding 
buffer (50 mM Tris (pH 7.6), 250 mM KCl, 25 mM dithiothreitol, 5 mM EDTA 
and 25% glycerol) and 500 ng/ml of poly dIdC (PdIdC) (for avoiding unspecific 
binding) at room temperature for 10 minutes. After incubation, roughly 20,000 
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cpm of 32P-labeled double stranded hot NF-κB oligonucleotide probe (4 µl) 
(5´-AGTTGAGGGGACTTTCCCAGGC-3´) was added to the prepared sample 
mixtures, mixed well. At the same time, 4 µl of wild-type/mutant (5´-
AGTTGATATTACTTTTATAGGC-3´) unlabelled NF-κB probe was added into 
one sample to note the binding specificity and then all samples were 
incubated for 30 minutes at room temperature before EMSA. All the samples 
were electrophorised on a 5% polyacrylamide gel in 1 × TAE, 200 V for about 
2 hours.  
2.5.4 Signal detection 
Gels were dried using a gel drier and exposed to phophoplates for 
autoradiography. Images were detected using a phosphoimager (Amersham). 
 
2.6 Luciferase reporter gene assay 
2.6.1 Cell culture 
Different cell lines were harvested by trypsinisation and 5 × 104/100 µl of 
medium/well were plated on to 96 well plates. They are allowed to grow over 
night at 37℃. 
 
2.6.2 Transfections using lipofectamine  
On the following day, they were transfected with pGL3-Basic and other 
luciferase vectors (0.2 µg of each vector/well) in triplicate and internal control 
pRL-SV40 (0.002 µg/well) using Lipofectamine2000. Briefly, two solutions 
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were prepared first as follows. 
Solution I: 0.2 µg of each Luciferase reporter plasmid DNA and 0.002 μg 
pRL-SV40 (Renilla) DNA was diluted in 25 μl of opti-MEM medium without 
serum. 
Solution II: 0.5 µl of Lpofectamine 2000 was diluted in 250 µl of opti-MEM for 
each DNA samples and incubated at room temperature for 5 minutes. The 
equal amount of solution I and solution II was mixed and allowed to stand for 
20 minutes at room temperature and then added, dropwise, to the cell culture. 
The cells were incubated at 37℃, 5% CO2. The wells were fed with fresh 
medium after 24 hours and then further incubated for 24 hours prior to 
luciferase assay test.  
 
2.6.3 Luciferase assay test & analysis 
After 48 hours, the growth medium was removed and the wells are washed 
with 1× PBS. 100 μl of 1 × PLB was added to each well and incubated at 
room temperature for ten minutes with agitation. Twenty microliters of each 
lysate sample was transferred in to a polypropylene tube to test. Thirty 
microliters of Luciferase assay reagent II was added and read in a 
luminometer. The reading corresponds to firefly luciferase activity. Stop & Glo 
reagent (30 μl) was added and the reading was taken which corresponds to 
renilla activity. The process was repeated for each sample in fresh tubes each 
time. The luciferase activity of each well was normalized by the pRL-SV40 
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Renilla value using the formula; Ln = L/R (Ln: normalised luciferase activity; L: 
luciferase activity reading and R: Renilla activity reading). Transcriptional 
activity of the control, pGL3-Basic, was used to further standardize Ln using 
the formula; RLU = Ln/pGL3-basic (RLU: relative luciferase unit).  
 
2.7 Stable transfection  
About 1 million cells/2 ml/well were cultured in 6 well-plates overnight to about 
90% confluence. The transfection was carried out as explained above except 
8 μg of each DNA and 10 μl of Lipofetamine 2000 were added to each well. 
The cells were then subcultured at 1:10 ratio in fresh media after 48 hours 
transfection. DMEM medium with 800 – 1000 μg/ml G418 or/and 150 μg/ml 
hygromycin was used as a selection agent. The cells are cultured and 
routinely checked for the growth of cell colonies for about 7 – 10 days. Once 
the colonies are formed they were selectively trypsinised and transferred to 
T25 cm2 flask containing selective medium to enlarge the population and used 
for further test. 
 
2.8 Confocal microscopy, image analysis and atatistics  
2.8.1 Cell culture 
For immumofluorencence experiment cells were harvested by trypsinisation 
and 3 x 104 cells were plated on sterile 8-well chamber slide. They are allowed 
to grow over night at 37℃. Dose-dependent drug treatment or time-dependent 
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treatment was conducted on the following day. 
2.8.2 Fluorescence labeling of cells 
Following treatment, medium was removed from the chamber. Cells were 
gently washed twice with PBS avoiding their detachment from the surface of 
the chamber slide and then fixed by adding 500 µl of methanol/acetone (v/v = 
50/50) for 5 minutes. Fixed cells were washed two times with PBS then 
blocked with 5% BSA for 30 minutes at room temperature to block non-
specific binding of immunoglobulin. Cell were then incubated with the 
indicated primary antibodies for one hour at room temperature, washed there 
times in Hellendhal staining jar using PBS and then labeled with the indicated 
secondary antibodies for one hour in the dark. The cells were then washed 
there times in PBS. Coverslips were mounted onto slides using anti-fade 
mounting medium. Images were captured using laser scanning microscope 
(Carl Zeiss Laser Scanning Systems LSM 510).   
 
2.9 TP activity assay 
The enzyme activity in cell lysates was assayed as previously described 
(Yoshimura et al, 1990), with modifications. Briefly, 10 µl of supernatants were 
added to 90 µl of a reaction mixture consisting of 10 mM thymidine, 10 mM 
KH2PO4 and then incubated at 37 ℃ for 2 hours. The reaction was stopped by 
the addiction of 400 µl of 0.2 N sodium hydroxide. The absorbance at 300 nm 
was determined and the amount of thymine in the reaction solution mixture 
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was calculated using a calibration curve. The TP activity was expressed as 
nMol thymine/1µg protein/1hour. 
 
2.10 RNA extraction  
Cells were lysised in TRIzol (invitrogen). This method is based on the single 
step isolation procedure first developed by Chomczynski et al in 1987. Lysis 
buffer which contains guanidine isothiocyanate denature proteins including 
RNases in order to maintain RNA integrity. RNA was isolated from DNA by 
using phenol-chloroform phase separation, precipitated with isopropanol, 
dissolved in RNase-free water, and then stored at–20℃ until used. RNA 
concentration was determined spectrophotometrically by measuring 
absorbance at 260 nm (1 absorbance = 40 ng/ml RNA). 
 
2.11 Reverse transcriptase polymerase chain reaction 
Promega Access RT-PCR system was used in this study. This system 
coupled RT-PCR in a single tube in which a reverse transcriptase produces 
first strand cDNA from RNA, then a thermostable DNA polymerase produces 
second strand DNA and amplifies the specific DNA of interest. For each 
sample two reactions were conducted. A ratio of 1:2 oligodT primers∶RNA 
template was used in a volume of 25 μl containing 5 µl of 5 x AMV/Tfl reaction 
buffer, 1 µl of TAMV-reverse transcriptase, 1 µl of Tfl DNA polymerase, 2 µl of 
25 mM MgSO4, 1 µl of dNTPs (10 mM of ATP, CTP, GTP and GTP) and  
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nuclease free water up to 25 µl. Reverse transcripton was performed at 45℃ 
for 45 minutes, following inactivation of AMV RT and denaturation of the 
RNA/cDNA hybrid by incubation at 94℃ for 2 minutes. The CEA-specific 
primers, forward: 5´-CGC CAA AAT CAC GCC AAA TAA TAA-3´ and reverse: 
5´-ACC CCA ACC AGC ACT CCA ATC AT-3´, were used to amplify a 171 bp 
PCR product. The human housekeeping gene GAPDH was used as the RNA 
loading control which was amplified by the same RT-PCR system using the 
following primers, forward: 5´-CAT GAC AAC TTT GGT ATC GTG-3´; reverse: 
5´-GTG TCG CTG TTG AAG TCA GA-3´. Amplification was performed using 
standard cycling parameters: 94℃ 30 seconds for denaturation, 58℃ 1 
minute for annealing and 68℃ 1 minute for extension; after the final PCR 
cycle the final extension was at 68℃ for 5 minutes and then kept at 4  until ℃
further analysis. The RT-PCR products were separated on a 1% agarose gel 
and the bands visualized and photographed under UV light. 
 
2.12 Purification of PCR products 
PCR products were purified by using StrataPrep® PCR Purification kit. Briefly 
Equal volume of DNA-binding solution was added to the aqueous portion of 
the PCR products. This PCRproduct-DNA-binding-solution mixture was 
transfer to a microspin cup and spin at 12,000 g for 30 seconds. The PCR 
products retaining in the fiber matrix of the microspin were washed with 1× 
washing buffer then eluted using 50 µl of elution buffer. 
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2.13 Molecular biology protocols 
2.13.1 Preparation of LB plates 
LB medium was prepared by dissolving 25 g LB broth powder into 1 L of 
deioned water and to this 20 g agar was added. This was autoclaved and 
allowed to cool to 50℃ prior to the addition of ampicillin (50 μg/ml). The 
medium was mixed to ensure equal distribution of antibiotic and 
approximately 15 ml poured per 10 cm2 Petri dish. The plates were left to set 
at room temperature before being stored at 4℃. 
2.13.2 Transformation of competent bacterial cells 
Component bacteria DH5α was pursed from invitrogen and kept at -70℃. An 
aliquot of 200 μl competent bacteria DH5αwas allowed to thaw on ice. 10 ng 
of DNA was added and incubated on ice for 15 minutes. The cells were 
subjected to a heat shock at 42  for ℃ 120 seconds and returned to ice for 2 
minutes. To the cells, 1 ml of SOC medium was added and incubated at 37  ℃
for one hour in a shaking incubator. One hundred microliters of the reaction 
was spread onto a LB plate containing the appropriate antibiotic and 
incubated overnight at 37 .℃  
 
2.13.3 Preparation of plasmid DNA 
2.13.3.1 Mini-preps 
Miniprep purification was carried out using Qiafilter miniprep kit as 
manufactures instructions. Briefly, cells were pelleted by centrifugation at 
16,000 g for 5 minutes and re-suspended by pipetting in 100 μl of re-
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suspension buffer (50 mM Tris-HCl, 10 mM EDTA, pH 8.0 containing 100 
μg/ml RNase A). Cells were treated with 100 μl of lysis buffer (200 mM NaOH, 
1% (w/v) SDS), mixed and incubated for 5 minutes. Lysis was terminated by 
the addition of 100 μl of neutralisation buffer (3 mM potassium acetate, pH 
5.5). The cell lysates were centrifuged for 10 minutes at 16,000 g and the 
supernatant loaded onto miniprep columns. The columns were centrifuged for 
1 minute at 16,000 g and washed twice with 750 μl wash buffer (1.0 mM NaCl, 
50 mM Tris-HCl, pH 7.0, 15% (v/v) isopropanol). After washing, bound DNA 
was eluted into a clean 1.5 ml eppendorf tubes with 100 μl DNase, RNase-
free H2O. 
 
2.13.3.2 Maxi-preps 
The Qiagen Qiafilter kit was used to produce larger scale DNA samples. 
Purification of DNA was carried out according to manufactures instructions. 
Briefly, a 400 ml culture of transformed bacteria was pelleted by centrifugation 
for 15 minutes at 6,000 g at 4℃. All traces of media were removed and the 
pellet resuspended in 10 ml of chilled buffer P1 (50 mM Tris-HCL pH 8.0, 10 
mM EDTA, 100 μg/μl Rnase A). Cell lysis was achieved by the addition of 10 
ml buffer P2 (200 mM NaOH, 1% (w/v) SDS) and incubated for 10 minutes at 
room temperature. 10 ml of buffer P3 (3.0 M potassium acetate pH 5.5) was 
added to neutralized the reaction and the solution was immediately applied to 
a QIAfilter cartridge and left for 10 minutes at room temperature to settle. 
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Meanwhile, a Qiagen tip 500 was equilibrated by the addition of buffer QBT 
(750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol). After 10 
minutes, the lysed cells were added onto the equilibrated tip and allowed to 
filter through. The column was washed with 60 ml of buffer QC (1.0 M NaCl, 
50 mM MOPS pH 7.0, 15% (v/v) isopropanol). The DNA was eluted by the 
addition of 15 ml of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% (v/v) 
isopropanol) to the tip. The DNA was precipitated by the addition of 10.5 ml 
isopropanol and pelleted by centrifugation at 12,000 g for 30 minutes at 4℃. 
The DNA pellet was washed with 5 ml of room temperature 70% (v/v) ethanol 
and then centrifuged for 15 minutes at 12,000 g at 4℃. The supernatant was 
carefully removed and the pellet allowed to air dry prior to resuspension in 0.5 
- 1ml of DNase, RNase-free H2O. 
 
2.13.3.3 Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance 
of a 1:40 dilution of the sample at 260 nm. An A260 value of 1 unit was taken 
to correspond to 50 μg/ml of double stranded DNA. The sample concentration 
could be determined using the following formula 
 
Sample concentration = OD 260 x dilution factor (40) x 50 μg/ml 
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2.13.3.4 Digestion of DNA with restriction endonucleases 
According manufacturer, one unit of restriction endonuclease activity was 
capable of completely digesting 1 μg of DNA. Digests were prepared using 
the appropriate restriction enzyme (1 – 2 units), buffer as specified by the 
manufacturer, and 1 μg of DNA, in a final volume of 20 μl. Reactions were 
incubated at 37℃ for a minimum of 2 hours. 
 
2.13.3.5 Agarose gel electrophoresis of DNA 
Digested DNA samples or PCR reactions were examined using gel 
electrophoresis. Samples were diluted in 5 × DNA loading buffer. 1.0% (w/v) 
agarose gel was prepared by mixing agarose with 1 × TAE and 2.5 mg/ml 
ethidium bromide. The gels were set in a horizontal gel tank and once set 
immersed in 1 × TAE. Samples were loaded and the gels ran at 100 V for 1 
hour. The DNA fragments were visualized under ultraviolet light. The size of 
each fragment was assessed by comparison with DNA molecular markers. 
 
2.13.3.6 DNA Purification from agarose gels 
The required DNA fragments were excised from the gel with a sterile 
disposable scalpel blade inside the UV transilluminator hood. Excised gel 
fragments were transferred to a sterile tube. The fragments were purified 
using the QiaQuick gel extraction according to the manufacturer’s instructions. 
Excised DNA fragments were dissolved in buffer QG followed by addition of 
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isopropanol. The solution was loaded onto a purification column, after 
centrifugation, DNA was eluted from the purification column using 30 μl of 
sterile water. 
 
2.13.3.7 Alkaline phosphatase treatment of plasmid vectors 
The 5´ phosphate group of digested plasmid vector was removed to minimize 
re-ligation of the vector to itself. 200 ng of digested vector was incubated with 
2 units of shrimp alkaline phosphatase for 30 minutes at 37℃. The reaction 
was stopped by heating the sample at 37℃ for 15 minutes. The treated 
plasmid was isolated first by resolving on an agarose gel by electrophoresis 
and then extracted as previously described in section. 
 
2.13.3.8 Ligation of DNA 
Once plasmid DNA and/or PCR fragments had been digested and puried as 
described above, ligation of digested PCR or DNA fragments to the digested 
vector DNA was achieved using a Rapid DNA ligation kit. A molar ratio of 1:3 
and 1:6 vector∶PCR product/DNA fragment was used in a volume of 10 μl 
containing 1 unit of ligase and the supplied buffer. The reaction was incubated 
at room temperature for 4 minutes. The ligation reactions were transformed as 
detailed in section 2.11.2. 
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2.13.3.9 DNA sequencing 
DNA samples were posted to the Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland) for sequencing analysis. 
 
2.14 Flow cytometric analysis of DNA content 
The different cell lines were cultured in 6 well plates and grown overnight in 
the incubator. Cells were grown in medium without drug and with one drug, 
two drugs or even three drugs for 24 hours. Cells were harvested by 
trypsinization and washed with PBS. After fixation in 70% ice-cold ethanol for 
10 minutes and incubation with RNase A (100 μg/ml) and propidium iodide (50 
μg/ml) for 30 minutes at room temperature, 10,000 cells from each sample 
were subjected to fluorescence activated cell sorter (FACS) Scan (Becton 
Dickinson) analysis. 
 
2.15 Generation of recombinant adenovirus 
Adenoviruses were generated using the AdEasyTM adenoviral vector system.  
The generation of recombinant involves a number of cloning steps. The gene 
of interest is firstly inserted into a shuttle vector, which is then recombined 
with the adenovirus genome. 
 
2.15.1 Cloning into pShuttle vector 
pκB8-CEA205-TP, pκB4-CEA205-TP, pCEA205-TP and pShuttle were cut 
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with NotI and XbalI. The sticky ends are ligated by T4 ligase system. 
Following transformation plasmids were checked by restriction digest and 
were sequenced if they contained the correct insert. pShuttle vectors with 
gene of interest were amplified and purified and store at – 20℃.  
 
2.15.2 Homologous recombination 
pShuttle vectors with interest gene were linearised using PmeI and Complete 
digestion was confirmed by agarose gel electrophoresis side-by-side with 
uncut vector. The linearized vectors were precipitated using ethanol, 
dephosphorylated and purified using StrataPre PCR Purification Kit. One 
microgram of linearised/dephosphorylated shuttle vectors and 100 ng of 
pAdEasy-1 were mixed with BJ5183-AD-I electroporation competent cells in 
electroporation cuvettes on ice. Cells were electroporated with a single pulse 
using Gene-Pulser(Bio-rad) set at 200 Ω, 2.5 kV, 25 µF. 1 ml of sterile LB 
broth was added to each transformation and incubated at 37℃ for 1 hour with 
shaking at 225 – 250 rpm. Cultures were plated on LB-kanamycin plates 
overnight at 37℃. Only the smallest colonies were selected from the plates 
(large colonies represent re-ligation of shuttle vector) and grow in small scale 
cultures. Plasmids were checked by digestion with PacI on a 1.0% agarose 
gel. Plasmids that had undergone homologous recombination were selected 
and larger culture grown. Plasmids were linearised with PacI and purified by 
ethanol precipitation and then quantify.  
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2.15.3 Preparation of primary adenovirus stock 
HEK293 cells were plated at a density of 7 x 105 cells per T25 cm2 overnight. 
5 µg of linearised adenoviral plasmids were transfected into HEK293 cells 
using 6 µl LipofectamineTM2000. Medium was replaced after 24 hours 
transfection and then every two days until plaques in the monolayer appeared; 
Plaques appear when adenoviruses have been generated and have infected 
surrounding cells. When a majority of the cells were detached a primary stock 
of adenovirus was prepared. 
Floating and attached cells were collected in the growth medium; cells were 
then pelleted by centrifugation (1500 rmp for 5 minutes). Each flask of cells 
was resuspended in 0.5 ml PBS and subjected to three rounds of rapid 
freezing and thawing by transferring between a dry-ice/methanol bath and a 
37  water bath (approximately 5 minutes incubation in each). Cell debris was ℃
removed by centrifugation at 12,000 g for 10 minutes. The supernatant 
containing the recombinant adenovirus was collected. 
 
2.15.4 Amplification of adenovirus stock 
Twenty microliters of the primary stock was diluted in 5 ml of medium and 
added into a T175 cm2 flask of 70% confluent HEK293 cells. After 2 hours 
incubation at 37 , 35 ml of additional medium was added into flask, again ℃
medium was changed every 2 - 3 days until plaques were formed. Once the 
majority of cells had detected, the cells were harvested and the supernatant 
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was reserved for the purification. Adenovirus isolated by freeze-thawing. This 
secondary stock was then used to infect 10 - 20 flasks of HEK293 cells in the 
same manner to provide a tertiary stock.  
 
2.15.5 Purification of adenovirus stock 
Adenovirus stock was purified using AdEasyTM Virus Purification kits. The 
Stock was diluted with the reserved supernatant (30 ml) from amplification 
step.  30 µl of Benzonase® nuclease was added into the mixture, mixed 
immediately and incubated at 37  for 30 minutes. After incubation, ℃
benzonase nuclease-treated supernatant was clarified by a 0.45 µm filter 
attached to a syringe then the filtered supernatant passed through a 
Sartobinf® Filter Unit, Virus simultaneity bind to filter unit. The virus was 
washed with 30 ml of washing buffer then eluted from filter unit using elution 
buffer.   
 
2.15.6 Adenovirus infection of colon cancer cells    
The titration of adenovirus was performed by Dr Weiguang Wang. Colon 
cancer cells were plated on 6-well plate at a density of 1 x 106 cells per well 
overnight. The required amount of adenovirus was added to each well, and 
mixed immediately. Cells were infected for the indicated times. 
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2.16 20s proteasome activity assay 
The 20s proteasome activity was assayed using assay kit from Calbiochem. 
Briefly, 100 µL of assay buffer (50 mM Tris-HCl), 5 µl of different drugs, 5 µl of 
DMSO working as negative control, 5 µl of MG132 (positive control), 4 µl of 
1mM suc-LLVY-AMC substrate were added into 96-well plate in order, then 4  
µl of 20s proteasome was added to each well, incubated at 37  for 2 hours. ℃
After incubation, production of hydrolyzed AMC groups was measured with 
FluoroSkan plate reader with an excitation filter of 355 nm and an emission 
filter of 460 nm. 
 
2.17 Statistics analysis 
Significance was determined using a Student-t test and ANOVA. Errors in all 
charts represent the standard deviation within the data.  
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Chapter 3 
 Evaluation of Cancer Specific NF-κB-CEA and NF-κB-
hTERTcore Enhancer-promoter Systems for Gene-
directed Enzyme Prodrug Therapy 
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3.1 Introduction 
The clinical application of traditional chemotherapy is limited by the lack of 
selectivity of anti-cancer drugs to malignant cells leading to dose-limiting 
toxicity. Gene directed enzyme prodrug therapy (GDEPT) improves the 
selectivity of traditional chemotherapy by converting a non toxic prodrug into 
an active anti-cancer drug inside the tumour cells. The carcinoembryonic 
antigen (CEA), expressed at low levels in normal tissues, is overexpressed in 
the epithelial cancer cells[268]. The CEA promoter has been used to drive 
enzyme encoding gene to express in GDEPT. Although the use of CEA to 
target gene therapy has resulted in specificity[269,270], the therapeutic efficacy 
of tumour-specific gene therapy using the CEA promoter may be limited 
because of the low transcriptional activity of this promoter, especially in the 
case of distant metastases[264]. The CEA promoter is 10 - 300 times weaker 
compared to stronger but non specific Rous sarcoma virus or cytomegalovirus 
promoters[265]. Although CEA enhancer was used to increase the CEA 
promoter activity, this is still highly dependent on the intrinsic level of CEA 
expression[265,269]. Therefore some researchers also tried to use cre/loxP 
system to improve CEA promoter activity and it is efficient in some 
experimental tumours[264]. However, it has reported that Cre/Lox-dependent 
transcriptional activity is not enhanced relative to the expression using cancer 
specific promoters[266]. This balance between selectivity and effectiveness is 
the major obstacle for using CEA promoter-based prodrug gene therapy in 
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vivo and in clinical trials. 
 
Compared with normal cells, most cancer cells possess high NF-κB activity 
which can be further induced by exposure to anti-cancer drugs, radiation or 
cytokines[7,166]. In response to stimuli,  NF-κB can influence downstream gene 
expression by binding to DNA target site (kB site). κB site is a strong cis-
acting enhancer sequence possessing very weak transcriptional activity on its 
own. In the cells with high NF-κB activity, κB enhancer specifically magnify 
relevant promoter activity in a cis-acting manner [271,272]. In a reporter vector 
the enhancing activity of NF-κB can be further improved by multi-tandem 
copies of κB element located upstream of a weak promoter sequence. Base 
on all of this information, NF-κB binding sites could be an idea candidate as a 
cancer specific enhance to help improve CEA promoter activity  
 
Thymidine phosphorylase (TP) plays a critical role during the conversion of 
Capecitabine (CAP) to 5-FU which is one of the most effective anti-cancer 
drugs for solid cancer chemotherapy[273]. Tumour specific high level TP 
expression would potentially enable the enrichment of 5-FU in tumour cells 
while reducing exposure of normal tissues. However, TP is only detected in 
24% to 66%[221] of tumours with 5-FU resistant tumours  expressing even 
lower levels[222]. Consequently, insufficient conversion of CAP into 5-FU 
currently is a major limitation of CAP-based chemotherapy. Strong promoters 
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such as CMV have been used to increase TP and cytidine deaminase (CD) 
expression in cancer cells[274] and demonstrated enhanced cytotoxicity of 5’-
deoxy-5-fluorocytidine (5-FC) and 5’-DFUR in vitro and in vivo[275-278]. Yet, the 
lack of specificity of these promoters limits the clinical development of GDEPT 
strategies.  
 
In this study, NF-κB binding sites enhancer and CEA promoter systerm was 
developed to drive TP encoding gene expression to enrich high level of TP 
enzyme specifically inside the tumour cells. Four and 8 tandem copies of κB 
element (κB4) were constructed upstream of CEA205 promoter respectively, 
which only contain basal region of human CEA promoter. CAP is converted 
into 5-FU in vivo by a three-enzyme-catalysed process, first two steps happen 
in the liver, the final step involving conversion of 5’-deoxy-5-fluorouradine (5’-
DFUR) to 5-FU by TP. So 5’-DFUR instead of CAP was used to conduct 
cytotoxic assy. CEA is heterogenously overexpressed in more than 90% of 
primary CRC[258], hence colon cancer cell lines were used to evaluate the 
enhancer-promoter system. 
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3.2 Results 
3.2.1 Background CEA and TP gene expression and the transcriptional 
activity of NF-κB in CRC and normal cells.  
In order to evaluate the efficacy of NF-κB-CEA enhancer-promoter system in 
5´-DFUR prodrug based GDEPT, it is essential to determine the background 
status of TP (protein), CEA (mRNA and protein) and NF-κB (transcriptional 
activity) in cancer and normal cells. In a panel of 8 CRC cell lines, only two 
(LoVo and HCT116) expressed the 55 kDa TP protein at moderate levels 
(25%). No TP protein expression was detected in the remaining 6 CRC and 
normal endothelial and epithelial cells (Fig. 3.1). The 180 kDa CEA protein 
was detected in 4 CRC cell lines (50%). Although the CEA mRNA was 
detected in most of the CRC cell lines (7/8, Fig. 3.3 A), it was only expressed 
at relatively high levels in 3 cell lines (LoVo, Caco2 and HT29) and at very low 
levels in the other 4 cell lines (DLD-1, HCT116, H630 and RKO). In contrast 
with cancer cell lines, no CEA protein and mRNA were identified in normal 
cells (Fig. 3.3B). The transcriptional activity of NF-κB in CRC and normal cells 
was also examined. High NF-κB activity was detected in all 8 CRC cell lines 
by luciferase assay. In contrast, the normal human cells only demonstrated 
negligible background levels of NF-κB activity (Fig. 3.2). 
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Figure 3.1: The expression of CEA and TP protein in CRC and normal cell lines. 
The CEA and TP protein expression levels were determined by western blotting analysis. 
100 μg of whole protein was loaded to each well. The dilution of antibody: anti-TP 1:250; 
CEA 1:2000. Vinculin was used as loading control. 
 
 
 
   
Figure 3.2: The transcriptional activity of NF-κB in CRC and normal cell lines. 
The transcriptional activity of NF-κB was determined by luciferase reporter gene assay. 
Cells were co-transfected with pNF-Tal-Luc and pSV40-Renilla DNA. The luciferase activity 
of each transfection was normalized by the Renilla reading. Luciferase activity was used as 
a measure of the transcriptional activity of NF-κB.  
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3.2.2 The transcriptional activity and specificity derived from different 
combinations of CEA basal promoters and NF-κB enhancer.  
In order to improve the transcriptional activity of CEA promoter and 
maintaining its cancer-targeting specificity, a novel NF-κB-CEA chimeric 
enhancer- promoter system was designed by Dr Weiguang Wang. In this 
system, the basal CEA promoter sequences were placed downstream of the 4 
directly linked NF-κB DNA binding sites in tandem (κB4). There are 4 cis-
acting DNA binding sites located within –303 to -143 base pairs of the CEA 
promoter region. The transcription factors Sp1, Sp1-like and USF bind to the 
Figure 3.3: The transcription of CEA mRNA in CRC and normal cell lines 
The transcription of CEA mRNA was detected by RT-PCR. GAPDH were used as loading 
control for western blot and RT-PCR. A: CRC cell lines; B: normal cell lines. 
B 
A 
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first 3 DNA binding sites and the transcription factors for the 4th element are 
still not clear[252]. All vectors in this section were constructed by Dr Weiguang 
Wang before the project started. 
 
In order to develop an optimal enhancer-promoter system, the transcriptional 
activity and specificity of the luciferase reporter vectors driven by the basal 
CEA promoter regions covering the first 3 (CEA205) or 4 (CEA421) DNA 
binding elements in combination with or without κB4 enhancer were compared. 
The transcriptional activities of the κB4 enhancer, CEA basal promoters 
(CEA205 and CEA421) and chimeric enhancer-promoter elements (κB4-
CEA205 and κB4-CEA421) were examined in CRC and normal human 
endothelial and epithelial cells. As showed in Fig. 3.4, both CEA205 and 
CEA421 basal promoters demonstrated selective transcriptional activity in all 
CRC cell lines but not in normal endothelial and epithelial cells. In 
combination with κB4, the transcriptional activity of both CEA205 and CEA421 
in cancer cell lines was enhanced. The κB4 enhancer demonstrated a greater 
enhancing effect on the CEA205 promoter than on the CEA421 promoter (Fig. 
3.4). The κB4 enhancer alone showed very low transcriptional activity in all 
tested cancer cell lines (Table 3.1). Only background transcriptional activity of 
CEA promoters, κB4 enhancer and the chimeric κB4-CEA enhancer-promoter 
cassette was detected in normal cells (Fig. 3.4 and Table 3.1).  
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3.2.3 Comparison of the transcriptional activity and specificity between 
κB4-CEA205 with SV40 virus promoter 
The transcriptional activity of both κB4-CEA205 and κB4-CEA421 in cancer 
cell lines was enhanced. The κB4 enhancer demonstrated a significantly 
greater enhancing effect on the CEA205 promoter than on the CEA421 
promoter. So in this part, κB4-CEA205 was picked up to compare the 
transcriptional activity of κB4-CEA205 with a strong SV40 virus promoter. To 
avoid the transcriptional interference between the SV40 promoter in pRL3-
SV40 and pGL3-SV40, the CRC cell lines were singly transfected with pκB4-
CEA205 and pGL3-SV40. Equal amount of protein (10 µg) from each 
transfection was subjected to luciferase assay. The transcriptional activity of 
Figure 3.4: The transcriptional activity and specificity of CEA205 and CEA421 basal 
promoters in combination with or without κB4 in CRC and normal human cell 
cultures. The cells were co-transfected with luciferase expression vectors (pCEA205-
Luc, pκB4-CEA205-Luc, pCEA421-Luc, pκB4-CEA421-Luc and pGL3-Basic) and Renilla 
expression vector (pRL3-SV40). The luciferase activity of each transfection was 
normalized by the Renilla reading. The luciferase activity is represented by the ratio of the 
specific promoter over the activity of pGL3-Basic. The column represents the mean of 
three measurements and the bar represents the SD. 
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κB4-CEA205 enhancer-promoter system was highly comparable to that of the 
strong SV40 virus promoter in all CRC cell lines (Fig. 3.5A). The SV40 
promoter also demonstrated high transcriptional activity in a panel of 7 normal 
human cell lines and primary cell cultures. In contrast, the transcriptional 
activity of pκB4-CEA205 in normal cells was negligible (Fig. 3.5B). 
 
 
 
 
Figure 3.5: The transcriptional activity and specificity of κB4-CEA205 with SV40 
virus promoterThe cells were singly transfected with pGL3-SV40 or pκB4-CEA205-Luc 
and the absolute luciferase activity in equal amount of protein from different 
transfections was compared. The luciferase activity of each transfection didn’t 
normalized by the Renilla reading. The readings were higher than co-transfection’s. 
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3.2.4 5´-DFUR cytotoxicity in CRC cell lines transiently transfected with a 
TP expression vector.  
Due to the strong and cancer specific transcriptional activity, the CEA205 
promoter and κB4-CEA205 enhancer-promoter cassette were subjected to 
further study. In the TP expression vectors, the TP cDNA was placed under 
the control of the CMV, CEA205, κB4-CEA205 or κB4 promoter respectively. 
Two CRC cell lines with low CEA expression (H630 and RKO) were 
transiently transfected with pκB4-TP, pCEA205-TP, pκB4-CEA205-TP, 
pcDNA3-TP or pcDNA3 empty vector. After 48 hours transfection, the cells 
were harvested and subjected to different analysis. High levels of TP protein 
were detected in both pcDNA3-TP and pκB4-CEA205-TP transfected cells. 
Only very low levels of TP protein were detected in the pCEA205-TP 
transfected cells and no TP protein was detected by western blotting analysis 
in the pcDNA3 and pκB4-TP transfected cell lines (Fig. 3.6). In line with 
protein expression levels, the pcDNA3-TP and pκB4-CEA205-TP transfected 
cells also possessed high TP enzyme activity (Fig. 3.7). The TP activity and 
protein expression patterns were highly consistent one another in the 
transfected cells. The transiently transfected cells were then subjected to MTT 
analysis. In comparison with the control (pcDNA3 transfected), the pκB4-
CEA205-TP transfected RKO and H630 cells were 7.6 and 10 times more 
sensitive to the 5´-DFUR-induced cytotoxicity. The cytotoxicity of 5´-DFUR to 
the pκB4-CEA205-TP and pcDNA3-TP transfected cell lines was comparable. 
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In comparison with pcDNA3-TP and pκB4-CEA205-TP transfected cells, the 
pκB4-TP and pCEA205-TP transfection only slightly increased the cytotoxicity 
of 5´-DFUR to the CRC cell lines (Fig. 3.8 and Table 3.2). 
 
Figure 3.6: The TP expression status in transiently transfected CRC cell lines 
TP protein expression levels were determined by western blot. The cells were singly 
transfected with indicated TP vectors. 100 μg of whole protein was loaded a 10% SDS-
PAGE gel. Vinculin: protein loading control. 
 
 
Figure 3.7: The TP enzyme activity in different transfected cells 
The TP enzyme activity was determined by enzyme activity assay. Cells were transfected 
with indicated vectors.10 μg of each whole protein was used. Each sample was tested in 
triplicate. The experiment was repeated three times. 
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Figure 3.8: The cytotoxicity of 5´-DFUR in transiently transfected CRC cell lines 
The cytotoxicity was tested by MTT assay. Cells were transfected with indicated vectors 
for 48 hours before subjected to the MTT assay. The curves were derived from 3 
replicates and bars represent SD. Figure A for RKO and Figure B for H630. 
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3.2.5 Construction of pFastBacDualΔpromoter/κB4-CEA205-TP 
Based on the positive results, pFastBacDualΔpromoter/κB4-CEA205-TP was 
constructed as a vector for stable transfection. The parental vectors are 
pFastBac Dual Vector (Fig. 3.9) and pPCR-Script kB4-CEA205-TP (Fig. 3.9). 
PCR-Script kB4-CEA205-TP was constructed by Dr Wang before the start of 
this project. The Vector pFastBac Dual was supplied by Initrogen. The 
pFastBac™ Dual vector has two strong promoters, the polyhedrin promoter 
and the p10 promoter. polyhedrin promoter and  p10 promoter were cut off 
with XhoI and XbaI . The fragment of κB4-CEA205-TP from pPCR-Script kB4-
CEA205-TP was cloned into these two cutting sites. The recombination vector 
was checked by restriction digestion with BglⅡ and the construct was also 
confirmed by DNA sequencing analysis. 
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3.2.6 The bystander effect of pFastBacDualΔpromoter/κB4-CEA205-TP 
transfected CRC cells on the neighbouring cells.  
In order to produce perform the bystander effect analysis, the H630 and RKO 
cell lines were stably transfected with pcDNA3-TP or 
pFastBacDualΔpromoter/ κB4-CEA205-TP. Two positively transfected clones 
were selected from each cell line for further study. The TP protein expression 
Figure 3.9: Generation of pFastBacDualΔpromoter/κB4-CEA205-TP 
Schematic diagram of pFastBacDualΔpromoter/κB4-CEA205-TP, pFastBac Dual Vector, 
pPCR-Script kB4-CEA205-TP. Agarose gel image is the ligation of κB4-CEA205-TP 
gene from the pPCR-Script kB4-CEA205-TP to pFastBacDualΔpromoter/κB4-CEA205-
TP. DNA marker: 1kb DNA ladder. 
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and TP enzyme activity in the pFastBacDualΔpromoter/κB4-CEA205-TP 
transfected cell lines were high and comparable to that in the pcDNA3-TP 
transfected cells (Fig. 3.10). Furthermore, the cytotoxicity of 5´-DFUR to the 
pcDNA3-TP and pFastBacDualΔpromoter/κB4-CEA205-TP stably transfected 
cell lines was determined by MTT analysis. The pFastBacDualΔpromoter/κB4-
CEA205-TP stable transfection significantly enhanced the cytotoxicity of 5´-
DFUR to both RKO (10-fold) and H630 (12-fold) cell lines. The IC50s of 5´-
DFUR to the pFastBacDualΔpromoter /κB4-CEA205-TP transfected cells 
were similar to those of pcDNA3-TP transfected cells (Table 3.3). It has been 
reported that the small portion of CMV promoter-driven TP transfected cells 
can effectively convert 5´-DFUR into 5-FU which can be released and perform 
cytotoxic effect onto the neighbouring cells (bystander effect)[275]. Figure 3.11 
show that when pcDNA3-TP or pFastBacDualΔpromoter/ κB4-CEA205-TP 
transfected RKO or H630 cells composed only 5% of the whole cell population, 
the sensitivity of H630 and RKO cell lines to 5´-DFUR was significantly 
enhanced. If the percentage of the transfected cells was further increased, the 
IC50s of 5´-DFUR in these cells were further reduced but the curves 
significantly levelled off. The bystander effect of pFastBacDualΔpromoter/ 
κB4-CEA205-TP and pcDNA3-TP transfected cells was comparable.  
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Figure 3.10: The TP protein expression and enzyme activity in the TP cDNA stably 
transfected cancer cell lines 
A is western blotting result for TP protein expression; pFBD/KCT-1 and pFBD/KCT-2: 
pFastBacDual/κB4-CEA205-TP clone 1 and clone 2. C1: clone1, C2: clone2. Vinculin: 
protein loading control. And B is TP enzyme activity. The column represents the mean 
of three measurements and the bar represents the SD. 
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Figure 3.11: The bystander killing effect of CMV- or κB4-CEA205-driven TP cDNA 
transfection cells 
Cell viability was measured as described in Materials and Methods. All data of cell 
viability were expressed as a percentage relative to the untreated controls in the absence 
of 5’-DFUR. The curves were derived from 3 replicates and the bars represent SD. A is 
H630 cell line and B is RKO cells. 
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3.2.7 Construction of κB8 enhancer and CEA205 promoter vectors 
The κB4-CEA205 system demonstrated very promising results. It has been 
reported that in a reporter vector the enhancing activity of NF-κB can be 
further improved by multi-tandem copies of κB element located upstream of a 
weak promoter sequence. Eight cis-acting DNA binding sites may enhance 
the CEA promoter region. Based on these information κB8 containing vectors 
were constructed in order to compare κB8-CEA205 with κB4-CEA205 system. 
pκB8-CEA205-Luc was constructed from the parental vectors pκB4-CEA 205-
Luc (Fig. 3.12 A) and κB8 binding site PCR product (Fig. 3.12B). The κB4 
binding site was cut out with KpnI and BglⅡ. The fragment of κB8 binding site 
was cloned into the parental vector with these two cutting sites. pκB8-Luc was 
constructed from pκB8-CEA205-Luc by cutting off CEA205 promoter part 
using BglⅡand NcoI. pκB8-CEA205-TP was derived from pκB8-CEA 205-Luc, 
the Luc fragment was replaced by TP cDNA by using HindⅢ and Xbal. pκB8-
TP was came from pκB8-CEA205-TP by cutting off CEA205 promoter region 
using BglⅡand HindⅢ, then protruding ends were sealed by klenow. The 
recombination vectors were checked by restriction digestion (Fig. 3.13) and 
DNA sequencing analysis.   
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Figure 3.12: Generation of pkB8 –CEA205-Luc vector 
A. Map of pκB4-CEA205-TP with restriction enzyme cutting sites for validation; Figure B is 
agarose gel image of kB8 binding site: Lane I shows PCR product of kB8 binding site; Lane 
II is kB8 bing site template. Figure C demonstrates the κB4 and κB8 fragments digested 
from κB4-CEA205-Luc (1) and κB8-CEA205-Luc (2) respectively using kpnI and BglⅡ, DNA 
marker: 100 bp DNA ladder for B and 1kb DNA ladder for C. 
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3.2.8 The transcriptional activity of κB8-CEA205 and κB4-CEA205 
construction. 
First the transcriptional activity and specificity of the κB8-CEA205 and κB4-
CEA205 enhancer-promoter systems were compared. As showed in Fig. 3.14 
A, κB8-CEA205 further increase the transcriptional activity in all CRC cell 
lines compared to κB4-CEA205. The κB8 enhancer alone showed very low 
transcriptional activity in all tested cancer cell lines (Table 3.4). Furthermore, 
the transcriptional activity of κB8-CEA205 was compared with two strong 
Figure 3.13: Validation of pkB8-CEA205-TP, pkB8-Luc and pkB8-TP 
The vectors were validated by restriction enzyme digestion. A1: pκB8-Luc cut with kpnI 
and Xbal. A2: pκB8-CEA205-TP cut with HindIII and BamHI. There are two more small 
piceses (61bp, 70bp) which cannot be identified no the gel. B: pκB8-TP cut with kpnI and 
Xbal. DNA marker: 1kb DNA ladder. 
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promoters, SV40 and CMV as well. To avoid the transcriptional interference 
between the SV40 promoter in pRL3-SV40 and pGL3-SV40, the CRC cell 
lines were singly transfected with pκB8-CEA205-Luc, pGL3-SV40 and pCMV-
Luc. Equal amount of protein (10 µg) from each transfection was subjected to 
luciferase assay. The transcriptional activity of κB8-CEA205 enhancer-
promoter system was higher than SV40 virus promoter but still lower than 
CMV promoter in all CRC cell lines (Fig. 3.14B). 
    
 
Figure 3.14: Comparison of the transcriptional activity of κB8-CEA205 enhancer - 
promoter system with other promoter systems 
The cells were singly transfected with luciferase expression vectors (pκB8-CEA205-Luc, 
pκB4-CEA4205-Luc, pκB4 pκB8 pGL3-SV40, pCMV-Luc and pGL3-Basic). The 
luciferase activity is represented by the ratio of the specific promoter over the activity of 
pGL3-Basic. The column represents the mean of three measurements and the bar 
represents the SD. 
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3.2.9 5’-DFUR cytotoxicity in CRC cell lines transiently transfected with 
κB8-CEA205-TP vector.  
Compare to κB4-CEA205 enhancer-promoter cassette, κB8-CEA205 show 
stronger   transcriptional activity in all tested colon cancer cells. Furthermore 
the 5’-DFUR cytotoxicity of in CRC cell lines transiently transfected with κB8-
CEA205-TP vector was tested. In the TP expression vectors, the TP cDNA 
was placed under the control of the CMV, κB4-CEA205 or κB8-CEA205 
promoter respectively. Four CRC cell lines (LoVo, RKO, CaCo2 and H630) 
were transiently transfected with pκB8-CEA205-TP, pκB4-CEA205-TP, 
pcDNA3-TP vector. After 48 hours transfection, the cells were harvested. The 
whole protein was extracted and subjected to western blotting analysis of TP 
protein expression. High levels of TP protein were detected in pcDNA3-TP 
pκB8-CEA205-TP and pκB4-CEA205-TP transfected cells; there is no 
detectable difference of TP expression between pκB8-CEA205-TP and pκB4-
CEA205-TP (Fig. 3.15A). RKO and LoVo were randomly chosen to subject to 
MTT Assay. The MTT Assay results show that the pκB8CEA205-TP 
transfected cells only slightly increased the sensitivity of 5´-DFUR to the RKO 
and LoVo cell lines comparison with the pκB4-CEA205-TP transfected ones, 
(Fig. 3.15B Table 3.5).   
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Figure 3.15: The TP expression and cytotoxicity of 5´-DFUR in transiently 
transfected CRC cell lines. 
A. TP protein expression levels determined by western blotting. Vinculin: protein loading 
control. B. The inhibitory effect of 5´-DFUR on the transiently transfected cells. The 
curves were derived from 3 replicates and bars represent SD. 
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3.2.10 Generation of κB binding site enhancer telomerase promoter 
containing vectors 
The most attractive cancer promoter in nowadays is telomerase promoter. It 
has found that more than 85% of human cancers possess active telomerase, 
regardless of their tissue origins. Whereas normal somatic tissues have either 
much lower or undetectable activity[249]. The enzyme is composed of an 
essential RNA template, telomerase-associated protein, and human 
telomerase reverse transcriptase (hTERT)[279-281]. The hTERT gene was 
cloned by several groups and found to have a key role in telomerase 
activity[282]. The hTERT expression is highly correlated with 
telomerase  activity[281]. A number of studies have used telomerase promoters 
to drive transgene expression for therapeutic benefit. Pan and Koeneman first 
described the use of the hTERT promoter in a retroviral system and combined 
it with a Cre/loxP site-specific recombination system to allow the killing of p53-
negative tumour cells while sparing normal wild-type cells[250]. Since then, 
many papers have reported the use of both promoters in several different 
tumour types in combination with several different transgenes. However, 
telomerase expression and activity can vary greatly even among cancers, so 
the application of this promoter is limited by the weaker activity as well. The 
above study showed that κB binding site can significantly enhance the activity 
of CEA promoter. Therefore the next step of this project was designed to 
investigate the enhancing effect of κB binding site on the transcriptional 
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activity of tolemarase promoter hTERT. hTERTcore promoter region was 
used in this study as deletion analysis of the hTERT promoter revealed that a 
core promoter region, including approximately 200 bp upstream of the 
transcription start site, was most important for transcriptional activity in cancer 
cell lines but was not activated in normal cells[283]. The κB4-hTERTcore-Luc 
and hTR-Luc were constructed by Dr Weiguang Wang before the project 
started. pκB8-hTERTcore-Luc was derived from parental vector: pκB8-
CEA205-Luc and κB4-hTERTcore-Luc. The κB8 fragment from pκB8-
CEA205-Luc was subcloned into hTERTcore-Luc backbone at BglII and 
Hind  sites (Fig. 3.16). phTERTcoreⅢ -luc came from κB8-hTERTcore-Luc by 
cutting off κB8 binding site using BglⅡ and kpnI. pκB8-hTERTcore-TP was 
constructed by Dr Weiguang Wang. phTERTcore-TP was derived from 
phTERTcore-Luc and pκB4-CEA305-TP. TP part was cloned into hTERTcore 
backbone at HindⅢ and XbaI sites. The recombination vectors were validated 
by restriction digestion (Fig. 3.17) and DNA sequencing analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Generation of pκB-hTERTcore-Luc vector 
A. The schematic figure of pκB8-hTERTcore -TP which shows restriction enzyme cutting 
sites for confirmation; B is agarose gel image of pκB8-hTERTcore –TP digested by kpnI 
and XbaI for the confirmation. Lane 1 is pκB4-hTERTcore –TP and Lane 2 is pκB8-
hTERTcore-TP. DNA marker: 1kb DNA ladder. 
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Figure 3.17: Restriction enzyme digestion of phTERTcore-TP and phTERTcore-Luc 
A. Restriction enzyme digestion of hTERTcore-TP with HindIII and BamHI. Lane 1: 
phTERTcore-luc, the band of 5015bp is one enzyme cut fragment; Lane 2: phTERTcore-
TP; B. Restriction enzyme digestion of hTERTcore-Luc with NotI and NcoI. Lane 1: 
hTERTcore-Luc and Lane 2: pKB8-hTERTcore-Luc. DNA marker: 1kb DNA ladder. 
 
 
3.2.11 The transcriptional activity of κB8-hTERTcore and κB4-hTERTcore 
construction 
Following the construction of κB enhancer and hTERTcore promoter systems, 
the transcriptional activities of the κB enhancer, hTERTcore promoters and 
chimeric enhancer-promoter elements (κB8-hTERTcore and κB4-hTERTcore) 
were examined in CRC, breast cancer cell lines and normal cells. As showed 
in Fig. 3.18, both κB8 and κB4 enhanced the transcriptional activity of 
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hTERTcore promoter in all cell lines but not in normal cells. The κB8 enhancer 
demonstrated a significantly greater enhancing effect on the hTERTcore 
promoter than the κB4. The transcriptional activity of κB8-hTERTcore was 
even higher than hTR (Fig. 3.18A, B, and C). The κB4 enhancer alone 
showed very low transcriptional activity in all tested cancer cell lines. The 
transcriptional activity of κB8 alone is slightly higher than the κB4 alone in all 
cell lines (Table 3.6, 3.7). Only very low background transcriptional activity 
was detected from hTERTcore promoters, κB8, κB4 enhancer and the 
chimeric κB-hTERTcore enhancer-promoter cassette transfected normal cells 
(Fig. 3.18C).  
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Figure 3.18: The transcriptional activity of κB-hTERTcore enhancer-promoter 
system. 
The cells were co-transfected with luciferase expression vectors (pκB8-hTERTcore-Luc, 
pκB4-hTERTcore-Luc, pκB4 pκB8 and pGL3-Basic) and Renilla expression vector 
(pRL3-SV40). The luciferase activity of each transfection was normalized by the Renilla 
readings. The luciferase activity is represented by the ratio of the specific promoter over 
the activity of pGL3-Basic. The column represents the mean of three measurements and 
the bar represents the SD. 
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3.2.12 The TP protein expression in CRC cell lines transiently 
transfected with TP expression vectors 
Due to the strong and cancer specific transcriptional activity of κB-hTERTcore 
enhancer-promoter cassette detected by luciferase reporter gene assay, the 
TP expression vectors were constructed. In the TP expression vectors, the TP 
cDNA was placed under the control of the CMV, κB8-hTERTcore and κB4-
hTERTcore respectively. Two CRC cell lines (H630 and RKO) were transiently 
transfected with pcDNA3-TP, pκB4-hTERTcore-TP, pκB8-hTERTcore-TP or 
pcDNA3 empty vector. After 48 hours transfection, the cells were harvested 
and the expression levels of TP protein were determined by western blotting 
analysis. High levels of TP protein were detected in both pcDNA3-TP and 
pκB8-hTERTcore-TP transfected cells. Only low levels of TP protein were 
detected in the pκB4-hTERTcore transfected cells and no TP protein was 
detected in the pcDNA3 mock transfected cell lines (Fig. 3.19). 
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Figure 3.19: The TP expression status in transiently transfected CRC cell lines 
TP protein expression levels were determined by western blotting assay. The cells were 
singly transfected with indicated TP expression vectors. Whole protein (100 μg/lane) was 
loaded onto a 10% SDS-PAGE gel. Vinculin: protein loading control. 
 
 
3. 2.13 Generation of Adenovirus 
Attempts to transfect some colon cancer cell lines with plasmid-based vector 
using lipofetamine failed to identify an efficient and reproducible method for 
plasmid transfection. To overcome these difficulties an adenoviral approach to 
infect colon cancer cell lines was chosen. Expression foreign protein in colon 
cancer cell lines using adenoviral approach has been previously reported[284].  
 
The TP gene placed under CEA205, hTERTcore, hTR, SV40, CMV promoter, 
κB-CEA205 and κB-hTERTcore enhancer promoter systems were used to 
generate recombinant adenoviruses (see the relevant sections in Materials 
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and Methods for detail). Briefly, these genes were firstly cloned into the MCS 
of pShuttle vector. Figure 3.20 shows that gene of interest was cloned into 
pShuttle vector by NotI and XbaI. All TP containing pShuttle vectors, parental 
vectors and restriction enzymes were listed into Table 3.8. All of the pShuttle 
vectors with different inserts were verified by restriction digestion with HindIII. 
The insert-containing pasmids were also verified by DNA sequencing before 
continuing to generate the adenovirus. The TP expression in H630 and RKO 
cell lines transfected with pShuttle vectors was determined by western blotting 
analysis (Fig. 3.21). 
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Figure 3.20: Introduction of gene into pShuttle vector 
Maps of vectors used to introduce the gene of interest into pShuttle vector. The fragment 
(C) from TP containing vectors (B) was cloned into NotI-XbaI site of pShuttle vector (A). 
D. the enzyme digestion of pShuttle and pShuttle-TP vectors with Hind ; the pshuttle Ⅲ
has one Hind  cutting site, therefore there is only one 6.6kb band; pShuttleⅢ -TP has two 
Hind  cutting sites. There are two bands: one is around 6.6 kb; the other is 1517bp. Ⅲ
DNA marker: 1kb DNA ladder. 
 
Figure 3.21: TP expression of TP containing pShuttle vectors 
Western blotting analysis of TP expression, Colon cells H630 and RKO were transfected 
with the indicated vectors for 48 hours. The whole protein (100 μg) was loaded onto 
10%SDS gel. A: pShuttle-TP, B: pShuttleκB4-TP, C: pShuttleCEA205-TP, D: 
pShuttleκB4CEA205-TP, E: pShuttleκB8CEA205-TP, F: pShuttlehTERTcore-TP, G: 
pShuttleκB4hTERTcore-TP, H: pShuttleκB8hTERTcore-TP, I: pShuttleSV40-TP, J: 
pShuttlehTR-TP, K: pShuttleCMV-TP, L:-VE.  
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The pShuttle vectors with gene of interest were linearised with PmeI (Fig. 
3.22A) and the recombinated with the adenovirus genomic DNA (pAdEasy-1) 
in electro-competent bacteria (BJ5183) as shown in Figure 3.23 to generate 
the recombinant adenovirus genome. Recombination of the shuttle vector and 
pAdEasy-1 was checked by restriction digestion with PacI (Fig. 3.22B). The 
recombinant adenovirus genomes were linearised with Pac-I and then 
transfected into HEK293 cells. The HEK293 cell line was generated through 
transfection of mechanically sheared segments of the Ad5 genome. The cells 
contain a fragment of the Ad5 genome integrated into the chromosome 19 
which encodes the E1 gene. By transfecting the genome of replication 
incompetent adenoviruses into HEK293 cells the ability of the virus to 
replicate is restored as the HEK293 cells provide the packaging protein from 
the E1 gene. 
 
Figure 3.22: Restriction enzyme digestion of TP containing pShuttle vectors and 
Recombination of pAdEasy-1 
A2: pShuttle vector containing gene of interest linearised with pmel, which produce a 
~8.3kb fragment; A1: uncut pShuttle vector; B1: pAdEasy linearised with PacI; Lane 2: 
Recombination of pAdEasy cut with pacI, instead of between the left arms, recombination 
took place at the origins of replicationan, so an around 4.5 kb fragment was produced. B2: 
uncut recombination. DNA marker: 1kb DNA ladder. 
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Figure 3.23: Generation of recombinant adenovirus.   
This figure was adopted from AdEasyTM Adenoviral Vector System manual. 
The shuttle vectors constructed in last step are linearised and co-transfected with the 
pADEasy-1 vector into BJ5183 electro-competent bacteria. Homologous recombination 
occurs generating the complete recombinant adenovirus genome. This is linearised and 
transfected into HEK293 cells, which contains the packaging gene E1 allowing 
replication of recombinant adenovirus. 
 
 133 
3.2.14 Infection of recombinant adenovirus 
The recombinant adenovirus was enriched from HEK293 cells and purified 
using a purification kit by following the instruction of the supplier (see 
Materials and Methods section for details). Purified recombinant adenovirus 
was tittered based on production of viral hexon proteins and an adeno-virus-
specific antibody was used to identify infected cells, the infectious unit was 
calculated from the resulting number of positive cells/unit dilution. Colon 
cancer cell lines H630 and RKO were infected with purified Adenovirus for 72 
hours. Maximizing protein yield depends on using accurate virus titration and 
on using an optimal ratio of virus particles per cell commonly referred to as 
the multiplicity of infection (MOI), therefore the cells were infected with 
different amount of CMV-TP, κB8-hTERTcore-TP and κB4-CEA205-TP. Cells 
were lysed and the expression of the recombinant proteins was examined by 
western blot (Figure 3.24). Expression of TP protein were detected, however, 
there was no correlation between the amount of adenovirus added and the 
expression levelof the TP protein  
 
Figure 3.24: Adenovirus infection of colon cancer cells 
Cultured cells were infected with indicated amounts of adenovirus. Increasing the amount 
of AdCMV-TP, AdκB8-hTERTcore-TP and AdκB4-CEA205-TP did not alter the expression 
of proteins. A: Untransfected, B: 100mol pAdκB4CEA205-TP, C: 50mol  pAdκB4CEA205-
TP, D: 10mol pAdκB4CEA205-TP, E:100mol pAdκB8hTERTcore-TP, F: 50mol 
pAdκB8hTERTcore-TP, G: 10mol pAdκB8hTERTcore-TP, H:100mol p AdCMV -TP, I: 
50mol p AdCMV –TP, J: 10 mol p AdCMV –TP.  
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3.3 Discussion 
As with other cancer specific promoter systems, low transcriptional activity 
limits the clinical use of the CEA promoter in GDEPT. It has been reported that 
the transcriptional activity of CEA promoter is significantly improved by 
multimerization of the essential CEA promoter region and/or fusing the CEA 
promoter with a CEA enhancer sequence. Although the transcriptional activity 
of CEA promoter is significantly improved by these modifications, all of these 
approaches are highly cell line and CEA activity dependent. The 
transcriptional activity of these modified promoter systems remains at very low 
levels in the low CEA expressing cancer cells[265,269]. High NF-κB activity is a 
very common feature of cancers[285]. In this study, 4 linked NF-κB binding sites 
in tandem (κB4) were first exploited as a cancer specific enhancer to improve 
the transcriptional activity of the CEA promoter. The enhancing effect of κB4 
on the transcriptional activity of two basal CEA promoters covering the first 3 
(CEA205) and 4 (CEA421) DNA binding sites on the CEA promoter region 
were examined. Both promoters demonstrated comparable transcriptional 
activity which was further enhanced by κB4 in CRC cell lines. In comparison 
with that on CEA421, the κB4 enhancer demonstrated stronger enhancing 
effect on CEA205 promoter (Fig. 3.4). The luciferase assay showed that the 
transcriptional activity of κB4-CEA205 was comparable to that of SV40 
promoter (Fig. 3.5). Therefore, the κB4-CEA205 cassette was subjected to 
further study. Although high CEA protein expression and NF-κB transcriptional 
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activity are commonly detected in cancer cells, the low levels of both are also 
detectable in some normal tissues[257]. Therefore we also tested the potential 
transcriptional leakage of the κB4-CEA205 enhancer-promoter system. In 
agreement with a previous report[286], the NF-κB binding sites by itself, as an 
enhancer element,  only possessed very low transcriptional activity. The 
transcriptional activity in cancer cell lines was highly increased by the 
combination of κB4 and CEA promoter and meanwhile the cancer-targeting 
specificity was still remained (Fig. 3.4 and Table 3.1). The results 
demonstrated that κB4 enhancer efficiently improved the transcriptional 
activity of CEA basal promoter without impairing its cancer specificity. The 
fidelity of the κB4-CEA205 enhancer-promoter system was therefore 
improved by the increased transcriptional contrast between the cancer and 
normal cells. 
 
To determine the potential of κB4-CEA205 cassette for gene therapy 
application, TP/5´-DFUR was used as a model to test the efficacy of the κB4-
CEA205 enhancer-promoter system. TP is a key enzyme for CAP, a 5-FU 
prodrug[159]. Since the TP activity in various cancers is highly heterogeneous, 
the clinical response of cancer patients to CAP remains relatively low[159]. In 
this study, the TP protein expression was only detected in 2 CRC cell lines. 
Transient transfection of pκB4-CEA205-TP and pcDNA3-TP resulted in high 
and comparable expression levels of TP protein in human CRC cell lines. In 
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contrast, the pCEA205-TP transfected cells only expressed TP protein at very 
low levels. The TP protein expression in these cell lines were reflected by the 
TP activity assay results. These results indicated that the transcriptional 
efficacy of κB4-CEA205 was comparable to that of CMV strong virus promoter. 
In line with the TP protein and enzyme activity results, the MTT assay 
demonstrated that the cytotoxicity of 5´-DFUR to H630 and RKO cell lines 
was highly sensitised by the transfection of pcDNA3/TP or pκB4-CEA205-TP 
(8.8 – 14.5-fold, Fig. 3.7; Fig 3.8 and Table 3.2). 
 
The low transfection rate in vivo is one of the limitations for the clinical 
application of GDEPT which can be overcome by bystander effect. Using 
strong virus promoters, it has been reported that the 5-FU derived from 5´-
DFUR can diffuse from the transfected cancer cells to exert bystander killing 
effect on their neighbour cells in a gap junction-independent manner[275,287]. In 
this study, we also compared the bystander effect of 
pFastBacDualΔpromoter/κB4-CEA205-TP and pcDNA3/TP transfected cancer 
cell lines. Figure 5C and 5D show that the cytotoxicity of 5´-DFUR to RKO and 
H630 cell lines was significantly enhanced by the mixture of only 5% of 
pcDNA3/TP or pFastBacDualΔpromoter/κB4-CEA205-TP transfected cells. 
The bystander effect was levelled off when further increasing the TP-
transfected cells in the mixture. As well, the bystander effect of pcDNA3/TP 
and pFastBacDualΔpromoter/κB4-CEA205-TP transfection was very similar in 
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both cell lines.  
 
The κB4-CEA205 system produces very promising results and  also It has 
been reported that in a reporter vector the enhancing activity of NF-κB can be 
further improved by multi-tandem copies of κB element located upstream of a 
weak promoter sequence. Eight linked NF-κB binding sites in tandem (κB8) 
were constructed upstream of CEA205 promoter to further improve the 
transcriptional activity of the CEA promoter. The enhancing effect of κB8 on 
the transcriptional activity of CEA205 promoter region was examined. In 
comparison with κB4, κB8 further enhanced the transcriptional activity of 
CEA205 promoter in CRC cell lines (Fig.3.14A and Table 3.4). The luciferase 
assay showed that the transcriptional activity of κB8-CEA205 was stronger 
than of SV40 promoter, but still weaker than CMV promoter (Fig. 3.14B). 
Transient transfection of pκB8-CEA205-TP pκB4-CEA205-TP and pcDNA3-
TP resulted in comparable expression levels of TP protein in four human CRC 
cell lines. The MTT assay demonstrated that The RKO and LoVo cell lines 
transfected with pκB8-CEA205-TP became slightly sensitive to 5’-DFUR than 
the transfection of pκB4-CEA205-TP (Fig. 3.15 and Table 3.5). These results 
indicated that although κB8 enhancer can further increase the transcriptional 
activity of CEA promoter compared to κB4, κB8 cannot further improve the 
enzyme expression and cytotoxicity. 
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hTERT promoter have been used to drive transgene expression for 
therapeutic benefit. It is similar to CEA that hTERT is also a weak promoter. 
Therefore κB8 and κB4 were used to improve the activity of hTERTcore 
promoter including approximately 200 bp upstream of the transcription start 
site. Both κB8 and κB4 improve the transcriptional activity of hTERTcore 
promoter in CRC and breast cancers but not in normal cell lines (Fig. 3.21). In 
comparison with κB4, the κB8 enhancer demonstrated stronger enhancing 
effect on hTERTcore promoter (Table 3.6, 3.7). Transient transfection of pκB8-
hTERTcore-TP resulted in increasing expression levels of TP protein than 
transfection of pκB4-hTERTcore-TP in human CRC cell lines H630 and RKO, 
but it’s still much weaker than pcDNA3-TP (Fig. 3.22). Cytotoxicity assay did 
not carry out due to the transfection efficiency. 
 
Adenoviral vectors were constructed to overcome low efficiency of 
transfection using lipofetamine on some colon cancer cell lines. Infection with 
TP containing adenoviral vectors in colon cancer cell line H630 expressed the 
TP proteins immediately after harvesting the virus vector (Figure. 3.24) but it 
failed to express at high levels after stored at -20℃ for several days. The virus 
vectors constructed in this project will be used in the study carried out by 
other researchers in the future. 
  
The molecular mechanisms of enhancing effect of κB4 on CEA and 
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hTERTcore promoter activity in this study were still not clear. Although by 
definition, enhancer is a DNA element which efficiently regulates promoter 
activity distantly and orientation-independently[288,289], the relationship between 
enhancer and promoter elements is far more complex. A cooperative 
interaction between NF-κB and Sp1 has been demonstrated in human 
immunodeficiency virus long terminal repeat (HIV-1 LTR) promoter region 
[286,290]. The cooperation between NF-κB and Sp1 in the HIV-1 LTR is highly 
space and orientation-dependent. The promoter activity is significantly 
impaired by the insertion of DNA fragments between the κB and Sp1 binding 
sites. Mutation of the adjacent κB and Sp1 DNA binding sites completely 
abolishes the phorbol myristate acetate (PMA) inducible transcriptional 
activity[286]. It was also reported that an Sp1-dependent promoter is distantly 
enhanced by an NF-κB enhancer[291]. The cooperation between NF-κB and 
Sp1 needs direct contact of both proteins and other transcription 
modulators[286,291]. Chromatin modulation is also involved. Two Sp1 and Sp1-
like DNA binding sites are located on the CEA promoter region (FP2 and 
FP3)[252,292]. Therefore, the interaction between NF-κB and Sp1 may also play 
a role in our κB4-CEA205 enhancer-promoter system. The κB4 enhancer 
demonstrated higher enhancing effect on CEA205 than CEA421 in most CRC 
cell lines (Fig. 3A). The distance between the κB4 and the 5´ Sp1 in κB4-
CEA205 and κB4-CEA421 fragments was 29 and 250 nt respectively. The 
spatial rule may also partially apply to the enhancer-promoter systems in this 
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study. Sp1 is a common element in cancer specific promoters e.g. CEA, 
survivin and hTERT[252,292-294]. Therefore, investigation of the relationship 
between κB4 and Sp1 might provide evidence for using κB4 to improve the 
transcriptional activity of other cancer specific promoters. 
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Table 3.1 Transcriptional activities of κB4, CEA205 and κB4-CEA205 in CRC and normal cells 
 LoVo Caco2 H630 HCT116 HCT15 HT29 DLD-1 RKO EAhy926 HUVEC HMEC HNEpC 
pκB4-Luc 5.6±0.7 13.0±4.5 13.0±2.7 14.0±2.1 13.8±4.0 2.3±0.7 34.4±3.4 12.2±0.3 1.0±0.5 1.0±0.08 1.0±0.08 0.7±0.003 
pCEA205-Luc 20.4±8.3 31.3±5.1 31.3±4.7 101.1±5.2 72.8±5.3 11.3±2.0 191.3±18.9 42.0±2.3 1.1±0.6 1.1±0.02 1.1±0.02 2.3±0.01 
pκB4-CEA205-Luc 180.6±23.9 183.9±16.9 183.9±2.6 379.3±21.4 558.3±83.8 19.6±6.4 993.6±68.1 207.4±3.8 1.0±0.003 0.95±0.003 0.95±0.003 1.8±0.02 
The data represent mean relative luciferase units from 3 replicates ± SD. 
 
Table 3.2 The cytotoxicity of 5´-DFUR on the transiently transfected CRC cell lines 
 pcDNA3 pcDNA3/TP pκB4-TP pCEA205-TP pκB4-CEA205-TP 
H630 33.4 ± 3.2 2.3 ± 1.0 28.3 ± 1.9 25.1 ± 0.8 3.3 ± 1.2 
RKO 33.6 ± 9.1 3.8 ± 2.5 20.7 ± 2.5 15.6 ± 1.1 4.4 ± 0.2 
The data represent the mean IC50 (µm) of 5´DFUR from 3 replicates ± SD. 
 
Table 3.3 The cytotoxicity of 5´-DFUR on the stably transfected CRC cell lines 
 pcDNA3 pcDNA3/TP 
ppFastBacDualΔpromoter/κB4-CEA205-TP 
C1                               C2 
H630 27.7 ± 12.9 0.94 ± 0.54 0.96 ± 0.02 0.94 ± 0.03 
RKO 28.3 ± 13.2 1.16 ± 0.71 0.9 ± 0.07 1.0 ± 0.06 
The data represent the mean IC50 (µm) of 5´DFUR from 3 replicates ± SD. C1 and C2: clones 1 and 2. 
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Table 3.4 Transcriptional activity ofκB8, κB8-CEA205, κB4-CEA205 and κB4 in CRC cells 
The data represent mean relative luciferase units from 3 replicates ±SD 
 
.Table3.5 The cytotoxicity of 5´-DFUR on the transiently transfected CRC cell lines 
 pκB8-CEA205-TP pCMV-TP pκB4-CEA205-TP 
RKO 1.75± 1.3 1.66± 1.2 2.25± 2.17 
LoVo 2.58± 0.85 2.34± 0.15 3.07± 1.22 
The data represent the mean IC50 (µm) of 5´DFUR from 3 replicates ± SD. 
 
Table 3.6 Transcriptional activity of κB8-hTERTcore, κB4-hTERTcore, hTR, hTERTcore and κB8 in CRC cells 
 H630 RKO LoVo CaCo2 HCT116 HCT15 DLD-I BE HT29 
pκB8-hTERTcore-Luc 97.8±4.9 88.6±16.3 95.8±9.3 85.3±10..9 143.1±7.8 156.9±17.7 295.5±37.1 175.5±8.6 243.1±24.4 
PκB4-hTERTcore-Luc 20.6±1.9 19.9±2.0 34.1±2.1 27.2±1.8 35.9±3.9 50.2±3.8 79.1±6.8 51.5±8.2 65.1±8.4 
phTERTcore-Luc 3.4±0.2 8.0±0.6 6.0±0.4 3.8±0.3 9.2±5.2 9.2±31.25 15.4±80.9 15.4±2.7 33.9±26.7 
phTR-Luc 31.7±4.1 115.9±10.9 26.3±3.4 27.7±2.2 21.0±4.4 88.5±6.8 84.8±16.4 48.6±8.4 103.5±9.2 
pκB8-Luc 22.5±2.4 32.0±3.0 34.1±4.2 24.3±3.6 47.7±11.5 40.4±3.6 121.6±7.8 20.8±3.4 64.3±7.8 
The data represent mean relative luciferase units from 3 replicates ± SD. 
 
 H630 RKO LoVo CaCo2 HCT116 HCT15 DLD-I BE HT29 
pκB8-CEA205-Luc 823.4±  40.5 331.9± 60.5 92.3 ±5.5 76.7± 6.8 92.1± 7.5 95.1± 11.1 576.5 ±48.6 246.2 ±8.7 10.5 ±2.8 
pκB4-CEA205-Luc 295.8± 18.4 219.7 ±38.2 57.5±9.4 53.8±6.4 51.6±7.4 49.5±3.4 222.0±30.7 90.8±47.65 2.9±0.6 
pκB8-Luc 35.9±0.27 25.1±0.33 5.2±0.26 2.0±0.1 3.5±0.6 4.4±0.5 10.8±0.8 17.3±0.7 1.7±0.1 
pκB4-Luc 8.3±0.1 4.3±0.2 2.0±0.3 1.5±0.05 2.8±0.1 3.0±0.6 4.6±0.3 2.5±0.4 1.1±0.1 
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Table 3.7 Transcriptional activity of κB8-hTERTcore, κB4-hTERTcore, hTR, hTERTcore and κB8 in a serial cell lines 
 MCF7 ZR75 LDAN NCI-H23 NCI-H125 CALU G-CCM A431 MDA 
pκB8-hTERTcore-Luc 154.0±12.5 67.0±4.6 71.8±5.3 22.8±1.7 94.7±8.8 31.0±2.0 30.0±0.5 13.9±3.2 66.5±1.9 
PκB4-hTERTcore-Luc 16.3±4.5 12.6±1.8 21.1±4.5 7.2±1.8 34.1±4.0 6.6±1.5 1.9±1.7 5.9±1.4 7.4±1.2 
phTERTcore-Luc 2.5±4.3 6.3±1.5 5.8±1.3 6.6±0.7 7.6±2.7 1.9±0.9 1.4±0.4 2.2±0.2 3.1±0.3 
phTR-Luc 18.0±1.3 9.2±0.7 32.9±4.3 19.4±2.8 54.0±4.0 6.0±1.5 1.8±1.7 13.9±1.4 12.4±1.2 
pκB8-Luc 21.0±2.2 14.3±1.0 10.6±2.2 3.4±1.0 5.0±0.9 1.6±0.4 5.1±0.8 3.2±2.2 5.1±0.2 
The data represent mean relative luciferase units from 3 replicates ± SD. 
 
Table 3.8 TP containing pShuttle vectors 
 Parent vectors Enzyme  Parent vectors Enzyme 
pShuttle-κB8-CEA205-TP pShuttle pκB8-CEA205-TP NotI/XbaI pShuttle-κB4-hTERTcore-TP pShuttle PκB4hTERTcore-TP NotI/XbaI 
pShuttle-κB8-hTERTcore-TP pShuttle pκB8-hTERTcore-TP NotI/XbaI pShuttle-TP pShuttle pcDNA3-TP KpnI/XbaI 
pShuttle-CEA205-TP pShuttle pCEA205-TP NotI/XbaI pShuttle-CMV-TP pShuttle-TP pShuttle-CMV KpnI/HindIII 
pShuttle-hTERTcore-TP pShuttle phTERTcore-TP NotI/XbaI pShuttle-hTR-TP pShuttle-hTR-Luc pκB4-hTERTCore-TP HindIII/XbaI 
pShuttle-κB4-TP pShuttle pκB4-TP NotI/XbaI pShuttle-SV40-TP pShuttle-SV40-Luc pκB4-hTERTcore-TP HindIII/XbaI 
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Chapter 4 
Potentiation of Gemcitabine Cytotoxicity in Colon and 
Breast Cancer Cell Lines by Disulfiram and Copper Complex  
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4.1 Introduction 
Gemcitabine (2´, 2´-difluorodeoxycytidine, dFdC) shows activity against a wide 
range of haematological and solid cancers used alone or in combination with 
other anti-cancer agents. The chemoresistance is still the major obstacle for the 
success of dFdC based chemotherapy. Due to its complex metabolism of action 
and multiple cellular targets, the resistant mechanisms of cancer cells to dFdC 
are multifactorial[102]. Although extensive research has been performed, the 
molecular mechanisms of dFdC resistance are still far from fully elucidated. 
Human cancer cells with induced NF-κB nuclear activity have demonstrated 
resistance to chemotherapy[7,166]. Inhibition of NF-κB activity by IκB enhances the 
cytotoxicity of anti-cancer drugs to cancer cell lines[167]. Disulfiram (DS) has very 
strong anti-cancer effect on solid cancers and protects normal tissues from 
chemotherapy-induced damage. It also potentiates the cytotoxicity of some anti-
cancer drugs[295,296]. There have been several reports demonstrated that DS is a 
strong proteasome inhibitor[175,297]. DS inhibits proteasome activity by forming a 
complex with copper which blocks the degradation of IκB and NF-κB nuclear 
translocation[166]. DS inhibits 5-FU induced NF-κB activation, sensitizes colon 
cancer cell lines to 5-FU and efficiently reverses 5-FU resistant in the resistant 
colon cancer cell lines[166]. There are overlapping anti-cancer mechanisms and 
anti-cancer spectrum between dFdC and 5-FU[102,298]. The status of cross-
resistance between these two drugs is still largely unknown. Investigation of the 
cross-resistance between these two drugs will provide useful information for their 
clinical application. Firstly, the cross-resistant status between 5-FU- and dFdC-
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resistant cell lines was investigated. Secondly, the effect of NF-κB activity on 
dFdC resistance was determined. Finally, the in vitro chemosensitizing effect of 
DS on the cytotoxicity of dFdC was analysed in 5-FU and dFdC resistant cancer 
cell lines. 
 
4.2 Results 
4.2.1 Cytotoxicity of 5-FU and dFdC to cancer cell lines and cross-resistant 
status between 5-FU and dFdC.  
The cytotoxicity of 5-FU and dFdC to the drug sensitive cell lines H630WT, 
HCT116WT and MCF7WT and resistant cancer cell lines H630GEM, HCT116GEM and 
MCF7FU2.5 was determined by MTT assay as described in material and method 
part. The IC50 values of 5-FU and dFdC to these cell lines are shown in Table 4.1. 
The acquired dFdC resistant colon cancer cell lines (H630GEM and HCT116GEM) 
were highly resistant to dFdC (1,800 – 2,000-fold). The 5-FU resistant colon 
(H630R10) and breast (MCF7FU2.5) cancer cell lines were 37 and 40-fold resistant 
to 5-FU respectively. To determine the cross-resistance, the 5-FU and dFdC 
resistant cell lines were cross treated with dFdC and 5-FU, respectively. The 
colon cancer cell line H630R10 was highly cross-resistant to dFdC (> 580-fold). 
The 5-FU resistant breast cancer cell line (MCF7FU2.5) showed resistance to 
dFdC (~ 3-fold). In contrast, the dFdC resistant cell lines were only resistant to 5-
FU (2.8 and 1.5-fold for H630GEM and HCT116GEM respectively). 
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Table 4.1: The cytotoxicity of 5-FU and dFdC in cancer cell lines 
The IC50 figure is mean from 3 replicates. SD in parentheses. *H630GEM, HCT116GEM: 
DS 0.35μM, CuCl2 0.5μM; H630R10: DS 0.3 μM, CuCl2 0.5μM; H630WT and HCT116WT: 
DS 0.2μM, CuCl2 0.5μM. 
                                                                                                  
 
4.2.2 The expression status of dCK, RRM1 and TS protein in drug resistant 
and sensitive cell lines.  
The down-regulation of dCK and overexpression of RRM1 protein are the 
common features for dFdC resistent cancers[102]. The protein expression levels of 
these two enzymes were determined by western blot. In comparison with relevant 
parental cell lines, the dCK protein was almost undetectable in both dFdC 
resistant H630GEM and HCT116GEM colon cancer cell lines and slightly down-
regulated in 5-FU resistant colon (H630R10) and breast (MCF7FU2.5) cancer cell 
line (Fig. 4.1A). In contrast, there was no significant difference in RRM1 
expression between dFdC resistant colon cancer cell lines, 5-FU resistant breast 
cancer cell line and relevant sensitive parental cell lines. It was intriguing that in 
comparison with the sensitive cell line, RRM1 protein was expressed at 
 H630WT H630R10 H630GEM HCT116WT HCT116GEM MCF7WT MCF7FU2.5 
5-FU (µM) 11.6 (0.5) 
438.1 
(43.3) 
31.9 
(7.6) 
30.6  
(0.7) 
44.7  
(9.9) 
3.3  
(0.2) 
135.0 
 (23.0) 
dFdC 
(nM) 
w/o DS 
17.1 (1.7) >10,000 
37,864 
(4,262) 
17.3 (4.2) 
32,521 
(7,425) 
17.4  
(5.0) 
50.2 
 (4.5) 
dFdC 
(nM) 
+DS/CuCl
2* 
7.8 
(1.4) 
10.7 
(2.1) 
34.9 
(6.0) 
4.4 
(0.4) 
56.2 
（11.4） 
ND ND 
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significantly lower level in the 5-FU resistant H630R10 cell line. As a major 
molecular target of 5-FU, TS gene amplification and protein overexpression are 
commonly detected in 5-FU resistant cancer cell lines. There was a 1-3 folds 
cross-resistance of dFdC resistant cell lines to 5-FU. Therefore, the TS protein 
expression levels were also compared in the dFdC resistant and sensitive cell 
lines. Western blot demonstrated that TS protein was over-expressed in the 
dFdC resistant colon cancer cell lines (Fig. 4.1B). 
 
 
Figure 4.1: Western blotting analysis of the expression status of dCK, RRM1 and TS  
A. dCK and RRM1 protein expression levels in dFdC and 5-FU resistant and sensitive cell 
lines. B. Comparison of TS protein levels in dFdC resistant and sensitive colon cancer cell 
lines. Vinculin: protein loading control. 
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4.2.3 NF-κB status in drug resistant and sensitive cancer cell lines.  
It has been reported that NF-κB is correlated with anti-cancer drug resistance. 
NF-κB status in drug resistant and sensitive cancer cell lines was investigated by 
EMSA analysis. In comparison with relevant sensitive parental cell lines, all drug 
resistant cell lines, apart from HCT116GEM, demonstrated high NF-κB DNA 
binding activity (Fig. 4.2A). Reporter gene assay was carried out to compare the 
transcriptional activity of sensitive and resistant cell lines. In consistent with 
EMSA result, the higher transcriptional activity was also detected in most of the 
resistant cancer cell lines. In contrast, the dFdC resistant HCT116GEM showed a 
relatively lower NF-κB reporter gene activity than its sensitive counterpart (Fig. 
4.2B). 
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Figure 4.2: NF-κB activities in drug resistant and sensitive cancer cell lines 
A. The NF-κB DNA binding activity was determined by EMSA assay. Five micrograms of 
nuclear extracts from different cell lines were used. B.The transcriptional activity of NF-κB in 
drug resistant and sensitive cell lines. The cells were co-transfected with pNF-κB-Tal-Luc or 
pGL3-Basic and pRL3-SV40 vectors. The luciferase activity of each transfection was 
normalized by the Renilla reading (the formula in the text). The column represents the mean 
of three measurements and the bar represents the SD. 
 
 
4.2.4 The influence of dFdC on NF-κB activity 
Most of tested drug resistant cell lines show high NF-κB DNA binding activity and 
higher transcriptional activity than sensitive ones. Previously, it has been reported 
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that some anti-cancer drugs, e.g. 5-FU, can induce NF-kB nuclear activity. dFdC 
might have the same effect. To determine the influence of dFdC on NF-κB activity, 
the H630WT and HCT116WT were exposed to dFdC for different time lengths and 
then subjected to EMSA analysis. The 5-FU treated cells were used as positive 
control. The NF-κB DNA binding activity was induced by dFdC in a time-
dependant manner (Fig. 4.3A). To verify the binding specificity, 5 mg of nuclear 
extracts from H630WT cells were pre-incubated with 20 times higher 
concentration of unlabeled wild-type or mutant NF-kB probe before EMSA. The 
retarded bands were removed by the unlabeled wild-type NF-kB probe but not by 
the mutant one (Fig. 4.3B, Lanes 2 and 3). To determine the involved NF-kB 
subunits, the nuclear extract was pre-incubated with different NF-kB antibodies 
(p65, p50, p52, c-Rel and RelB) for 30 minutes and examined by EMSA. Figure 
4.4B illustrates that the supershifting bands were only produced by NF-kB p50 
and p65 antibodies (Lanes 4 and 5) but not by p52, c-Rel, RelB or VEGF (Fig. 
4.3B, Lanes 6 – 9).  
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Figure 4.3: Influence of NF-κB activity by dFdC 
A. dFdC induced NF-κB activity in a time-dependent manner. The nuclear extract (5 mg/lane) 
from H630WT and HCT116WT cell lines exposed to 10 mM dFdC or 50 μM 5-FU for different 
time lengths (0 – 180 minutes) was subjected to EMSA. B. Binding specificity and supershift 
assay. Nuclear extract of H630WT cells was incubated with antibodies or unlabeled NF-κB 
probes and tested by EMSA. 
 
 
4.2.5 NF-κB-induced dFdC resistance.   
According to results from part 4.2.3 and 4.2.4, dFdC induce NF-κB activity of 
sensitive cell lines in a time-dependent manner. Also once the cell lines became 
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resistant to 5-FU and dFdC, most of them show higher DNA binding activity and 
transcriptional activity than sensitive ones. The question of how the NF-κB 
influences the sensitivity of cancer cell lines to dFdC is still unclear. To determine 
this, the breast cancer cell line, MCF7  was stably co-transfected with NF-κB p50 
and p65 subunits. The positive clones were selected. Expression status of NF-κB 
p50 and p65 protein was detected in the transfected cells by western blot, 
positively transfected cells (p50/p65p, p2, c4) overexpress p50 and p65 proteins 
(Fig. 4.4). In comparison with the negative control cells (pcDNA3 mock 
transfected), EMSA and reporter gene assay results demonstrated high NF-κB 
DNA binding and transcriptional activity respectively in the positively transfected 
cells (Fig. 4.5A and 4.5B).  
 
 
Figure 4.4: The NF-κB protein expression in NF-κB subunits p50 and p65 
transfected MCF7 cells. 
The p65, p50 expression level was determined by western blotting. 100 μg of each 
sample was used. P is pooled colne. P2 is pooled clone 2. C4 is clone 4. Vinculin was 
used as loading control. 
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Figure 4.5: NF-κB DNA binding and transcriptional activity of NF-κB in p65/p50 co-
transfectedand parental MCF7 cell lines 
A. NF-κB DNA binding activity was determinded by EMSA assay. B. the transcriptional 
activity of NF-κB. The cells were co-transfected with pNF-κB-Tal-Luc or pGL3-Basic and 
pRL3-SV40 vectors. And the luciferase activity was determined using a luminometer. The 
luciferase activity of each transfection was normalized by the Renilla reading (the formula 
in the text). The column represents the mean of three measurements and the bar 
represents the SD. 
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MTT assay was carried out to investigate the cytoxicity of dFdC on p65, p50 
transfected and pcDNA3 transfected cells. The results showed that in 
comparison with the pcDNA3 mock transfected cells, the p50 and p65 
transfection induced ~ 3.2 – 4-fold resistance to dFdC (Table 4.2). The down-
regulation of dCK and overexpression of RRM1 protein are the common features 
for dFdCresistance. So the protein expression levels of these two enzymes in 
transfected cells were determined by western blot. The expression levels of 
RRM1 and dCK protein between positively transfected and pcDNA3 mock 
transfected cell lines were comparable (Fig. 4.6). The TS protein was also 
expressed at very similar levels in p65 plus p50 transfected and pcDNA3 
transfected cells (Fig. 4.6). 
 
Table 4.2 The cytotoxicity of gemcitabine in NF-κB p50 and p65 transfected MCF7 cells 
 pcDNA3 C4 P P2 
GEM (nM) 23.2 (8.5) 73.9* (7.4) 92.0* (22.6) 81.5* (12.0) 
The IC50 figure is mean from 3 replicates. SD in parentheses.*VS pcDNA3, P<0.05 
Figure 4.6: dCK, RRM1 and TS protein expression status in NF-κB p50 and p65 
subunits transfected and control cells.  
The expression levels of dCK, RRM1 and TS were determined by western blotting. 
Vinculin was used as loading control. 
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4.2.6 The influence of inhibition of NF-κB on cytoxicity of dFdC  
Cells became resistent to dFdC by increasing the expression of NF-κB subunits 
p50 and p65. The next series of study was to determine whether inhibition of NF-
κB can sensitize the cells to dFdC.  For this purpose, colon cancer cell line 
HCT116WT was transfected with by IκBα super-repressor (IκBSR). High level of 
expression status of IκBα was detected in the transfected cells by western blot 
(Fig. 4.7A). Reporter gene assay results demonstrated that IκBSR transfected 
cells possessed ~ 1.5 – 4-fold lower NF-κB transcriptional activity than that in the 
control cells (pcDNA3 mock transfected; Fig. 4.7B). Positive clone 2 and pooled 
cells (p1) were subjected to cytoxicity assay (Fig. 4.8). In comparison with the 
pcDNA3 mock transfected cells, the IκBSR transfection demonstrated ~ 1.5- to 
1.8-fold more sensitive to dFdC and ~ 1.9- to 2-fold more sensitive to 5-FU (Table 
4.3). 
Table 4.3 The cytotoxicity of 5-FU and dFdC in IκBSR transfected HCT116 cells 
 pcDNA3 C2 P1 
5-FU(μM) 22.4(1.86) 10.3(2.1) 11.4(0.9) 
dFdC (nM) 11.8(1.1) 7.6(0.2) 6.3(1.6) 
The IC50 figure is mean from 3 replicates. SD in parentheses. 
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Figure 4.7: IκBα expression level and NF-κB transcriptional activity of IκBSR 
transfected cells 
A. western blotting analysis of IκBα expression, Vinculin was used as loading control. B. NF-
κB transcriptional activity was determined by reporter gene assay. The cells were co-
transfected with pNF-κB-Tal-Luc or pGL3-Basic and pRL3-SV40 vectors. The luciferase 
activity of each transfection was normalized by the Renilla reading. The luciferase activity is 
represented by the ratio of the specific promoter over the activity of pGL3-Basic. The column 
represents the mean of three measurements and the bar represents the SD. 
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Figure 4.8: Cytotoxicity of 5-FU and dFdC to IκBSR transfected cells. 
The cells were treated with drugs for seventy two hours before analysis of cytotoxicity by 
MTT assay. Curves were derived from three replicates and the bars represent standard 
deviations. 
 
 
4.2.7 DS and copper complex potentiated dFdC cytotoxicity in drug 
resistant and sensitive cancer cell lines.  
It has been reported that DS inhibits 5-FU induced NF-κB activation and 
sensitizes colon cancer cell lines to 5-FU and efficiently reverses 5-FU resistant 
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in the resistant colon cancer cell lines[166]. Also the above results showed that 
dFdC resistance was NF-κB-correlated. So, next step of this study was to test if 
DS can also improve the cytotoxicity of dFdC in cancer cell lines. The toxicity of 
DS alone to the dFdC and 5-FU resistant colon cancer cell lines was tested first 
(Fig. 4.9A). It was similar to some cancer cell lines tested by other groups[195,299], 
the dose response curves for these cell lines were biphasic. DS alone showed 
highest cytotoxicity at around 1 μM concentration, whereas more cancer cells 
survived when DS concentration increased to ~ 5 – 6 μM. This biphasic effect of 
DS may hinder the potential clinical use of this drug in cancer treatment. It has 
been reported that copper can improve the inhibiting effect of DS on proteasome 
activity. Therefore, the reversion of the biphasic effect of DS by combining use of 
DS with copper was tested. The data derived from three dFdC and 5-FU resistant 
colon cancer cell lines demonstrated that although the cytotoxicity of DS was not 
significantly enhanced by copper, the second survival peak was diminished by 
combination of DS and copper (Fig. 4.9B). Copper alone was not toxic to these 
three cell lines (data not shown). The IC30 values of DS/Cu complex (H630GEM 
and HCT116GEM: 0.2 μM; H630R10: 0.3 μM) were determined by narrowing down 
the concentrations (Fig. 4.9C). Furthermore, the cytotoxicity of dFdC along with 
DS/Cu complex was examined. Table 4.1 shows that the cytotoxicity of dFdC in 
colon and breast cancer cell lines was highly potentiated and the dFdC 
resistance was reversed by combining use of DS/Cu complex at IC30 
concentration with dFdC.  
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Figure 4.9: Cytotoxicity of DS, DS/Cu and DS/Cu/dFdC in colon cancer cell lines 
A. DS alone was cytotoxic to H630WT, HCT116WT and H630R10 cell lines but demonstrated 
biphasic effect. The second survival peaks demonstrated in all three cell lines at DS 
concentrations of ~ 6 – 10 μM. B. The biphasic effect of DS was diminished by the combining 
use of CuCl2 with DS. C. The cytotoxicity curves of H630GEM, HCT116GEM and H630R10 cell 
lines treated with DS in combination with CuCl2. The column and bar: mean and SD 
respectively, n = 3. 
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4.2.8 Cell morphology change after treatment of single and combination 
drugs 
Figure 4.10 shows the morphology of cancer cell lines after exposed to different 
drug combinations for 72 hours. The results of morphology are in support of the 
MTT cytotoxicithy assay results. There was a morphological difference observed 
between the cells treated with dFdC alone and the combination of CuCl2, 
Disulfiram and dFdC. Only the cell treated with DS/Cu/dFdC demonstrated 
morphological changes e.g. cell body shrinking, nuclear condensation, bubble-
like blebs and debris.  
 
Figure 4.10: The morphology of HCT116GEM, H630GEM and H630R10 after treatment 
Cells were treated with drugs for 72 hours before the pictures were captured. dFdC: 1 μM of 
gemcitabine; DS/Cu (disulfiram and copper complex): H630GEM and HCT116GEM were treated 
with 0.35 μM and H630R10 was treated 0.3 μM. DS/Cu/dFdC: The cell lines were treated with 
the above concentrations of DS/Cu plus 1 μM of dFdC. The pictures on the right show that 
cells become round and shrinking. 
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4.2.9 DS and copper complex inhibited dFdC-induced NF-κB activity  
The EMSA analysis was performed to determine the inhibiting effect of DS/Cu 
complex on the dFdC-induced NF-κB activity in two colon cancer cell lines. 
Figure 4.11A shows that the DS/Cu complex significantly inhibited NF-κB DNA 
binding activity at a very low concentration (~ 1 μM). In contrast, DS alone did not 
inhibit (H630WT) or only inhibited NF-κB activity at relatively high concentration 
(HCT116WT, ~ 25 μM). Zinc is another bivalent metal atom which can be chelated 
by DS to form complex. The effect of DS/Zn complex on the dFdC-induced NF-
κB activity in two colon cancer cell lines was investigated as well. The DS/Zn 
complex also only demonstrated inhibition of NF-κB activity at relatively high 
concentrations (~ 10 μM) (Fig. 4.11B).   
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Figure 4.11: The effect of DS, DS/Cu and DS/Zn on dFdC induced NF-κB DNA binding 
activity in H630WT and HCT116WT cell lines.  
A. The effect of DS/Cu complex on dFdC induced NF-κB DNA binding activity. B. The effect 
of DS or DS/Zn on dFdC induced NF-κB DNA binding activity. The nuclear extract (5 μg/lane) 
from cells treated with different compound for 24 hours was subjected to EMSA assay. 
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4.2.10 DS and copper complex inhibits proteasome activity 
The 26S proteasome maintain the orderly degradation of cellular proteins. 
Proteasome inhibition can cause cellular apoptosis by affecting the levels of 
various short-lived proteins, resulting in inhibition of NF-κB activity. Proteasome 
inhibitors inhibit NF-κB activity in cells by blocking the degradation of IκB[300]. 
Previously It has been reported the complex of DS-copper is capable of inhibiting 
the proteasome activity[297]. The 20S subunit is the core catalytic complex of 26S 
proteasome. Therefore the inhibition of copper alone, zinc alone(10 μM), DS 
alone(10 μM), DS/Cu(10 μM each) and DS/Zn(10 μM each) on purified rabbit 
20S proteasome was tested. DMSO was used as vehicle control. The 
commercially available proteasome inhibitor, MG132 was used as positive control. 
The results showed that both CuCl2 and DS/Cu manifested inhibiting effect on 
20S proteasome at different levels. DS/Cu demonstrated strongest inhibition 
effect on the 20S proteasome activity which was over 3-fold higher inhibition than 
CuCl2 alone and was also stronger than equal molar concentration of MG132. 
Zinc alone and DS/Zn also showed inhibiting effect on the proteasome activity 
but the inhibiting effect was much weaker than DS/Cu (Fig. 4. 12A Table 4.4). 
Figure 4.12B demonstrates that CuCl2, DS/Cu complex and MG132 inhibited 20S 
proteasome in a dose-dependent manner.   
 
Table 4.4 20S proteasome activity  
 -VE DMSO DS CuCl2 
CuCl2-
+DS 
ZnCl2 
ZnCl2 
+DS 
1μMM 
G132 
10uM 
MG132 
F P 
Activity 
92.8 
(5.9) 
64.4 
(6.5) 
41.0 
(1.0) 
15.2 
(1.4) 
5.6 
(0.8) 
21.7 
(4.1) 
19.2 
(1.0) 
26.9 
(1.4) 
7.9 
(0.1) 
967.026 .000 
The figure is mean from 3 replicates. SD in parentheses 
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Figure 4.12: Inhibition of DS-Copper complex on 20S proteasome activity 
DMSO was used as vehicle control. MG132 was used as positive control. The column 
represents the mean of three measurements and the bar represents the SD. B: CuCl2, 
DS/Cu complex and MG132 inhibited 20S proteasome in a dose-dependent manner 
 
 
4.3 Discussion 
Both 5-FU and dFdC are antimetabolites widely used singly or in combination in 
the chemotherapy of a variety of solid cancers[301-305]. Although objective 
responses and survival benefits have been improved, complete responses to 
dFdC and 5-FU based chemotherapy are uncommon. The acquired resistance 
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induced by repetitive exposure of cancer cells to anti-cancer drugs is one of the 
major limitations for the success of dFdC and 5-FU based chemotherapy. Despite 
extensive studies before, the molecular mechanisms involved in dFdC resistance 
are still largely obscure. Investigation of dFdC resistance and the cross-
resistance between dFdC and 5-FU will provide useful information for cancer 
chemotherapy. In this study, dFdC resistance and cross-resistance between 
dFdC and 5-FU was invested in two acquired dFdC resistant colon (H630GEM and 
HCT116GEM) and 5-FU resistant colon (H630R10) and breast (MCF7FU2.5) cancer 
cell lines. In comparison with the relevant sensitive parental cell lines, both dFdC 
resistant cell lines were highly resistant to dFdC (HCT116GEM: 1800-fold and 
H630GEM: 2200-fold. Consistent with previous report [298,306], only very mild 5-FU 
resistance was detected in both dFdC resistant cell lines (HCT116GEM: 1.5-fold 
and H630GEM: 3-fold). The 5-FU resistant breast cancer cell line, MCF7FU2.5, was 
also mild resistant to dFdC (~ 3-fold). In contrast, the 5-FU resistant H630R10 cell 
line was highly resistant to dFdC (> 580-fold). The in vitro acquired cross-
resistance between 5-FU and dFdC was cell line dependent. The cross-
resistance could reach very high level although most of the cross-resistance was 
mild (~ 2 – 3-fold). Results of this study indicated that the cross-resistance 
between 5-FU and dFdC was a common feature in cancer cell lines which may 
have clinical indication for cancer chemotherapy. 
 
dCK enzyme plays a key role in conversion of dFdC into its active form and RNR 
is one of the major targets for dFdC[96,307]. Therefore, it is not surprised that dFdC 
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resistant cell lines commonly manifest dFdC deficiency and/or RRM1 
overexpression. The dFdC protein was almost undetectable in both dFdC 
resistant cell lines. In contrast, the protein expression levels of RRM1 were 
comparable between the dFdC resistant and parental cell lines (Fig. 4.2A). 
Therefore, the dFdC resistance in these cell lines may mainly be induced by dCK 
deficiency. Although one of the 5-FU resistant cell lines (H630R10) was highly 
cross-resistant to dFdC, the dCK protein expression was only very slightly 
downregulated. Intriguingly, the RRM1 protein expression was downregulated in 
both 5-FU resistant cell lines, especially in H630R10 cells (Fig. 4.2A). Thus, both 
dCK and RRM1 may not be the determinants of cross-resistance of 5-FU 
resistant cell lines to dFdC. TS is one of the major targets of 5-FU. TS protein 
over-expression is a common feature of 5-FU resistance. The dFdC resistant cell 
lines manifested very mild cross-resistance to 5-FU (Table 4.1). It has reported 
before that TS over-expression and gene amplification alone only induces 5-FU 
resistance at low levels[308,309]. The 5-FU cross-resistance in dFdC resistant cell 
lines may be conferred by the over-expression of TS protein. 
 
High constitutive and/or inducible NF-κB activity is related to anti-cancer drugs, 
including dFdC, resistance[7,310-312]. Targeting NF-κB sensitises cancer cells to 
several anti-cancer drugs[167,312,313]. It has been reported before that NF-κB is 
related to 5-FU resistance[7,154,308,314]. Because 5-FU and dFdC are anti-
metabolism drugs sharing common anti-cancer mechanism, NF-κB status in both 
drug resistant cell lines was analysed. High NF-κB DNA binding and 
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transcriptional activity was detected in all of the 5-FU resistant and one of the 
dFdC resistant (H630GEM) cell lines (Fig. 4.3A and B). High dFdC -induced NF-κB 
DNA binding activity, composing of subunits p50 and p65 (Fig. 4.4A and B), was 
detected in colon cancer cell lines. Therefore, high NF-κB activity was a common 
feature of 5-FU and dFdC resistant cell lines.  
 
To determine the importance of NF-κB activity in dFdC resistance, human breast 
cancer cell line MCF7 was co-transfected with NF-κB subunits p50 and p65. The 
NF-κB p50 and p65 protein overexpression and high NF-κB DNA binding as well 
as the transcriptional activity were detected in the transfected cell lines (Fig. 4.5, 
4.6). MTT assay demonstrated that NF-κB induced dFdC resistance (3 – 4-fold) 
in MCF7 cells (Table 4.2). The protein expression levels of both dCK and RRM1 
were comparable between the NF-κB transfected and control cell lines (Fig. 4.7). 
Therefore NF-κB induced dFdC resistance in the transfected cell lines was dCK 
and RRM1 independent. When human colon cancer cell line was transfected with 
IκBSR, the transfected cells were more sensitive to dFdC and 5-FU compared 
with pcDNA3 mock transfected cells, Whereas the sensitizing effect was 
relatively weak (1.5 – 2-fold). This indicated that apart from NF-κB pathway, the 
cancer cell sensitivity to dFdC and 5-FU was also determined by other factors. 
Due in part to the disappointing results associated with chemoresistance and the 
non-specific side effects induced by high-dose chemotherapy, current research 
efforts are directed toward the identification of novel chemosensitizers which 
target antiapoptotic factors and improve therapeutic index of conventional anti-
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cancer drugs without further putting on patient's medication burden[315,316]. 
Inhibition of NF-κB has been widely accepted as a promising means for reversing 
chemoresistance and sensitizing cancer cells to conventional anti-cancer drugs 
[190]. It has previously reported that DS inhibits NF-κB activity and potentiates 
cytotoxicity of 5-FU to colon cancer cell lines[166]. In this study, the results 
demonstrated that DS was cytotoxic to 5-FU and dFdC resistant colon cancer cell 
lines in vitro. DS also significantly enhanced the cytotoxicity of dFdC and 
reversed the chemoresistance in dFdC resistant cancer cell lines (Table 4.1).  
Consistent with a recent report[195], the in vitro cytotoxic effect of DS was biphasic 
on the cancer cell lines. DS showed maximum cancer killing at ~ 1 μM but the 
second cancer cell survival peak appeared at relatively high DS concentrations 
(~ 6 – 10 μM). The biphasic effect has also been observed in the inhibition of NF-
κB activity by diethyldithiocarbamate (DDTC) and pyrrolidine 
dithiocarbamate[193,317]. The recent studies indicate that copper (Cu) ion is 
essential for the cytotoxicity of DS to cancer cells[182,297,318]. Cu is one of essential 
trace element for human beings playing important role as a redox cofactor in 
many Cu-dependent enzymes and tightly regulated in humans. High Cu in the 
cell can produce highly toxic reactive oxygen species (ROS). As a strong chelator, 
DS can facilitate intracellular Cu uptake and trigger production of ROS in cancer 
cells and induce cancer cell apoptosis. Apart from triggering apoptosis, ROS also 
strongly induces NF-κB activity which induces the expression of a wide range of 
anti-apoptotic factors which diminish the apoptotic effect of ROS[319,320]. The 
result of this study demonstrated that the biphasic effect of DS was completely 
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removed by addition of trace amount of CuCl2 into culture medium (Fig. 4.9A and 
B) and enhanced cytotoxicity of DS in cancer cell lines. The EMSA study showed 
that DS/Cu complex strongly inhibited NF-κB DNA binding activity which highly 
mirrored its cytotoxic effect in two colon cancer cell lines (Fig. 4.11A). The NF-κB 
inhibiting effect was only observed in the cells treated with much higher 
concentrations of DS alone or DS/Zn complex (Fig. 4.11B). DS/Cu complex may 
simultaneously induce ROS and inhibit NF-κB activity. It has recently been 
reported that DS/Cu complex is a strong proteasome inhibitor[297]. The activation 
of NF-κB is highly relied on the proteasome-mediated degradation of IκB. The 
20S proteasome inhibition effect was examined in vitro. DS/Cu complex 
significantly inhibit the 20S proteasome activity in a dose dependent manner 
compare to vehicle DMSO (Table 4.4). The consistent existence of DS/Cu 
complex in cancer cells may inhibit proteasome activity and block the 
degradation of IκB and the nuclear translocation of NF-κB. 
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Chapter 5 
Disulfiram/copper Complex Reversed the Cross-
resistance between 5-fluorouracil and Other Anti-cancer 
Drugs 
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5.1 Introduction  
The resistance to chemotherapeutic drugs is the major limitation for the 
clinical success of cancer chemotherapy. Resistance to anti-cancer drugs can 
be either intrinsic (present in the cancer cell before treatment) or acquired 
after treatment. Cancer cells can develop resistance to not only the drug being 
administered, but also to some other anti-cancer drugs with different 
molecular structure and intracellular targets. The mechanisms of resistance 
and cross-resistance are very complicated and commonly dependent on drug 
metabolism pathway and the genetic and epigenetic background of the cancer 
cells. To date, there is still no completely clear and globally satisfactory 
explanation for the development of multiple drug resistance. It is apparent that 
in many cases there is a coordinated involvement of several different systems. 
It has been showed in the last chapter that the 5-FU resistant colon cancer 
cell line H630R10 was 37-fold resistant to 5-FU in comparison with the 
sensitive parental cell line H630WT. The H630R10 also demonstrated high level 
of cross-resistance to dFdC (> 580-fold). 
 
Because 5-FU is a cornerstone chemotherapeutic agent in different cancer 
and commonly used in combination with many other anti-cancer drugs, the 
cross-resistance of 5-FU and other anti-cancer drugs will severely affect the 
therapeutic outcomes. Elucidation and tackling cross-resistance between 5-
FU and other anti-cancer drugs will provide valuable information for 
chemotherapy in clinic. This study investigated the cross-resistance of 5-FU 
and a panel of anti-cancer drugs, e.g. topoisomerase inhibitors (topotecan, 
etoposide and doxorubicin), alkylating agent lomustine (CCNU) in H630R10 
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cell line. The reversing effect of DS/copper complex on the cross-resistance of 
5-FU and the above anti-cancer drugs was also investigated. 
 
5.2 Results 
5.2.1 Cytotoxicity of topotecan, etoposide, doxorubicin and CCNU to 
colon cancer cell lines  
The cytotoxicity of topotecan, etoposide, doxorubicin and CCNU to the drug 
sensitive cell line H630WT, and FU-resistant cell line H630R10 was determined 
by MTT assay. In comparison with parental cell line H630WT, H630R10 was 
significantly cross-resistant to topotecan and etoposide. In comparison with 
the sensitive H630WT cell line, the H630R10 cell line manifested 9.18, 67.88, 
5.77 and 2.74-fold resistance to topotecan, etoposide, doxorubicin and CCNU 
respectively (Fig. 5.1, Table 5.1).  
 
Table 5.1: The cytotoxicity of five anti-cancer drugs on H630WTand H630R10 cell 
lines 
IC50 (μM) Anti-
cancer drug 
n 
H630WT H630R10 
Resistant 
fold 
P 
Topotecan 3 3.09±1.83 28.38±10.6 9.18 0.015 
Etoposide 3 3.48±2.17 236.23±48.39 67.88 0.001 
Doxorubicin 3 0.52±0.42 3.0±1.99 5.77 0.102 
CCNU 3 53.51±19.18 146.83±62.04 2.74 0.067 
The IC50 Value is mean from three replicates ± SD. Resistant fold is the IC50 ratio of resistant cell line to 
sensitive cell line. 
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5.2.2. Expression of the proliferation-related proteins in H630R10 and 
H630WT cell lines  
Cancer is biologically characterized by the enhanced proliferative rate which 
is also the Achilles’ heel of cancer for chemotherapeutic targeting. Most of 
anti-cancer drugs mainly target fast dividing cells. Most of the resistant cancer 
cell lines possess longer doubling time than those of their sensitive 
counterparts[321]. Our previous publication demonstrated that H630R10 cell line 
grows much slower than the parental H630WT cell line[154] and several 5-FU 
resistant cancer cell lines also manifested longer doubling time[321]. The lower 
proliferation rate may protect the cancer cells from anti-cancer drug targeting 
Figure 5.1: Cytotoxicity of topotecan, etoposide, doxorubicin and CCNU to 
H630WT and H630R10 colon cancer cell lines. 
The cells were treated with drugs for seventy two hours before subjected to MTT 
assay. Curves were derived from three replicates and the bars represent standard 
deviations. The drugs were labeled on the top of each graphic curve. ETP: etoposide, 
Top: topotecan, Dox: doxorubicin. 
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and confer them multi-resistant phenomenon to different anti-cancer drugs. 
PCNA and ki-67 are widely accepted proliferation markers. In this study, the 
expression levels of these two proteins were determined using western 
blotting and fluorescent immunocytochemistry analyses. Western Blot 
analysis for the proliferation marker PCNA revealed a lower expression level 
of PCNA in H630R10 cell line than that in H630WT cell line (Fig. 5.2A). 
Consistent with western blotting result, Immunofluorescent result showed that 
in comparison with the parental counterpart, fewer H630R10 cells expressed 
both PCNA and ki-67 markers. The positively stained H630R10 cells also 
demonstrated much lower expression levels (Fig. 5.2B).  
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Figure 5.2: Expression of the proliferation-related markers in H630R10 and H630WT 
cell lines. 
A. the PCNA protein expression level was determined by western blotting. Vinculin was 
used as protein loading control. B. Immunofluorescence in H630WT (top) and H630R10 
(bottom) cell lines stained with anti-PCNA (left) and anti-Ki-67 (right) antibodies. Arrows 
represent positively stained cells. 
 
 
 
5.2.3 Optimization of concentration of DS/copper complex 
In comparison with parental cell line H630WT, H630R10 was highly resistant to 
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topotecan, etoposide, doxorubicin and CCNU. It has been demonstrated in 
the last chapter that DS significantly enhanced the cytotoxicity of dFdC and 
reversed dFdC resistance in the resistant cell lines. In this chapter, the effect 
of DS/copper complex on the cross-resistance of H630R10 to other anti-cancer 
drugs was investigated. First, the cytotoxic effect of DS alone on H630R10 and 
H630WT was tested. It was in agreement with previous report[192,193], the MTT 
results showed a biphasic action when treated with a varying range of 
concentrations of DS. The cancer cells were highly sensitive to the cytotoxic 
effect of DS at lower concentration (~ 1 μM) but more cancer cells survived 
from higher concentration treatment (~ 5 – 10 μM). There were 71.3% survival 
rate of H630R10 cells treated with 10 μM of DS and 32.6% surviving H630WT 
cells after exposed to 5 μM DS (Fig. 5.3). 
 
 
 
Figure 5.3: The cytotoxic effect of DS on H630R10 and H630WT 
The cells were exposed to DS for 72 hours and then subjected to MTT assay. Three 
independent determinations were performed and the bars represent standard 
deviations. 
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DS is a chelator which can chelate divalent metal ion to form complex. In the 
recent years, cumulated evidence indicated that copper played critical role in 
the cytotoxicity of DS. It was also demonstrated in the last chapter that in 
combination with copper, the biphasic cytotoxic effect of DS was eliminated. 
Based on these results, four different concentrations of CuCl2 (0.1 μM, 0.5 μM, 
5 μM and 15 μM) were tried over different concentrations of DS ranging from 
0 to 1 μM to find the precise ratio of DS and CuCl2 for the combination. MTT 
assay showed that treatment of H630R10 with a combination of CuCl2 and DS 
removed the second survival peak that was observed when treated with DS 
(Fig. 5.4). There was no significant difference between DS in combination with 
different concentrations of CuCl2. Therefore the CuCl2 concentration of 0.5 μM 
was chosen to be used in the combination with other anti-cancer drug. The 
IC50s value of DS were 0.43 μM ± 0.14 and 0.54 μM ± 0.14 for H630WT and 
H630R10 cell lines respectively. The IC30 concentration of DS (0.3 μM for 
H630R10 and 0.2 μM for H630WT) in combination with 0.5 μM of CuCl2 was 
used to test the enhancing effect on the cytotoxicity of different anti-cancer 
drugs. 
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Figure 5.4: Cytotoxicity of DS/Copper Complex 
The cytotoxicity of DS in H630WT and H630R10 cell lines was determined in combination 
with four different concentrations of CuCl2 (0.1, 0.5, 5 and 15 μM). Curves were derived 
from three replicates and the bars represent standard deviations. 
 
 
5.2.4 DS/copper complex reverse the cross resistance of 5-FU resistant 
cells to other anti-cancer drugs. 
A combination treatment with CuCl2 and DS along with the anti-cancer drugs 
was tested by MTT assay. Since different concentrations of CuCl2 
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demonstrated similar effect on the cytotoxicity of DS in both cell lines, 0.5 μM 
CuCl2 was arbitrarily chosen for the combination use in all further studies. A 
combination of 0.3 μM DS, 0.5 μM CuCl2 was chosen for the resistant 
H630R10 cell line. DS/copper complex significantly sensitized H630R10 cell line 
to topotecan (354.75-fold), etoposide (787.43-fold), doxorubicin (375-fold) and 
CCNU (6.16-fold) (Fig. 5.5 and Table 5.2). The parental cell line, H630WT, was 
tested as well. The cytotoxicity of topotecan, etoposide, doxorubicin and 
CCNU was significantly enhanced by combination of different anti-cancer 
drugs with DS (0.2 μM) and CuCl2 (0.5 μM). The IC50 values of topotecan, 
etoposide, doxorubicin and CCNU for the parental H630WT cell line were also 
reduced from 3.09 μM, 3.48 μM, 0.52 μM, and 53.50 μM to 0.50 μM, 0.33 μM, 
0.007 μM and 27.50 μM respectively (Fig. 5.6, Table 5.3). 
 
Table 5.2: The cytotoxicity of DS/copper complex along with anti-cancer drugs on 
H630R10 cell line 
IC50 (μM) 
Anti-
cancer drug 
n 
Drugs alone 
With 
DS/Copper 
Sensitization 
fold 
P 
Topotecan 3 28.38±10.6 0.08±0.13 354.75 0.001 
Etoposide 3 236.23±48.39 0.30±0.39 787.43 0.001 
Doxorubicin 3 3.0±1.99 0.008±0.01 375.00 0.059 
CCNU 3 146.83±62.04 23.83±32.17 2.74 0.038 
The IC50 Value is mean from three replicates ± SD. DS: 0.3 μM; CuCl2: 0.5 μM CuCl2 
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Table 5.3 The chemosensitizing effect of DS/copper complex on the cytotoxicity of 
different anti-cancer drugs in H630WT cell line 
IC50 (μM) 
Anti-cancer drug 
Drugs alone With DS/Cu 
Sensitization fold 
Topotecan 3.09±1.83 0.50±0.64 6.10 
Etoposide 3.48±2.17 0.33±0.28 10.55 
Doxorubicin 0.52±0.42 0.007±0.005 74.29 
CCNU 53.51±19.18 27.50±17.50 1.95 
The IC50 figure is mean from three replicates ± SD. DS: 0.2 μM, CuCl2: 0.5 μM  
 
 
                                                           
Figure 5.5: DS/copper complex enhanced the cytotoxicity of anti-cancer drugs in 5-
FU resistant cancer cell line. 
The H630R10 cells were treated with drugs for seventy two hours before subjecting to MTT 
assay. Curves derived from three replicates and the bars represent standard deviations. 
The drugs were labeled on the top of each graphic curve. The drug was labeled on the 
top of each curve. 
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5.2.5 DS/copper released anti-cancer drug-induced G2/M block and 
enhanced anti-cancer drug-induced apoptosis 
Cells were treated with topotecan, etoposide, doxorubicin and CCNU with 
DS/Cu or without DS/Cu for 48 hours. Cell cycle analysis showed that, after 
48 hours of treatment, 10 μM of topotecan, 10 μM etoposide, and 1 μM 
doxorubicin and 50 μM CCNU induced G2/M block in agreement with findings 
reported in the literature[322](Fig. 5.7A, 5.7B). When DS/Cu complex was 
Figure 5.6: The chemosensitizing effect of DS/copper complex on the cytotoxicity 
of the conventional anti-cancer drugs in H630WT cancer cells 
H630WT cells were treated with combination of drugs for seventy two hours before 
subjecting to MTT assay. Curves derived from three replicates and the bars represent 
standard deviations. The drugs were labeled on the top of each graphic curve.  
  
183 
combined with doxorubicin, topotecan, or etoposide, the G2/M block was 
disrupted and cell death was greatly enhanced (Fig. 5.7C). Percentage of 
cells in different cell cycle phases after treatment was listed in Table 5.4. 
 
Table 5.4: DNA content of H630R10 cell line after drug treatment                                                                                                           
 n -VE DS/Cu Top Top+DS/Cu ETP ETP+DS/Cu 
Apoptosis 
3 
17.15 
(3.23) 
40.63 
(19.7) 
21.14 
(11.6) 
54.36* 
(17.66) 
22.79 
(11.01) 
52.97* 
(15.22) 
G2/M 
3 
13.56 
(2.28) 
9.34 
(2.73) 
30.74 
(9.21) 
8.43# 
(5.24) 
33.97* 
(13.97) 
11.26¤ 
(6.43) 
 
Dox n Dox Dox+DS/Cu CCNU CCNU+DS/Cu F P 
32.17 
(6.14) 
3 32.17 
(6.14) 
58.30* 
(14.65) 
14.55 
(9.63) 
42.58 
(10.97) 
5.329 .001 
15.81 
(1.16) 
3 15.81 
(1.16) 
7.86 
(3.79) 
18.13 
(9.63) 
10.97 
(0.19) 
6.611 .000 
The Value is mean from three replicate ±SD. DS: 0.3 μM; CuCl2: 0.5 μM were used  * VS. –VE P <0.05;  
#VS Top P <0.05;  ¤VSETP P <0.05. 
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Figure 5.7: Cell cycle and apoptosis status analysed by flow cytometry 
Cells were exposed to single or combination of drugs and subjected to analysis after 48 
hours treatment. Three independent determinations were performed. B. Percentage of 
G2/M phase cell in all 10.000 events. C. Percentage of apoptosis cells in all 10.000 
events. Top: topotecan; ETP: etoposide; DOX: doxorubicin. 
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5. 3. Discussion 
Chemoresistance is one of the major hurdles in the success of cancer 
chemotherapy. Tumour cells may accumulate molecular genetic alterations 
and become resistant to anti-cancer drugs. This study was focused on the 
colorectal cancer cell line, H630R10, which has previously been reported to be 
highly resistant to the thymidylate synthase inhibitor, 5-FU[154,308,309]. The 
result from chapter 4 showed that this cell line is also resistant to dFdC. 
Resistance to dFdC has been attributed to the deregulation of several 
molecules including, dCK, RRM1, CNT and ENT which are different from 
those related to 5-FU resistance. It is postulated that the cross resistance 
displayed by H630R10 towards these drugs acting by different mechanisms is 
possibly governed by deregulation of some common molecular pathways. 
Understanding cross-resistance can help discovery of important information 
about the cause of chemoresistance and hence the ways to target 
chemoresistance.  
 
In order to further investigate whether this cell line was also resistant to other 
anti-cancer drugs, MTT assays were carried out after treatment of this cell line 
with a panel of the DNA interactive agents – topotecan, etoposide, doxorubicin 
and CCNU. The IC50 values obtained from these results were higher than 
those of the parental sensitive cell line (Fig. 5.1, Table 5.1). These data 
indicated that H630R10 was a multi-cross resistant to different anti-cancer 
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drugs with different molecular resistant mechanisms. In line with a previous 
study[154], the resistant cell line was found to grow at a much slower rate than 
its parental cell line in vitro. A lower expression of PCNA protein, a component 
of the DNA replication and repair machinery, in H630R10 than in H630WT cell 
line observed through western blot and immunofluorescence results 
supported this conclusion. This observation was further strengthened by a 
reduced expression of another proliferation marker ki-67 in the resistant cell 
line (Fig. 5.2). Topoisomerase IIα is expressed at low levels in quiescent cells. 
Since drugs acting by the mechanism of inhibiting topoisomerase I inhibition 
can specifically target cells with high topoisomerase activity, they were unable 
to target the H630R10 cell line efficiently because of the low proliferation status 
and hence a lower topoisomerase activity. H630R10 cell line was able to 
escape the action of topoisomerase II inhibiting drugs as well.  
 
There have been extensive studies on the anti-apoptotic activity of NF-kB in 
cancer[323,324]. The members of the NF-kB family are known to be key players 
in genetic aberrations like translocation breakpoints and amplifications leading 
to carcinogenesis[65]. NF-kB is maintained in its inactive state in the cytoplasm 
by IkB[325]. The ubiquitin-proteasome system targets the regulatory IkB protein 
through a signal transduction cascade causing its degradation and activation 
of NF-kB. Treatment of cancer with radiotherapy and anti-cancer agents is 
mainly based on induction of apoptosis. The anti-apoptotic property of NF-kB 
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can hamper effective therapy. Hence targeting NF-kB might help tackle this 
problem. Previous study has reported that H630R10 cell line possesses higher 
NF-κB DNA binding activity and NF-kB over-expression may be, at least 
partially, responsible for the resistance to 5-FU in human cancer cells[166]. DS 
has previously been reported to induce apoptosis in 5-FU drug resistant cell 
lines by inhibiting NF-kB[166,314]. DS has been able to reduce the 5-FU induced 
nuclear translocation and hence the DNA-binding and constitutive activity of 
NF-kB in the drug resistant cell lines. Sulfhydryl groups on NF-kB is a 
probable target of DS[166] since DS has the potential to react with sulfhydryl 
groups and hamper the functioning of the enzymes containing them[183]. DS is 
also a 26S proteasome inhibitor[185] and hence might protect IkB from being 
degraded by the ubiquitin-proteasome system. This in turn might help inhibit 
NF-kB activation. The cytotoxicity assay showed a biphasic response of this 
cell line in a dose-dependent manner (Fig. 5.3). Although lower concentrations 
of DS proved to be highly cytotoxic, at a higher concentration of ~ 10 μM DS, 
71.27% of cells managed to survive indicating a poor toxicity of DS at this 
concentration to the resistant cell line. A similar pattern was also observed in 
the sensitive parental cell line although the inhibition of cytotoxicity occurred at 
a concentration of 5μM DS with 32.55% cell survival. Diethyldithiocarbamates 
are known to inhibit NF-kB in a dose-dependent biphasic pattern with high 
concentrations incapable of inhibiting NF-kB[192,326]. Hence DS may inhibit NF-
kB in a dose-dependent manner in the tested parental and sensitive cell lines. 
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These results indicate that at higher concentrations, DS may indeed prove to 
be toxic. It is known that cancer cells possess high amounts of copper in 
vivo[191,327]. It has also been reported previously that DS can complex with 
Cu2+ resulting in inactivation of Cu/Zn superoxide dismutase[179] and hence 
decreased production of reactive oxygen species that can activate NF-kB. In 
order to remove the second peak in the biphasic response pattern observed in 
the cytotoxicity assay, DS was supplemented with CuCl2. CuCl2 was also 
added to mimic the in vivo situation observed in cancer cells. The results were 
positive for the parental and sensitive cell lines with an IC50 value of 0.54 μM 
for the resistant cell line and 0.43 μM for the parental cell line at 0.5 μM CuCl2 
. 
In order to establish whether the cytotoxicity of the anti-cancer drugs tested in 
this study could be enhanced by DS/Cu complex, the H630R10 cell line was 
given a 72-hours treatment with a combination of CuCl2 (0.5 μM), DS (0.3 μM) 
and different anti-cancer drugs. The parental cell line was also given a similar 
treatment but at a DS concentration of 0.2 μM. The data obtained from 
cytotoxicity assay indicates that the IC50 value was lowered by multiple folds 
for each of the anti-cancer drugs when used in combination with CuCl2 and 
DS compare with anti-cancer drug alone (Table 5.2). The morphology of the 
cells was also very different when treated with the anti-cancer drug alone than 
when given the combination treatment with massive amounts of nuclear 
condensation in the latter case (Fig. 5.7).  
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Components of the cell cycle machinery are frequently altered in human 
cancer[62]. Many of the compounds under study as anti-tumour agents act as 
multiple steps in the cell cycle, and their effects may be cytostatic or cytotoxic, 
depending on the cell cycle status of the target cells. An understanding of the 
molecular interaction involved may suggest ways to sensitize cells to the 
effects of these compounds. In particular, combinations of drugs, applied in a 
specific sequence, may be used to maneuver a tumour cell population into a 
state where it is most susceptible to the cytotoxic effects of chemotherapeutic 
agents. In this study, flow cytometry assay was performed to analysis the DNA 
content. Flow cytometry data also showed that a majority of the cells that had 
blocked themselves in different cell cycle phases to protect themselves from 
the action of the anti-cancer drugs had undergone apoptosis after the 
combination treatment (Fig. 5.8 and Tables 5.4). All these data support the 
theory that a combination of CuCl2 and DS when supplemented with 
topotecan, etoposide, doxorubicin or CCNU can greatly enhance the cytotoxic 
effects of these drugs than when these drugs act alone on cancer cells. A 
reduced S-phase traverse observed in the case of each of the anti-cancer 
drug treated H630R10 cell line, as observed from the flow cytometry results, 
probably allows this cell line to protect itself from DNA repair. 
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 Chapter 6  
Chemo- sensitizing effect of triptolide on anti-cancer 
drugs in human cancer cell lines 
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6.1 Introduction 
Interest in exploiting traditional medicines for prevention or treatment of 
cancer is increasing. Tripterygium wilfordii Hook.f, a member of the 
Celastraceae family of plants, has been used in Chinese medicine for 
centuries[328]. Triptolide (PG490), a diterpenoid isolated from the Tripterygium 
wilfordii Hook. f, has been successfully used in clinical treatment of 
rheumatoid arthritis, autoimmune diseases and organ transplant anti-rejection 
for a long time[329-331]. 
 
There is a very close link between inflammation and cancer development[68]. 
Recently there are cumulated evidences indicating that NF-κB is one of the 
major bridges between these two events[332-335]. NF-κB is one of the major 
anti-apoptotic factors induced by chemotherapy and radiotherapy[53]. In most 
normal cells, NF-κB is retained in the cytoplasm as an inactive complex 
through binding to the inhibitor of NF-κB (IκB). However, following various 
stimuli, IκB is phosphorylated by IκB kinase (IKK), polyubiquinated and quickly 
degraded by the 26S proteasome leading to the nuclear translocation of NF-
κB. NF-κB is also activated at the transcriptional level by phosphorylation of 
its subunits[336,337]. Consequently, as a result of defects in the upstream 
signaling pathways that regulate IKK or high levels of inflammatory cytokines 
and hypoxia, many human cancer cells possess high constitutive levels of 
nuclear NF-κB activity. Chemotherapy, radiotherapy and some cytokines can 
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further induce nuclear NF-κB activity in these cells[57,338]. 
 
Many anti-inflammatory drugs also manifest strong anti-cancer activity[339]. As 
an anti-inflammatory medicine, PG490 also demonstrates strong anti-tumour 
activities in a broad range of solid tumours and leukemia[197,340]. PG490 
Induces apoptosis in solid tumour cells and sensitizes tumour cells to TNFα-
induced apoptosis in A549 non-small cell lung cancer (NSCLC), HT1080 
(fibrosarcoma) and MCF7 (breast cancer) cell lines. The molecular anti-cancer 
mechanisms of PG490 have not been fully elucidated. It has been reported 
that PG490 blocks the NF-κB activity induced by TNFα[200]. In this case, 
PG490 also blocks the TNFα-induced activation of NF-κB and inhibits the 
expression of NF-κB downstream anti-apoptotic genes c-IAP1 and c-IAP2 at 
transcriptional level. PG490 also significantly inhibits TNFα, PMA/Ionomycin 
induced NF-κB transcriptional activity in human T cells[204].  Infection of 
dengue virus induces the expression of cycloxygenase-2 (COX-2) and 
enhances the transcriptional activity of NF-κB and AP-1. These effects can be 
inhibited by co-exposure of these cell lines to PG490 at a low 
concentration[341]. PG490 was shown to inhibit induction of cytokine 
expression in T cells[342]. Cytokine expression in T cells depends, at least in 
part, on activation of NF-κB. 
 
This part of the study was aiming to investigate the enhancing effect of PG490 
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PG490 on the cytotoxicity of several conventional anti-cancer drugs to human 
lung, breast and colon cancer cell lines. The potential molecular mechanisms 
were also investigated. 
 
6.2 Results 
6.2.1 In vitro cytotoxicity of PG490 to cancer cell lines 
To investigate the cytotoxic effects of PG490 (see Fig. 6.1A for the structure) 
on colon (H630WT, HCT116WT and RKOWT), lung (A549, H125, WIL) and 
breast (MCF7, MDA-MB-231) cancer cell lines, the cancer cells were exposed 
to increasing concentrations of PG490 for 72 hours and then subjected to 
MTT assay. As shown in Fig 6.1, PG490 demonstrated strong cytotoxicity to 
all tested cell lines at nanomolar concentrations. In comparison with lung 
(A549, H125, and WIL) and breast (MCF7 and MDA-MB-231) cancer cell line, 
the colon cancer cell lines (H630WT, HCT116WT and RKOWT) were more 
sensitive to PG490. The IC50 concentrations of PG490 to different cancer cell 
lines were as follows: H630WT: 1.39 ± 0.35 nM, RKOWT: 2.62 ± 0.68 nM, 
HCT116WT: 5.51 ± 2.07 nM, A549: 7.23 ± 2.49nM, H125：19.87± 3.90 nM, 
WIL: 21.78 ± 1.37 nM, MCF7: 18.51 ± 3.05 nM and MDA-MB-231: 29.10 ± 
0.42 nM.  
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6.2.2 Morphological changes of various cell lines treated with PG490  
Apoptosis is characterized by marked changes in cellular morphology, 
including chromatin condensation, membrane blebbing, nuclear breakdown, 
and the appearance of membrane-associated apoptotic bodies, 
internucleosomal DNA fragmentation. Fig. 6.2 show the morphological 
changes after exposure of cells to different concentrations of PG490 for 24 
hours (H630WT, RKOWT, HCT116WT and A549) and 48 hours (H125). H630WT, 
RKOWT, HCT116WT and A549 showed visible apoptotic morphology appeared 
only under high concentration (≥ 25nM) of PG490 treatment; however, for 
H125 cells visible morphology change have not appeared even treated for 48 
hours. This is consistent with MTT result.  
 
6.2.2 Morphological changes of various cell lines treated with PG490  
Apoptosis is characterized by marked changes in cellular morphology, 
including chromatin condensation, membrane blebbing, nuclear breakdown, 
and the appearance of membrane-associated apoptotic bodies, 
internucleosomal DNA fragmentation. Fig. 6.2 shows the morphological 
changes after exposure of cells to different concentrations of PG490 for 24 
hours (H630WT, RKOWT, HCT116WT and A549) and 48 hours (H125). H630WT, 
Figure 6.1: PG490 inhibits growth of tumour cells 
The cancer cell lines (H630WT, HCT116WT and RKOWT: 5 x 103/well; others: 1 x 
104/well) were cultured in 96-well plates overnight and then treated with different 
concentrations of PG490 (nM) for 72 hours and the cell viability wastermined by an 
MTT assay. 
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RKOWT, HCT116WT and A549 showed visible apoptotic morphology appeared 
only under high concentration (≥ 25nM) of PG490 treatment; however, for 
H125 cells visible morphology change have not appeared even treated for 48 
hours. This is consistent with MTT result.  
 
 
Figure 6.2: The PG490 induced morphological changes in cancer cell lines 
The cells were cultured at a density of 1 x 106/well in 6-well plates overnight and then 
exposed to the indicated concentrations of PG490 (nM) for 24 hours or 48 hours 
(H125).The pictures on the right show that cells become round and shrinking.  
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6.2.3 PG490 induced apoptosis in cancer cell lines 
Cells (1 × 106/flask) were cultured in 25 cm2 flasks overnight and then treated 
with different concentrations of PG490 for 24 or 48 hours. The DNA contents 
were determined by flow cytometric analysis (Fig. 6.3, Fig. 6.4). The apoptotic 
cells were calculated by the percentage of the sub-G1 population. The 
percentages of the apoptotic cells treated with different concentrations of 
PG490 were listed in Table 6.1 and 6.2. In comparison with the untreated 
control cells, the A549, H125 and HCT116WT cancer cells treated with 25 nM 
PG490 manifested significantly higher percentages of apoptotic cells (P < 
0.05). Although the percentages of apoptotic population in H630WT and 
RKOWT cell lines were also increased after 25 nM PG490 treatment but there 
was no statistical significance between the treatment and control groups (P > 
0.05). When the concentration of PG490 increased to 50 nM, the apoptotic 
cell percentages in all cancer cell lines were significantly higher than those in 
the control groups (P < 0.05). 
Table 6.1 The percentage of apoptotic cells induced by PG490 in lung cancer cell 
lines  
 n 0nM 5nM 10nM 25nM 50nM F P 
A549 3 3.53±0.40 3.6±0.3 4.53±0.46 10.9±1.53* 40.27±6.60* 40.860 0.001 
H125 3 0.53±0.06 0.63±0.23 0.6±0.35 9.8±1.37* 11.6±1.31* 58.931 0.001 
The figure is mean ± SD calculated from three experiments. * P < 0.05 (vs. 0, 5 and 10nM) 
Table 6.2  The percentage of apoptotic cells induced by PG490 in colon cancer cell 
lines  
 n 0nM 5 10 25 50 F P 
H630WT 3 1.7±0.26 2.87±0.55 2.83±0.64 3.33±0.45 12.6±1.06* 143.105 <0.001 
RKOWT 3 2.36±0.54 2.57±0.46 2.85±1.84 3.95±0.87 28.25±3.76* 25.571 0.002 
HCT116WT 3 2.37±0.25 3.47±2.40 4.27±3.49 6.53±0.81# 19.10±3.35△ 24.326 0.004 
The figure is mean ± SD calculated from three experiments. * vs. 0, 5, 10 and 25 nM P < 0.05;  
# vs. 0nM P < 0.05; △ vs 0, 5 and 10 nM P < 0.05 
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Figure 6.4: Flow cytometric histogram of colon cancer cell lines treated with PG490 
The cells were cultured at a density of 1 x 106/well in 6-well plates overnight and then 
treated with the indicated concentrations of PG490 (nM) for 24 hours and then subjected 
to flow cytometric analysis of DNA contents. 
Figure 6.3: Flow cytometric histogram of lung cancer cell lines treated with 
PG490 The cancer cell lines were cultured at a density of 1 x 106/well in 6-well plates 
overnight and treated with the indicated concentrations of PG490 (nM) for 24 hours 
(all cell lines apart from H125) or 48 hours (H125). The cells were stained with 
propidium iodide (PI) as described in the text. The DNA contents were determined by 
flow cytometric analysis.  
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6.2.4 The influence of PG490 on the expression status of p21 and p53 
p53 is a transcription factor that participates in cell cycle checkpoint processes 
and apoptosis[343]. Under normal physiological conditions, p53 limits 
proliferation after damage to genomic DNA through two alternative 
mechanisms: by G1 (or G2) arrest; or by apoptosis[344]. It has been reported 
that p53 status affects the efficacy of cancer therapy. For example p53 
mutation dramatically reduce the probability that patients with B cell chronic 
lymphocytic leukaemia will enter remission after chemotherapy[48]. Mutation in 
p53 are also associated with tumour relapse in acute lymphoblastic 
leukaemia[48]. p21 is an important downstream effector in the p53-specific 
growth arrest pathway[345] but not in the p53-dependent apoptotic pathway[346]. 
In mice, tumours with intact checkpoint functions (p21+/+) have been shown to 
re-grow after treatment with -irradiation, whereas a significant fraction of 
checkpoint-deficient tumours (p21-/-) were completely cured[347]. Thus, 
expression of p21 in tumours might be of relevance concerning the possible 
therapeutic effects of agents causing DNA damage.  
 
Since PG490 is cytotoxic to tumour cells the PG490-induced apoptosis may 
also be mediated by p53. Fig. 6.5 showed the expression of p53 and p21 
proteins, before and after exposure to different concentration of PG490 for 24 
hours, in the five cell lines tested. PG490 treatment induced a dose-
dependent increase in p53 level in colon cancer cells H630WT, RKOWT and 
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HCT116WT; whereas in lung cancer A549 and H125 cells p53 protein levels 
were not significantly modified by the treatment (Fig. 6.5 A). In contrast with 
p53, p21 levels were increased by low concentration of PG490 treatment in a 
dose dependent fashion. High concentrations of PG490 (25 and 50 nM) 
inhibited p21 expression in three colon cancer cell lines (Fig. 6.5 B). p21 
expression of A549 and H125 have not been detected after repeat many 
times. 
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Figure 6.5: Effect of PG490 on p53/p21 levels. Subconfluent cells were treated as 
indicated above. After 24 hours, whole cell lysate was harvested followed by western 
blot analysis with a p53 mAb (A). The blot was then stripped and reprobed with a 
p21mAb (B). Tubulin was used as a loading control. 
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6.2.5 The effect of PG490 on the expression of cell cycle-regulating 
proteins  
The cell cycle is controlled by numerous mechanisms ensuring correct cell 
division.  Central players are the Cyclin dependent kinases (CDKs), which 
govern the initiation, progression, and completion of cell cycle events. The 
scheduled activity of the CDKs, which allows orderly transition between cell 
cycle phases, is controlled by their association with Cyclins and CDK 
inhibitors[348]. Different cyclins are required at different phases of cell cycles. 
The CyclinD bind to CDK4 and to CDK6 and CDK-Cyclin D complexes are 
essential for entry in G1[349]. Another G1 cyclin is cyclinE which associates with 
CDK2 to regulate progression from G1 into S phase[350]. 
 
Components of the cell cycle machinery are frequently altered in human 
cancer. As malignant cells evolve, both genetic and epigenetic mechanisms 
commonly affect the expression of cell cycle regulatory proteins, causing 
overexpression of Cyclins and loss of expression of CDK inhibitors. A major 
consequence is deregulated CDK activity, providing cells with a selective 
growth advantage. Amplification or overexpression of Cyclin D1 is important in 
the development of many cancers including parathyroid adenoma, breast, 
prostate and colon cancers, lymphoma and melanoma[351]. CyclinE has been 
found to be amplified, overexpressed or both in some cases of breast and 
colon cancer and in acute lymphoblastic and acute myeloid leukaemisa[352]. 
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Alternation of CDK molecular in cancer has been reported, although with low 
frequency. CDK4 overexpression has been identified in cell lines, melanoma, 
sarcoma and glioma[353]; CDK2 has been reported to be overexpressedin a 
subset of colon adenomas[354]. 
 
PG490 induces cell death and disturb the cell cycles. So the next step of this 
study was to compare the expression level of Cyclin D1, CyclinE and 
associated kinases cdk2, cdk4 between untreated and PG490 treated cells. 
Western blotting result showed that high concentration of PG490 inhibit the 
expression of CyclinD1 in all five tested cell line, and inhibit CyclinE in colon 
cancer cell lines H630WT, RKOWT and HCT116WT, lung cancer H125 whereas 
in lung cancer A549 CyclinE protein levels are not significantly modified by the 
treatment. CyclinE associated kinase CDK2 did not affected by treatment in 
four out of five tested cell lines; CDK2 was induced by high concentration of 
PG490 in lung cancer A549 cells. CDK4 was increased in colon cancer cell 
H630WT, RKOWT, whereas, it was reduced in colon cancer cell HCT116WT and 
lung cancer H125 by the treatment. PG490 did not affect CDK4 expression of 
lung cancer cell A549 (Fig. 6.6). 
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6.2.6 The effect of PG490 on the degradation of IκBα protein 
It has previously been reported that the anti-inflammatory, anti-proliferative, 
and pro-apoptotic properties of PG490 are closely associated with inhibition of 
NF-κB pathway[355]. PG490 Induces apoptosis in solid tumour cells and 
sensitizes tumour cells to TNFα-induced apoptosis on A549 (NSCLC), 
HT1080 (fibrosarcoma) and MCF7 (breast cancer) cell lines by blocking the 
NF-κB activity induced by TNFα[200]. IkBα is degraded by IKK resulting in the 
release of NF-κB dimmers. This is the key procedure for NF-κB activation and 
Figure 6.6: The effect of PG490 on the expression levels of cell cycle-regulating 
proteins The cancer cell lines were exposed to the indicated concentrations of 
PG490 for 24 hours and harvested. The whole protein was extracted and subjected to 
western blotting analysis. Tubulin was used as a loading control. 
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nuclear translocation[18,19]. Hence the effect of PG490 on the IκBα protein 
expression levels was determined using western blotting analysis. Colon 
cancer cell lines H630WT, RKOWT and HCT116WT were exposed to 50 nM 
PG490 for different time lengths. The IκBα protein levels in whole protein 
lysate were determined by western blotting analysis. The result showed that 
IκBα protein levels in H630WT and RKOWT cell lines were decreased after 12 
hours incubation with PG490. In contrast to the other two cell lines, the IκBα 
degradation of HCT116WT cells was induced by PG490 as early as 30 minutes 
(Fig. 6.7).  
 
 
6.2.7 The effect of PG490 on proteasome activity 
The degradation of IκB is highly proteasome-dependent. The result in section 
6.2.6 shows that IκBα protein levels were decreased after incubation with 
Figure 6.7: Effect of PG490 on the degradation of IκBα 
H630WT, HCT116WT, RKOWT cells were treated with 50nM PG490 for different time 
lengths. The IκBα expression levels were determined by western blotting analysis. 
Tubulin was used as a loading control. 
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PG490. Therefore the influence of PG490 on the proteasome activity was 
analyzed in this study. 20S subunit is the core catalytic complex of 26S 
proteasome. The inhibition of PG490 on purified rabbit 20S proteasome was 
tested. DMSO was used as vehicle control. MG132 (provide by manufacturer), 
which is a potent, cell permeable, and selective proteasome inhibitor and 
inhibits NF-κB activation by preventing IκB degradation, was used as positive 
control. Briefly 100 µL of assay buffer, 5 µl of PG490, 5 µl of DMSO, 5 µl of 
MG132 and 4 µl of 1mM suc-LLVY-AMC substrate were added into 96-well 
plate in order, then 4  µl of 20S proteasome was added to each well, 
incubated at 37℃ for 2 hours.  ANOVA analysis showed that compare to 
vehicle control DMSO, PG490 did not inhibit proteasome activity (P > 0.05); 
μM and 10 μM MG132 significantly inhibit proteasome activity(P < 0.05) (Fig. 
6.8, Table 6.3). 
 
Figure 6.8: The in vitro effect of PG490 on proteasmone activity  
The proteasome assay was carried out as described in material and method section. 
MG132 is positive control, and DMSO is vehicle control.  
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Table 6.3 The effect of PG490, DMSO and MG132 on proteasome activity 
 n DMSO PG490 1 µM MG132 10 µM MG132 F Value P Value 
20S Activity 9 61.18±9.20 53.79±12.05* 26.76±1.54 8.00±0.29 201.039 < 0.001 
* vs. 1 µM MG132, 10 µM MG132 P < 0.05 
 
6.2.8 The effect of PG490 on the expression of vascular endothelial 
growth factor in cancer cell lines 
Vascular endothelial growth factor (VEGF) promotes angiogenesis and is 
associated with the invasion and metastasis of malignant tumours[356]. 
VEGF promotes acute myelogenous leukemia (AML) cell growth and survival, 
and may contribute to drug resistance[357]. The effect of PG490 on the 
expression of VEGF in all tested cells lines was investigated. PG490 inhibited 
VEGF expression in H630WT, RKOWT, HCT116WT and A549 cell lines in a dose 
dependent manner. Compare to H630WT, PG490 inhibit VEGF expression of 
RKOWT and HCT116WT to a lesser extent. However, 1.25nM PG490 
significantly inhibited the VEGF expression of H125 cells (Fig.6.9).  
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6.2.9 PG490 enhance chemotherapy–induced cell death 
Since PG490 increase the p53 expression and perturb the cell cycle, PG490 
might enhance the cell death induced by other anti-cancer agents. The colon 
cancer cell H630WT, HCT116WT and RKOWT were treated with low nanomolar 
concentrations of PG490 in combination with 5-FU. The lung cancer cells 
A549, H125, WIL were treated with cisplatin (DDP), gemcitabine (Gem) and 
etoposide (ETO) in combination with nanomolar concentrations of PG490. 
The breast cancer cell MCF-7 and MDA-MB-231 were treated with paclitaxel 
(Pac) incombination with nanomolar concentration of PG490. The 
Figure 6.9: The effect of PG490 on VEGF protein expression 
Colon cancer cell line (H630WT, RKOWT HCT116WT) and lung cancer cell line A549 
were treated with different concentrations of PG490 for 24 hours. Lung cancer cell line 
H125 was treated for 48 hours. (1:500) Tubulin was used as a loading control. 
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concentration of PG490 was determined according to the IC30 value of PG490 
to each cell line in section6.1.  
                                                                                                                                               
6.2.9.1 Cytotoxicity of PG490/chemotherapy on colon cancer cell lines 
The MTT assay results showed that cell death induced by 5-FU and in 
combination with PG490 was significantly enhanced (Fig. 6.10). Statistic 
analysis showed that compare to IC50s of 5-FU alone to H630WT, RKOWT and 
HCT116WT, IC50s of 5-FU/PG490 were significantly reduced (Table 6.4). 
 
Table 6.4 IC50 of single and combination with PG490 on colon cancer cells 
 n 5-FU alone 5-FU+PG490 t P 
H630WT 3 22.67 ±5.93 5.27± 1.17 -4.988 0.032 
RKOWT 3 15.14 ±2.47 0.97± 0.25 -9.881 0.001 
HCT116WT 3 15.27± 0.65 1.85± 0.22 -26.784 <0.001 
The concentration of PG490 used for combination was 0.5 nM, 2 nM, 2 nM for H630WT, RKOWT; 
HCT116WT respectively. The figures in the table represent the IC50 values from three replicates ± SD.  
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Figure 6.10: Cytotocicity of 5-FU and 5-FU/PG490 to colon cancer cells 
A density of 5 x 103/well of 96 well plates was treated with 5-FU single and combination 
with PG490, as determined by MTT assay after 72 hours. 
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6.2.9.2 Cytotoxicity of PG490/chemotherapy on lung cancer cell lines 
The cytotoxicity was tested by MTT assay, the results showed that compare to 
single drugs, in combination of PG490 with DDP, Gem and ETO further inhibit 
the cell growth of A549, H125 and WIL cancer cell lines (Fig. 6.11). Statistic 
analysis showed that compared with the IC50s of single drug treatment, the 
IC50s of the anti-cancer drugs in the PG490/chemotherapy combination to 
A549 and WIL were significantly reduced (Table 6.5). For H125 cell line, IC50s 
of DDP, Gem were significantly reduced by the combination of these two 
drugs with PG490 however, the IC50 of ETO is not reduced significantly (P = 
0.103). 
Table 6.5 IC50 of single and combination with PG490 on lung cancer cells ( X ±S) 
 n DDP alone DDP+PG490 t P Gem alone Gem+PG490 t P 
A549 3 6.19± 0.97 1.38± 0.60 -7.312 0.004 11.15±3.66 2.93± 1.98 -3.423 0.027 
H125 3 21.49±7.78 3.31 ±2.66 -3.828 0.019 16.93±1.97 9.07± 1.38 -5.687 0.005 
WIL 3 48.99±0.87 2.35±1.41 48.717 <0.001 44.8± 2.21 29.15±4.80 -5.130 0.007 
 n ETO alone ETO+PG490 t P 
A549 3 1.50± 0.44 0.21± 0.06 -5.051 0.007 
H125 3 5.87± 0.10 2.91± 1.79 -2.860 0.103 
WIL 3 30.58±8.10 3.03± 0.80 -5.861 0.004 
The concentration of PG490 used for combination was 12.5nM for WIL and H125, 5nM for A549. 
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Figure 6.11: Cytotoxicity of combinations of anti-cancer drugs with PG490 on lung 
cancer cells The lung cancer cell lines at a density of 5x103/well were treated with DDP, 
Gem, ETO single or in combination of DDP, Gem and ETO with PG490. The viability was 
determined by MTT assay after 72 hours. 
 
6.2.9.3 Cytotoxicity of PG490/chemotherapy on breast cancer cell lines 
Breast cancer cells MCF-7 and MDA-MB-231 were treated with Gem, Pac 
alone and combination with PG490 for 72 hours before subjected to MTT 
assay. The results show that PG490 can significantly increase the cytotoxicity 
of Pac to MCF7 and MDA-MB-231(Fig. 6.12, Table 6.6). 
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Figure 6.12: Cytotocicity of combinations of anti-cancer drugs with PG490 on 
breast cancer cells 
Breast cancer cell lines were cultured at a density of 5×103/well in 96-well plates 
overnight and then treated with Pac alone or in combination with PG490. The viability 
was determined by MTT assay after 72 hours. 
 
Table 6.6 IC50 of single and combination with PG490 on lung cancer cells  
 n Pac alone Pac+PG490 t P Gem alone Gem+PG490 
MCF7 3 9.65±1.41 2.75±0.48 8.028 0.001 ≥4000 4.45±0.39 
MDA-MB-231 3 15.89±6.21 9.14±4.39 3.956 0.017 ≥4000 31.05±20.16 
The concentration of PG490 used for combination was 10 nM PG490 for MCF7 and 15 nM for            
MDA-MB-231. The figures in the table represent the IC50 value from three replicates ± SD. 
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6.2.10 Morphological change of cells treated with PG490 and anti-cancer 
drugs 
The morphology change is consistent with MTT result. Compare to single anti-
cancer drugs, combination of PG490 and anti-cancer drugs cause more cell 
shrink and nuclear breakdown (Fig. 6.13).  
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Figure 6.13: Morphological change of cells treated with combinations of anti-
cancer drugs with PG490  
The cancer cell lines were treated with PG490 (25 nm), DDP (15 µM), ETO (2.5 µM) and 
Gem (100 nM) alone or in combination of these drugs with PG490 (25 nM) for 24 hours 
(A549) or 48 hours (H125). The colorectal cancer cell lines (H630WT, RKOWT and 
HCT116WT) were treated with PG490 (25 nM) and 5-FU (25 µM) alone or in combination 
of PG490 (25 nM) and 5-FU (25 µM) for 24 hours. 
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6.2.11 PG490 enhanced anti-cancer drug-induced apoptosis 
To further investigate the synergistic effects of PG490 plus 5-FU, Gem, ETO 
and DDP and determine their effect on the apoptotic status, the cancer cell 
lines were treated with different combinations of PG490 and anti-cancer drugs. 
The apoptotic cell percentages were determined by flow cytometric analysis of 
DNA content.  
 
6.2.11.1: PG490 potentiated the apoptotic effect of 5-FU on colon cancer 
cell lines 
After 24 hours of treatment, 25 µM 5-FU and 25 nM PG490 arrested the cells 
in G1-SPhase (Fig. 6.14). However, when PG490 was combined with 5-FU 
and Gem, the G1 block was, to different extent, disrupted and the apoptosis in 
colon cancer cells H630WT, RKOWT and HCT116WT was significantly increase 
(Fig. 6.14, Fig. 6.15 and Table 6.7). 
 
Table 6.7 PG490 enhanced the apoptotic effect of 5-FU on colon cancer cell lines 
 n -VE PG490 5-FU 5-FU+PG490 F P 
RKOWT 3 2.30±0.31 3.04±1.48 3.25±0.61 15.33±0.40* 535.642 <0.001 
H630WT 3 1.67±0.15 3.27±0.72 1.83±0.35 17.5±1.80* 59.442 0.001 
HCT116WT 3 2.47±0.35 6.53±0.94# 3.54±0.93 14.59±1.26* 103.887 <0.001 
vs. –VE、PG490、5-FU P < 0.05;  # vs. –VE P < 0.05. The figures in the table represent the mean of three 
experiments ± S.D 
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Figure 6.14: Flow cytometric histogram of colon cancer cell lines treated with 
combination of 5-FU with PG490  
Cells were exposed to single drug or in combination of 5-FU with PG490 for 24 hours. 
The DNA contents in the PI stained cells were determined by flow cytometry analysis. 
 
 
Figure 6.15: PG490 enhanced 5-FU induced apoptosis in colon cancer cell lines 
Percentage of apoptotic cells in all three colon cancer cell lines were determined by flow 
cytometry after exposure to different combinations of drugs for 24 hours. The figure 
represents the mean ± SD from 3 independent experiments. 
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6.2.11.2: PG490 /chemotherapy induced apoptosis in lung cancer cells 
Compare to untreated cells, PG490, Gem, DDP and ETO all can increase the 
percentage of apoptosis cells; however, combination of PG490 with these 
drugs greatly enhanced the percentage of apoptosis cells (Fig. 6.16, Fig. 6.17, 
and Table 6.8). Statistic results show that for A549 cell line, PG490, Gem, 
DDP and ETO did not significantly increase apoptosis compared to untreated 
cells. Combinations of PG490 with these drugs significantly increase 
apoptosis (Fig. 6.16, Fig. 6.17, and Table 6.8); for H125 cells, PG490 alone 
significantly increase apoptosis compared to untreated cells, this may due to 
48 hours treatment rather than 24 hours; Gem, DDP and ETO did not 
significantly increased apoptosis. Like A549 cells, combinations of PG490 
with these drugs also significantly increase apoptosis of H125 cells (Fig. 6.16, 
Fig. 6.17, and Table 6.8).  
Figure 6.16: Flow cytometric histogram of lung cancer cell lines treated with 
combination of anti-cancer drugs with PG490 
Cells were incubated with single or combination of PG490 and conventional anti-
cancer drugs for 24 hours. The percentages of apoptotic cells were determined by 
flow cytometric analysis of the PI stained cells. 
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Table 6.8: PG490 enhanced anti-cancer drug induced apoptosis in lung cancer cell 
lines 
 n -VE PG490 DDP DDP+PG490 F P 
A549 3 3.6±0.36 10.73±1.34 4.37±0.49 45.07±9.76*#△ 47.711 0.001 
H125 3 1.11±0.26 10.73±1.08* 3.47±1.35 19.10±2.65*#△ 78.261 <0.001 
*  vs. –VE  P < 0.05 ; # vs. PG490 P < 0.05; △ vs. DDP P < 0.05  
 n -VE PG490 Gem Gem+PG490 F P 
A549 3 3.6±0.36 10.73±1.34 5.50±0.53 26.7±8.02*#△ 19.853 <0.001 
H125 3 1.11±0.26 10.73±1.08* 3.73±1.49 19.07±3.30*#△ 53.951 <0.001 
*  vs. –VE  P < 0.05 ; # vs. PG490 P < 0.05; △ vs. Gem P < 0.05  
 n -VE PG490 ETO ETO+PG490 F P 
A549 3 3.6±0.36 10.73±1.34 5.17±3.87 22.6±2.07*#△ 75.948 0.001 
H125 3 1.11±0.26 10.73±1.08* 6.47±2.51 28.43±6.22*#△ 32.326 <0.001 
*  vs. –VE P < 0.05 ; # vs. PG490 P < 0.05; △ vs. ETO P < 0.05 
 
Figure 6.17: PG490 enhanced apoptosis induced by anti-cancer drugs 
Percentage of apoptotic cells in all three cell lines determined by flow cytometric 
analysis of DNA contents after 24 hours exposure of the cancer cells to drugs in 
different combinations. The figures represent the mean ± SD from 3 independent 
experiments. 
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6.2.12 The effect of PG490 in combination with different anti-cancer 
drugs on the expression of apoptosis related proteins 
PARP catalyzes the poly(ADP-ribosyl)action of a variety of nuclear proteins 
with NAD as substrate. Because it is activated by binding to DNA ends or 
strand breaks, PARP was suggested to contribute to cell death by depleting 
the cell of NAD and ATP[358].  Apoptosis is characterized by cleavage of 
poly(ADP-ribose) polymerase (PARP). Such cleavage essentially 
inactivates the enzyme by destroying its ability to respond to DNA 
strand breaks. Caspase-3, a member of aspartate-specific cysteine proteases 
family that plays a central role in the execution of the apoptotic program, is 
primarily responsible for the cleavage of PARP during cell death[359,360]. The 
above results demonstrated that PG490 strongly enhanced the apoptosis 
induced by conventional anti-cancer drugs. Furthermore the cleavage of 
PARP and the activation of Caspase3 were analyzed in this part of the study. 
The treatment of cells with PG490 in combination with anti-cancer drugs 
resulted in the activation of Caspases-3, PARP cleavage (Fig. 6.18); PG490 
alone resulted in the PARP cleavage to a lower degree (Fig. 6.18). 
 
To determine which of the two apoptotic signaling pathways was essential for 
PG490/anti-cancer drug-induced caspase-dependent cell death, changes in 
the protein levels of some common Bcl-2 family proteins, which are commonly 
activated through the mitochondrial signaling pathway, were examined. The 
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cancer cell lines were subjected to different treatments for 24 hours. As 
shown in Fig. 6.18, compared to untreated cells, PG490/anti-cancer drug 
induced significantly higher expression of pro-apoptotic protein Bax, and a 
significant decrease of Bcl-2, an anti-apoptotic protein, was detected in all 
treated cells. Taken together, the mitochondrial pathway may play a critical 
role in the PG490/anti-cancer drug-induced cell death. 
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Figure 6.18: PG490/anti-cancer drug combination regulated the expression of 
the apoptosis-related proteins 
The cancer cell lines were exposed to anti-cancer drug alone or in combination with 
PG490 for 24 or 48 hours. The concentration of each drug: 5-FU 25 μM, PG490 25 
nM for colon cancer H630WT, RKOWT and HCT116WT cells; PG490 25 nm, DDP 15 
µM, ETO 2.5 µM and Gem 100 nM for A549 and H125 (48 hours). The cancer cell 
lines were treated with PG490 (25 nm), DDP (15 µM), ETO (2.5 µM) and Gem (100 
nM) alone or in combination of these drugs with PG490 (25 nM) for 24 hours (A549) 
or 48 hours (H125). Cells were then harvested for western blotting analysis with 
indicated antibody. Tubulin was used as loading control.  
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6.3 Discussion 
The results in this study revealed that as an anti-inflammatory drug, PG490 
alone was cytotoxic to all tested cells in nanomolar concentrations. Compared 
to lung and breast cancer cell lines, colon cancer cell lines were more 
sensitive to PG490. The IC50s of colon cancer cells to PG490 were much 
lower than breast cancer cell lines MCF-7, MDA-MB-231 and lung cancer cell 
lines H125 and WIL. Even though PG490 was very effective as a single agent 
in killing various cell lines, its benefits would be even greater if it could 
enhance the efficacy of various drugs currently used clinically in treating solid 
tumours. In this study, PG490 at low concentrations demonstrated 
significantly enhancing effect on the cytotoxicity of 5-FU to colon cancer cell 
lines H630WT, RKOWT and HCT116WT. Statistic analysis showed that 
compared with the IC50s of DDP, Gem, ETO alone, the IC50s of above drugs 
in the PG490/chemotherapy combination to lung cancer cells (A549 and WIL) 
were significantly reduced. For lung cancer H125 cell line, IC50s of DDP, Gem 
were significantly reduced by the combination of these two drugs with PG490. 
However, PG490 and ETO in H125 cells did not significantly increase cell 
death over that induced by ETO alone. This may be due to the fact that H125 
cells were relatively resistant to ETO and PG490 at low nanomolar 
concentration did not lower the apoptotic threshold enough to overcome 
cellular resistance to ETO. The results show that PG490 can significantly 
increase the cytotoxicity of Pac to MCF7 and MDA-MB-231 cell lines. 
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Low concentrations of PG490 (5 and 10 nM) did not cause the morphological 
change and apoptosis to all tested cells. The cell lines treated with high 
concentrations of PG490 (25 and 50 nM) demonstrated morphological 
changes that were associated with apoptotic phenotype. In comparison with 
the untreated control cells, the A549, H125 and HCT116WT cancer cells 
treated with 25 nM PG490 manifested significantly higher percentages of 
apoptotic cells (P < 0.05). Although the percentages of apoptotic population in 
H630WT and RKOWT cell lines were also increased after 25 nM PG490 
treatment there was no statistical significance between the treatment and 
control groups (P > 0.05). When the concentration of PG490 increased to 50 
nM, the apoptotic cell percentages in all cancer cell lines were significantly 
higher than those in the control groups (P < 0.05). Compared to PG490 and 
anti-cancer drugs alone, PG490 enhanced other anti-cancer drug-induced 
apoptosis. 
 
PG490/chemotherapy increased levels of caspase 3 and the cleaved form of 
PARP, all of which are markers of apoptosis. Proteins belonging to the Bcl-2 
family were also important for normal apoptosis. Overexpression of Bcl-2 
protein is thought to reduce the apoptotic capacity, while Bax protein seems to 
be necessary for induction of apoptosis. In this study, Bcl-2 and Bax protein 
levels showed an inverse relationship. These two proteins are activated 
through the mitochondrial signaling pathway[361]. The results from this study 
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indicated that the mitochondrial pathway may play a critical role in 
PG490/chemotherapy-induced cell death. 
 
The others have reported that PG490 blocks the TNFα-induced activation of 
NF-κB and inhibits the expression of NF-κB downstream antiapoptotic genes. 
PG490 also significantly inhibits TNFα, PMA/Ionomycin induced NF-κB 
transcriptional activity in human T cells[204]. PG490 inhibits transcription factor 
NF-κB and induces apoptosis of multiple myeloma cells[201]. However PG490 
did not induce the expression of IκBα in this study, this was consistent with 
previous reports that PG490 does not influence the NF-κB translocation and 
DNA binding[200]. Proteasome result also agreed with this finding. PG490 did 
not inhibit the 20s proteasome activity in this study as well.  
 
Different Cyclins are required at different phases of cell cycles. CDK4/6-
CyclinD complexes are essential for entry in G1, CDK2-CyclinE regulate 
progression from G1 into S phase. Components of the cell cycle machinery 
are frequently altered in human cancer. PG490 increased the proportion of 
cells in S phase and reduced the levels of Cyclin D1, which is overexpressed 
in many cancers[351,352]. These results  were in keeping with those of Yang et 
al[340], who has shown that PG490 caused a significant reduction in two pairs 
of cell cycle-promoting protein complexes, cyclin A/CDK2 and cyclin B/cdc2, 
and cyclin D1. PG490 inhibited cyclin E in colon cancer cell lines RKOWT, 
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HCT116WT and lung cancer cell line H125 but did not showed influence in 
lung cancer cell line A549 and colon cancer line H630WT. Cyclin E associated 
kinase CDK2 did not affected by treatment in four out of five tested cell lines. 
CDK2 was induced by high concentration of PG490 in lung cancer cell line 
A549. CDK4 was increased in colon cancer cells H630WT and RKOWT 
whereas it was reduced in colon cancer cell line HCT116WT and lung cancer 
cell line H125 by the treatment. PG490 did not affect CDK4 expression of lung 
cancer cell line A549. The inhibition of the cell cycle and induction of apoptosis 
may be responsible for anti-tumour effects of PG490. 
 
The activity of PG490 was originally reported to be p53-independent[198]. 
However the recent studies show that PG490-induced apoptosis may be at 
least partly mediated through p53 activation in cells with wild-type p53. Chang 
et al. showed that PG490-mediated enhancement of chemotherapy-induced 
apoptosis is accompanied by enhanced translation and accumulation of wild-
type p53 protein in HT1080 (fibrosarcoma) cell lines.[201] Jiang et al.[362] 
demonstrated that p53 expression is up-regulated in AGS (gastric cancer) cell 
lines after PG490 treatment. Suppression of p53 expression by p53 antisense 
oligonucleotides significantly abolishes PG490-induced apoptosis. These 
investigators also found that MKN-28 and SGC-7901 (gastric cancer) cell 
lines with mutant p53 did not show any significant changes in growth or 
apoptotic rates after treatment with PG490. In this study, the protein levels of 
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p53 were significantly increased in all tested colon cancer cells, slightly 
increased in lung cancer cell line A549 but no alteration in lung cancer cell 
line H125. The p53 downstream target gene p21 was seen in conjunction with 
up-regulation of p53 by PG490 in colon cancer cells H630WT, RKOWT. This is 
consistent with the upregulation of these genes that generally accompanies 
p53- mediated growth arrest and/or apoptosis in response to DNA damage. 
Even though PG490 did not effect the p53 expression of H125, it induced the 
p21 expression as well. Taken together, these results suggested that PG490 
may influence multiple signaling pathways some of which involve p53 in cells 
with wild-type p53 to arrest growth or induce apoptosis. 
 
Angiogenesis is defined as the formation of new blood vessels from 
preexisting vasculature. Preclinical studies have shown that angiogenesis is 
essential for tumour growth and metastasis. Therefore, inhibiting tumour 
angiogenesis has become a promising therapeutic approach for cancer 
treatment[363]. VEGF is recognized as a key factor required for growth of 
tumours. And inhibition of VEGF-induced angiogenesis significantly inhibits 
tumour growth in vivo[364,365]. PG490 inhibited VEGF expression dose 
dependently in all five tested cell lines. The inhibitory effect of PG490 on 
VEGF expression may interfere with tumour growth in vivo. This result was 
consistent with the findings of Hu et al, who has shown that PG490 inhibited 
vascular endothelial growth factor expression and secretion in endothelial 
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cells treated by 12-O-tetradecanoylphorbol 13-acetate  dose-dependently[366].  
 
In conclusion, PG490 has very attractive features as an anti-tumour agent with 
regard to its broad spectrum of activity and potency. This study has also 
suggested that PG490 affects a number of pathways within the cell that could 
be responsible for its anti-tumour activity: PG490 can induce apoptosis as 
indicated by cytotoxic assay, and increased levels of caspase 3 and the 
cleaved form of PARP, all of which are markers of apoptosis. These results 
were consistent with other studies on cultured cells[201,362] . Although my study 
demonstrated that PG490 had strong cytotoxicity to cancer cell lines and 
sensitizing several anti-cancer drugs in vitro, more work is still needed to 
elucidate the molecular mechanisms involved in the anti-cancer effect of 
PG490. 
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General Discussion 
Since the first chemotherapy method was developed in the 1940s, as a result 
of studying the effects of mustard gas on the immune system[367], 
chemotherapy have been significantly improved the outcomes of cancer 
treatment in the last three decades, but the clinical success of cancer 
chemotherapy has been severely hindered by the high non-specific toxicity of 
anti-cancer drugs to the vital tissues and organs and the de novo and anti-
cancer drug-induced chemoresistance. Scientists have begun to create anti-
cancer prodrug strategies that attack cancer cells more specifically than 
traditional chemotherapy drugs can. A prodrug is a compound which is not 
originally cytotoxic but can be converted to the active forms in cancer cells by 
some cancer specific enzymes after biotransformation in human body. In 
theory, prodrug can specifically target cancer cell and spare normal tissues 
and improve therapeutic index[159], but its efficacy has severely obstacled by 
the relatively low expression of drug-converting enzymes in most of the 
cancer cells. Since scientists discovered the molecular structure of genes and 
the molecular basis of numerous human diseases, they were fascinated by 
the possibility of treating certain diseases by transfer of foreign DNA into the 
affected cell. Gene-directed enzyme prodrug therapy (GDEPT) was designed 
to solve the lack of prodrug converting enzyme in prodrug based therapy by 
introducing a cDNA encoding drug-activating enzyme under the control of a 
cancer specific promoter into cancer cells where it will produce an active 
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enzyme. The greater selection of GDEPT is due to use tissue- or tumour 
specific promoters so that the transgene is only expressed in tumour cells and 
not in the surrounding tissue. Although in theory GDEPT is magic for cancer 
therapeutic but the clinical application of GDEPT is severely limited by the 
lack of cancer specific promoter with strong transcriptional activity and 
delivery systems[264,265]. In the foreseeing future, there is still lack the potential 
of development of cancer specific delivery system. Therefore improvement of 
transcriptional activity and specificity become one of the major focuses in 
GDEPT study. One of the aims of my project is to develop a promoter system 
with high transcriptional activity and cancer specificity. 
 
Two cancer specific promoter systems, CEA and hTERT, have been 
investigated for application in cancer gene therapy. The CEA protein is absent 
or expressed at very low levels in normal tissues[256] and heterogenously 
overexpressed in more than 90% of primary CRC[258]. GDEPT using CEA 
promoter have lead to high-level selective expression of transgenes in CEA-
positive cell lines[241]. However, the therapeutic efficacy of this strategy is 
limited because of the low transcriptional activity of the CEA promoter in 
majority of cancer tissues especially in the metastatic malignancies[264]. It is 
shown that the CEA promoter is 10-300 times weaker compared to stronger 
but non specific Rous sarcoma virus or cytomegalovirus promoters[265]. 
Consequently there is no sufficient enzyme for conversion of prodrug into anti-
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cancer drug. Another attractive cancer promoter is the telomerase promoter, 
hTERT. It has found that more than 85% of human cancers possess active 
telomerase, regardless of their tissue origins. Whereas normal somatic 
tissues have either much lower or undetectable activity[249]. This is a property 
that can set cancer cells apart from normal cells. A number of studies have 
used telomerase promoters to drive transgene expression for therapeutic 
benefit. However, the telomerase activity in cancer tissues can be varied 
significantly[368]  which becomes the major limitation the application of this 
promoter in the clinic. These have led to the search for more efficient system 
consisting of the promoter and enhancer which are expected to increase the 
expression of therapeutic gene while the CEA or hTERT provide the 
necessary specificity. 
 
By investigation of the signal transduction pathways in cancer cells, numous 
studies demonstrate that in comparison with the normal counterparts, most 
cancer cells possess high NF-κB activity which is generated by the cancer 
cells or the surrounding inflammatory cells[65]. Because NF-κB is a 
transcription factor, these findings make NF-κB DNA binding site a putative 
cancer specific element for cancer gene therapy application.  
 
In this study I used a TP/ 5’-deoxy-5-fluorouradine (5’-DFUR) model to test 
the hypothesis of joint the κB enhancer and CEA or hTERT to improve the 
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transcriptional activity of both promoters and maintain their cancer specificity. 
In this system, the basal CEA promoter or hTERT sequences were placed 
downstream of the 4 or 8 directly linked NF-κB DNA binding sites in tandem 
(κB4, κB8). The system was designed to serve two particular purposes: to 
exploit the high levels of intra-tumoural NF-kB expression and keep the 
relative tumour specificity of the CEA and hTERT promoter.  
 
Five cis-acting elements (FP1 to FP5) were identified in the promoter region 
of CEA gene[252]. It has been reported that the first 3 elements are essential 
for specific CEA transcription[252,269], therefore two CEA promoter regions, 
CEA205 which covered the first 3 elements and CEA421 covering 4 cis-acting 
elements, were examined. Both CEA205 and CEA421 promoters 
demonstrated selective transcriptional activity in all CRC cell lines but not in 
normal endothelial and epithelial cells. This is consistent with previous study, 
which demonstrated that the CEA promoter can be used to improve specificity 
of gene expression in colorectal cancer[241]. In combination with κB4, the 
transcriptional activity of both CEA205 and CEA421 in cancer cell lines was 
significantly enhanced. The κB4 enhancer demonstrated a greater enhancing 
effect on the CEA205 promoter than on the CEA421 promoter. This finding 
indicated that the first 3 elements were essential for specific κB4-CEA 
transcription. Moreover, the transcriptional activity of κB4-CEA205 enhancer-
promoter system was highly comparable to that of the strong SV40 virus 
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promoter in all CRC cell lines. This study then provides direct evidence that 
the κB4-CEA205 enhancer-promoter system possess the selectivity of CEA 
promoter, and significantly higher transcriptional activity than CEA promoter 
alone. Then κB4-CEA205 enhancer-promoter system was chose for 
subsequent experiments.  
 
Capecitabine (Xeloda, CAP) is an orally-administered chemotherapeutic 
agent used in the treatment of metastatic breast and colorectal cancers. It was 
designed as a prodrug of 5’-DFUR and 5-FU. CAP needs to be converted into 
5’-DFUR in liver. Therefore 5-’DFUR, the intermediate metabolite of CAP was 
chosen for this in vitro study. Prodrug 5’-DFUR can be convert to 5-FU by TP. 
However, TP is only detected in 24% to 66%[221] of tumours with 5-FU 
resistant tumours  expressing even lower levels[222]. Consequently, insufficient 
conversion of 5’-DFUR into 5-FU currently is a major limitation for the 
application. Strong promoters such as CMV have been used to increase TP 
and cytidine deaminase (CD) expression in cancer cells[274] and demonstrated 
enhanced cytotoxicity of 5-FC and 5’-DFUR in vitro and in vivo[275-278], 
however these strategies are limited by a lack of specificity. The TP gene 
sequences were placed downstream of κB4-CEA205 enhancer-promoter 
system in order to provide the local expression of TP in tumour cells. High 
levels of TP protein were detected in both pCMV-TP and pκB4-CEA205-TP 
transfected cells. Only very low levels of TP protein were detected in the 
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pCEA205-TP transfected cells. In line with protein expression levels, the 
pcDNA3-TP and pκB4-CEA205-TP transfected cells also possessed high TP 
enzyme activity. This provide the base for sufficient conversion of 5’-DFUR 
into 5-FU specifically in pκB4-CEA205-TP transfected cancer cells. The κB4-
CEA205-TP transfected cells become more sensitive to anti-cancer drug 5´-
DFUR. In comparison with the control (pcDNA3 transfected), the pκB4-
CEA205-TP transfected RKO and H630 cells were 7.6 and 10 times more 
sensitive to the 5´-DFUR-induced cytotoxicity. The cytotoxicity of 5´-DFUR to 
the pκB4-CEA205-TP and pCMV -TP transfected cell lines was comparable. 
However, pCEA205-TP transfection only slightly increased the cytotoxicity of 
5´-DFUR to the CRC cell lines. All these results indicated that κB4 was a 
strong enhancer for improving the transcriptional activity of CEA promoter. 
 
Low transfection rate is still one of the major barriers for the success of cancer 
GDEPT in the clinic. It has been reported that the small portion of CMV 
promoter-driven TP transfected cells can effectively convert 5´-DFUR into 5-
FU which can be released and perform cytotoxic effect onto the neighbouring 
cells (bystander effect)[275]. The cytotoxicity assay showed that the bystander 
effect of κB4-CEA205 and CMV promoter drive TP transfected cells was 
comparable. When κB4-CEA205-TP transfected RKO or H630 cells 
composed only 5% of the whole cell population, the sensitivity of H630 and 
RKO cell lines to 5´-DFUR was significantly enhanced. If the percentage of 
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the transfected cells was further increased, the IC50s of 5´-DFUR in these 
cells were further reduced but the curves significantly leveled off.  
 
Taken these all together, κB4-CEA205 system increased the transcriptional 
activity of CEA promoter, while keeping the specificity of CEA promoter. pκB-
CEA-TP transfection enhanced 5’-DFUR cytotoxicity to CRC cell lines in vitro. 
This may improve the therapeutic index of chemotherapy for colon cancer by 
specific targeting cancer cells and avoiding normal cells. The κB4-CEA205 
system produces very promising results. Eight cis-acting DNA binding sites 
may further enhance the transcriptional activity of the CEA promoter. As 
expected, κB8-CEA205 did show high transcriptional activity in CRC cell line 
than κB4-CEA205, however the TP protein expression level of κB8-CEA205-
TP transient transfected cells was not increased compare to κB4-CEA205-TP 
transfected ones, and κB8-CEA205-TP transient transfected cells became 
slightly more sensitive to 5´-DFUR. This clearly showed that although κB8 can 
further improve the transcriptional activity of CEA205 promoter, but did not 
increase the TP protein expression and cytotoxicity of 5´-DFUR to cancer cells.  
 
The κB enhancer improved the activity of CEA promoter in CRC cells. It would 
worthwhile to investigate if κB enhancer can also improve the activity of 
telomerase promoter which can be used for all kinds of cancer as most of 
human cancers possess active telomerase. Although the RNA subunit (hTR) 
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of the human telomerase complex is constitutively expressed in both tumour 
and normal somatictissues[279], expression of the catalytic subunit 
(hTERT) correlates with telomerase activity during cellular differentiation and 
neoplastic transformation[369]. It has proven that transcriptional activity 
of hTERT was dependent on the proximal 181 bp region of the promoter, 
which was essential for transactivation in immortalized and cancer cells[294]. 
This promoter region contains E-boxes and GC-boxes, the consensus binding 
sequence for Myc and Sp1, respectively.  Therefore, in this study, the 
hTERTcore region were placed downstream of the 4 and 8 directly linked NF-
κB DNA binding sites in tandem (κB4). The κB4, κB8 enhancer demonstrated 
a significantly greater enhancing effect on the hTERTcore promoter in several 
kinds of cancer, e.g. colon, breast, and lung cancer. Furthermore the TP 
protein expression level of κB8-hTERTcore-TP transfected cells is significantly 
higher than that of κB4-CEA205-TP transfected ones.  
 
The molecular mechanisms of enhancing effect of κB4 on CEA and hTERT 
promoter activity were still not clear. Two Sp1 and Sp1-like DNA binding sites 
are located on the CEA promoter region (FP2 and FP3)[252,292]. The 
hTERTcore promoter region contains E-boxes and GC-boxes, the binding 
sequence for Sp1 as well[294]. A cooperative interaction between NF-κB and 
Sp1 has been demonstrated in human immunodeficiency virus long terminal 
repeat (HIV-1 LTR) promoter region[286,290]. Therefore, investigation of the 
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relationship between κB4 and Sp1 might provide evidence for using κB4 to 
improve the transcriptional activity of other cancer specific promoters.  
 
Apart from non-specific toxicity, the resistance to chemotherapeutic drugs is 
another frustrating event for cancer treatment. Resistance to anti-cancer 
drugs can be either intrinsic (present in the cancer cell before treatment) or 
acquired after treatment. Cancer cells can also develop cross-resistance to 
many other drugs with different moelcular structures and intracellular targets. 
Although numerous factors have been identified, the molecular mechanisms 
for drug resistance are still not fully elucidated. It has been found that an 
elevated basal activity of NF-κB is held responsible for resistance against 
topoisomerase I and II inhibiting drugs[161]. While constitutive activation, which 
has been observed in solid tumours, is seen in the resistant phenotype[162].  
 
NF-κB is correlated with anti-cancer drug resistance and also 5-FU induced 
NF-κB activation[166]. Gemcitabine is another chemotherapy drug which shows 
activity against a wide range of haematological and solid cancers used alone 
or in combination with other anti-cancer agent. Due to its complex metabolism 
of action and multiple cellular targets, the resistant mechanisms of cancer 
cells to gemcitabine are multifactorial[102]. Although extensive research has 
been performed, the molecular mechanisms of gemcitabine resistance are still 
far from fully elucidated. There are overlapping anti-cancer mechanisms and 
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anti-cancer spectrum between gemcitabine and 5-FU[102,298]. Therefore it 
would be interesting to investigate whether gemcitabine resistance is related 
to NF-κB activation as well. Apart from HCT116GEM, all 5-FU and gemcitabine 
resistant cell lines demonstrated higher NF-κB DNA binding activity and 
higher NF-κB transcriptional activity than their sensitive counterpart. The NF-
κB DNA binding activity was induced by gemcitabine in a time-dependant 
manner in sensitive colon cancer cell lines. Furthermore breast cancer cells 
with highly expression of NF-κB subunit p65 and p50 become more resistant 
to gemcitabine than the parent cell line. The results from this study indicated 
that NF-κB was correlated to gemcitabine resistance.  
 
Although there are overlapping anti-cancer mechanisms and anti-cancer 
spectrum between gemcitabine and 5-FU, the cross-resistance of these two 
drugs is not clear. Elucidation of the cross-resistance between these two 
drugs will provide useful information for their clinical application. 5-FU 
resistant colon cancer cell line H630R10 was highly cross-resistant to 
gemcitabine (> 580-fold). The 5-FU resistant breast cancer cell line 
(MCF7FU2.5) showed mild resistance to gemcitabine (~ 3-fold). The down-
regulation of dCK and overexpression of RRM1 protein are the common 
features for gemcitabine resistance cancers[102]. In consistent with the 
literature, the protein expression levels of the dCK protein were almost 
undetectable in gemcitabine resistant colon cancer cell lines and slightly 
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down-regulated in 5-FU resistant colon and breast cancer cell line. However, 
there was no significant difference in RRM1 expression between gemcitabine 
resistant colon cancer cell lines, 5-FU resistant breast cancer cell line and 
relevant sensitive parental cell lines. Interestingly, RRM1 protein was 
expressed at significantly lower level in the 5-FU resistant H630R10 cell line in 
comparison with the sensitive cell line. TS gene amplification and protein 
overexpression are commonly detected in 5-FU resistant cancer cell lines. 
The gemcitabine resistant cell lines were only mildly resistant to 5-FU. TS 
protein was also slightly over-expressed in the gemcitabine resistant colon 
cancer cell lines. 
  
As determined in this study, 5-FU resistant colon cancer cell line H630R10 was 
highly cross-resistant to gemcitabine (> 580-fold). An investigation into the 
cross-resistant of this cell line to other drugs which have different anti-cancer 
mechanisms with Gemcitabine and 5-FU would be worthwhile. In comparison 
with parental cell line H630WT, H630R10 was highly resistant to topotecan, 
etoposide, doxorubicin and lomustine. The protein expression levels of the 
proliferation-related proteins PCNA and ki-67 were down-regulated in 5-FU 
resistant colon and breast cancer cell line. The lower proliferation rate may 
refer the multi-resistant phenomenon to H630R10 cells as all anti-cancer drugs 
mainly target fast dividing cells. 
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The role of NF-κB in the regulation of apoptosis in normal and cancer cells 
has been extensively studied. Constitutive NF-κB activity in B lymphocytes as 
well as in Hodgkin’s disease and breast cancer cells protects these cells 
against apoptosis[370]. It has also been reported that NF-κB protects tumour 
necrosis factor (TNF)-α, chemotherapeutic drugs and ionizing radiation 
induced apoptosis in cancer cells. These observations were explained by the 
up-regulation of antiapoptotic gene expression by NF-κB[370]. These results 
suggest that targeting NF-κB may improve the sensitivity of cancer cells to 
chemotherapy and radiotherapy. Inhibition of NF-κB activation has been 
shown to be a useful strategy for increasing the sensitivity towards cytostatic 
drug treatment in vitro and in vivo[167-170]. In a preclinical study, PS-1,145, a 
NF-κB inhibitor, strongly inhibits the proliferation of cancer cells and  
overcomes drug resistance in multiple myeloma[371]. These promising 
preclinical studies suggest the potential utility of specific NF-κB inhibitors in 
the treatment of multiple myeloma and other malignancies with constitutively 
activated NF-κB pathway. Inhibition of NF-κB pathway is currently being 
pursued to improve cancer therapeutic efficacy. Many natural substances 
have been found to downregulate NF-kB production, including curcumin[163], 
green tea[164] and resveratrol[165]. Wang et al. used Disulfiram (DS) to directly 
downregulate the activity of NF-κB and to improve cytotoxity of 5-FU[166]. 
Cusack et al. used the proteasome inhibitor PS-341 to inhibit degradation of 
IκB enhancing the chemosensitivity of CPT-11[167]. Weiver et al. used 
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constructed adenovirus vector, super-repressor IκBα-SR to block the 
degradation of IκB and enhance chemotherapy response[168]. Moreover, 
various pharmacological substances (e.g. thalidomide, bortezomib, 
sulphasalazine) have already entered clinical studies partially showing 
promising results for certain types of cancer[169,170]. Based on the above facts, 
the second part of this study focused on targeting NF-kB pathway to sensitise 
cancer cell lines to conventional anti-cancer drugs. 
 
DS is a member of the dithiocarbamate family and an aldehyde 
dehydrogenase inhibitor. DS has been used in clinic as an anti-alcoholism 
drug[172] for over 60 years.. DS is also an NF-κB inhibitor[372]. DS directly 
downregulate the activity of NF-κB and to improve cytotoxity of 5-FU[166]. DS-
copper complex can induce apoptotic cell death and inhibits the proteasomal 
activity in cultured breast cancer MDA-MB-231 and MCF10DCIS.com cells[297]. 
This study demonstrated that gemcitabine resistance was at least partially NF-
κB activation-related. DS/Cu complex might be able to reverse the resistance 
of Gemcitabine. The result in this study showed that the cytotoxicity of 
gemcitabine in colon and breast cancer cell lines was highly potentiated and 
the gemcitabine resistance was reversed by combining use of DS/Cu complex 
with gemcitabine. The DS/Cu complex significantly inhibited NF-κB DNA 
binding activity at a very low concentration (~ 1 μM). In contrast, DS alone did 
not inhibit or only inhibited NF-κB activity at relatively high concentration (Fig. 
4.11).  
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Zinc is another metal atom which can be chelated by DS to form complex. The 
effect of DS/Zn complex on the gemcitabine-induced NF-κB activity in two 
colon cancer cell lines was investigated as well. It has previously been 
reported that DS/Zn inhibits NF-κB activity in cancer cell lines and zinc can 
improve the cytotoxicity of DS. The clinical remission has also been achieved 
in one case of stage IV melanoma patient treated with DS and zinc[373]. In this 
study, the DS/Zn complex only demonstrated inhibiting effect on NF-κB 
activity at relatively high concentrations (~ 10 μM). Why  it is  copper may 
explain by the fact that molecular processes of angiogenesis include 
stimulation of endothelial growth by tumour cytokine production (i.e., vascular 
endothelial growth factor) and the requirement of copper(but not other trace 
metals) as an essential cofactor[374,375]. Consistently, while the zinc, iron 
concentrations where significantly lower in cancer patients, the copper 
concentrations were almost always found to be either elevated or significantly 
elevated (up to 2-3 fold) compared to age matched samples from normal 
tissue[376]. The elevated levels of copper are hallmark of range of 
malignancies, thus it provides for treatment approaches applicable to variety 
of malignant conditions. Therefore, there exist an opportunity to exploit these 
differences for the development of potential cancer strategies. 
 
Furthermore it was shown that Cu/DS complex can also reverse the drug 
resistance of colon cancer cell line H630R10 to topotecan, etoposide, 
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doxorubicin and lomustine. These drugs belong to four different groups of 
anti-cancer drugs which have diverse anti-cancer mechanisms. It could be 
concluded that Cu/DS can sensitize the cancer cells to several anti-cancer 
drugs, which has diverse anti-cancer mechanisms, by targeting NF-κB and 
proteasome which is consistent with precious study[167-170,297]. Some 
researcher investigated this effect from different angles. They demonstrated 
that high Cu in the cell can produce highly toxic reactive oxygen species 
(ROS). As a strong chelator, DS can facilitate intracellular Cu uptake and 
trigger production of ROS in cancer cells and induce cancer cell apoptosis. 
Apart from triggering apoptosis, ROS also strongly induces NF-κB activity 
which induces the expression of a wide range of anti-apoptotic factors and 
diminish the apoptotic effect of ROS[319,320].  
 
Triptolide (PG490) is another attractive traditional drug, which extracted from 
the Chinese medicinal herb, Tripterygium wilfordii Hook F (TWHF). Historically, 
the extracts of TWHF have been used for more than two centuries in 
traditional Chinese medicine to treat a variety of autoimmune and 
inflammatory diseases including rheumatoid arthritis[196]. Recently, it was 
reported that PG490 possesse anti-tumour properties and induced apoptosis 
in a broad range of solid tumours and leukemic cells[197-199]. PG490 also block 
NF-κB activity[200,204,341]. This attracts our attention. So I investigated if PG490 
can sentize cancer cells to anti-tumour drugs by targeting NF-κB pathway and 
  
244 
the mechanisim behide this. 
  
The results in this study show that triptolide in nanomolar concentrations 
induced significant cell death in all tested colon, lung and breast cells (Fig. 
6.1). However,  PG490 did not induce the expression of IκBα(Fig. 6.7),  this 
was consistent with previous reports that PG490 does not influence the NF-κB 
translocation and DNA binding[200]. Following various stimuli, IκB is degraded 
by the proteasome leading to the nuclear translocation of NF-kB. PG490 did 
not inhibit the 20S proteasome activity in this study (Fig. 6.8) as well this is 
agreed with that PG490 did not affect the expression level of IκBα.  
 
The molecular mechanisms responsible for triptolide’s anti-tumour activity are 
poorly understood. the p53 gene is inactivated in approximately 50% of 
tumours and p53 alteration has also been held responsible for the failure of 
most cancers to respond to radiotherapy and chemotherapy[377,378]. 
Furthermore, wild-type p53 protein level was increased during apoptosis 
induced by DNA-damaging agents[379]. The increased expression of wild-type 
p53 can induce apoptosis in myeloid leukemia and colon cancers[380,381]. 
Since PG490 induce apoptosis of all tested cells, the expression levels of p53 
and p21 which is an important downstream effector in the p53-specific growth 
arrest pathway were also teasted in this study. PG490 induces a dose-
dependent increase in p53 level in colon cancer cells H630WT, RKOWT, and 
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HCT116WT. This indicates that triptolide-induced apoptosis may be mediated 
by p53. In contrast with p53, p21 levels were increased by low concentration 
of PG490 treatment in a dose dependent fashion. High concentrations of 
PG490 (25 and 50 nM) inhibited p21 expression in three colon cancer cell 
lines (Fig. 6.5 B).  
 
Components of the cell cycle machinery are frequently altered in human 
cancer. Malignant cells evolve cause overexpression of Cyclins and loss of 
expression of CDK inhibitors. Amplification or overexpression of Cyclin D1 
CyclinE, CDK4 and CDK2 have been found to be amplified, overexpressed or 
both in some cases of breast and colon cancer and in acute lymphoblastic 
and acute myeloid leukaemisa [351-354].The next step of this study is to test the 
effect of PG490 on the expression of cell cycle-regulating proteins.  Western 
blotting results showed that high concentration of PG490 inhibit the 
expression of CyclinD1 in all five tested cell line, and inhibit CyclinE in colon 
cancer cell lines H630WT, RKOWT and HCT116WT, lung cancer H125 whereas 
in lung cancer A549 CyclinE protein levels are not significantly modified by the 
treatment. CyclinE associated kinase CDK2 did not affected by treatment in 
four out of five tested cell lines; CDK2 was induced by high concentration of 
PG490 in lung cancer A549 cells. CDK4 was increased in colon cancer cell 
H630WT, RKOWT, whereas, it was reduced in colon cancer cell HCT116WT and 
lung cancer H125 by the treatment. PG490 did not affect CDK4 expression of 
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lung cancer cell A549 (Fig. 6.6). 
 
Angiogenesis, the growth of a tumour blood supply, is essential for tumour 
growth, invasion, and metastasis[382]. Therefore, inhibiting tumour 
angiogenesis has become a promising therapeutic approach for cancer 
treatment[363]. Tumours without an additional blood supply do not grow larger 
than 1 to 2 mm3[374]. Molecular processes of angiogenesis include stimulation 
of endothelial growth by tumour cytokine production (i.e., vascular endothelial 
growth factor). PG490 inhibited VEGF expression dose dependently in all five 
tested cell lines (Fig. 6.9). This result was consistent with the findings of Hu et 
al, who has shown that PG490 inhibited vascular endothelial growth factor 
expression and secretion in endothelial cells treated by 12-O-
tetradecanoylphorbol 13-acetate dose-dependently[366].  
 
PG490 was very effective as a single agent in killing various cell lines; its 
benefits are even greater, as it can enhance cell death induced by other 
chemotherapeutic agents at low concentrations. Cell death induced by 5-FU, 
DDP, ETP and Gem in combination with PG490 was significantly enhanced. 
Combination of PG490 with other anti-cancer drugs may affect a number 
of pathways within the cell that could be responsible for its anti-tumour activity. 
First, they increased levels of caspase 3 and the cleaved form of PARP, all of 
which are markers of apoptosis. Second, they increase pro-apoptosis gene 
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Bax and decrease anti-apoptosis gene Bcl2 expression. At present, this 
appears to be the most likely mechanism by which PG490 is able to block 
tumour growth.  
 
In conclusion, PG490 has very attractive features as an anti-tumour agent with 
regard to its broad spectrum of activity and potency.  Potentially, PG490 could 
be developed into a new anti-tumour agent. The cytotoxic activity of PG490 
alone and its ability to cooperate with other cytotoxic agents may represent a 
novel method to enhance cytolysis of solid tumour cells in vivo. 
 
 
.  
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